Patent Application
20120309789
This invention relates to novel compounds, pharmaceutical compositions containing them and their use in therapy, in particular as antipsychotic agents.
Muscarinic acetylcholine receptors are members of the G protein coupled receptor superfamily which mediate the actions of the neurotransmitter acetylcholine in both the central and peripheral nervous system. Five muscarinic receptor subtypes have been cloned, M1 to M5. The muscarinic M1 receptor is predominantly expressed in the cerebral cortex and hippocampus, although it is also expressed in the periphery e.g. exocrine glands.
Muscarinic receptors in the central nervous system, especially M1, play a critical role in mediating higher cognitive processing. Diseases associated with cognitive impairments, such as Alzheimer's disease, are accompanied by loss of cholinergic neurons in the basal forebrain. Furthermore, in animal models, blockade or lesion of central cholinergic pathways results in profound cognitive deficits.
Cholinergic replacement therapy has largely been based on the use of acetylcholinesterase inhibitors to prevent the breakdown of endogenous acetylcholine. These compounds have shown efficacy versus symptomatic cognitive decline in the clinic, but give rise to side effects resulting from stimulation of peripheral muscarinic receptors including disturbed gastrointestinal motility and nausea.
The dopamine hypothesis of schizophrenia suggests that excess dopaminergic stimulation is responsible for the positive symptoms of the disease, hence the utility of dopamine receptor antagonists to reduce psychotic symptoms. However, conventional dopamine receptor antagonists can cause extrapyramidal side effects (EPS) in patients, including tremor and tardive dyskinesias.
M1 receptor agonists have been sought for the symptomatic treatment of cognitive decline. More recently, a number of groups have shown that muscarinic receptor agonists display an atypical antipsychotic-like profile in a range of pre-clinical paradigms. The muscarinic agonist, xanomeline, reverses a number of dopamine driven behaviours, including amphetamine induced locomotion in rats, apomorphine induced climbing in mice, dopamine agonist driven turning in unilateral 6-OH-DA lesioned rats and amphetamine-induced motor unrest in monkeys (without EPS liability). It also has been shown to inhibit A10, but not A9, dopamine cell firing and conditioned avoidance and induces c-fos expression in prefrontal cortex and nucleus accumbens, but not in striatum in rats. These data are all suggestive of an atypical antipsychotic-like profile.
Xanomeline has also been shown to reduce psychotic symptoms such as suspiciousness, hallucinations and delusions in Alzheimer's patients. However, the relatively non-selective nature of the compound gives rise to dose-limiting peripheral cholinergic side effects.
Certain M1 receptor agonists are known, for example in PCT/GB2006/003585. We have now found a novel group of compounds which are M1 receptor agonists.
In a first aspect therefore, the invention provides a compound of formula (I) or a salt or solvate thereof:
wherein:
As used herein, the term “alkyl” refers to straight or branched hydrocarbon chains containing the specified number of carbon atoms. For example, C1-6alkyl means a straight or branched alkyl containing at least 1, and at most 6, carbon atoms. C1-3alkyl means a straight or branched alkyl containing at least 1, and at most 3, carbon atoms. Examples of “alkyl” as used herein include, but are not limited to, methyl, ethyl, n-propyl, n-butyl, n-pentyl, n-hexyl, isobutyl, isopropyl, t-butyl and 1,1-dimethylpropyl.
As used herein, the term “alkoxy” refers to a straight or branched alkoxy group containing the specified number of carbon atoms. For example, C1-6alkoxy means a straight or branched alkoxy group containing at least 1, and at most 6, carbon atoms. Examples of “alkoxy” as used herein include, but are not limited to, methoxy, ethoxy, propoxy, prop-2-oxy, butoxy, but-2-oxy, 1-methylethyl-oxy, 2-methylprop-1-oxy, 2-methylprop-2-oxy, pentoxy or hexyloxy.
As used herein, the term “alkynyl” refers to a linear or branched hydrocarbon group containing one or more carbon-carbon triple bonds and the specified number of carbon atoms. For example, C2-6alkynyl means a linear or branched hydrocarbon group containing one or more carbon-carbon triple bonds and at least two, and at most six, carbon atoms. Examples of “alkynyl” as used herein include, but are not limited to, include ethynyl, propynyl, butynyl, pentynyl and hexynyl.
As used herein, the term “cycloalkyl” refers to a non-aromatic hydrocarbon ring containing the specified number of carbon atoms. For example, C3-6cycloalkyl means a non-aromatic ring containing at least three, and at most six, ring carbon atoms. Examples of “cycloalkyl” as used herein include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.
As used herein, the term “halogen” (or the abbreviated form “halo”) refers to the elements fluorine (which may be abbreviated to “fluoro”), chlorine (which may be abbreviated to “chloro”), bromine (which may be abbreviated to “bromo”) and iodine (which may be abbreviated to “iodo”). Examples of halogens are fluorine, chlorine and bromine.
As used herein, the term “solvate” refers to a complex of variable stoichiometry formed by a solute (in this invention, a compound of formula (I) or a salt thereof) and a solvent. Such solvents for the purpose of the invention may not interfere with the biological activity of the solute. Examples of suitable solvents include water, methanol, ethanol and acetic acid. The solvent used may be water and the solvate may also be referred to as a hydrate.
As used herein, the term “substituted” refers to substitution with the named substituent or substituents, multiple degrees of substitution being allowed unless otherwise stated. For example, there may be 1, 2, 3 or 4 substituents on a given group. For example there may be 3 fluoro groups on an R6 group. For example, there may be 1, 2, 3 or 4 substituents on a given substituted group. For example, if R6 is a C1-6alkyl group, it may be substituted by 1, 2, 3 or 4 fluoro groups; and if R6 is a C1-6alkoxy group, it may be substituted by 1, 2, 3 or 4 fluoro groups. For example, R6 may be a C1-6alkyl group substituted by 3 fluoro groups; and R6 may be a C1-6alkoxy group substituted by 3 fluoro groups. For example, R6 may be CF3. Similarly, if R5 is a C1-6alkyl group substituted by one or more fluoro groups, it may be substituted by 1, 2, 3 or 4 fluoro groups; and if R5 is a C1-6alkoxy group, it may be substituted by 1, 2, 3 or 4 fluoro groups. For example, R5 may be a C1-6alkyl group substituted by 3 fluoro groups; and R5 may be a C1-6alkoxy group substituted by 3 fluoro groups. For example, R5 may be CF3 or CH2F.
In one embodiment, R5 is selected from halogen, cyano, C1-6alkyl, C1-6alkyl substituted with one, two or three fluorine atoms, C1-6alkoxy, and C1-6alkoxy substituted with one, two or three fluorine atoms.
In one embodiment, R5 is selected from halogen, cyano, C1-4alkyl, C1-4alkyl substituted with one, two or three fluorine atoms, C1-4alkoxy, and C1-4alkoxy substituted with one, two or three fluorine atoms.
In one embodiment, R5 is selected from halogen, cyano, C1-2alkyl, C1-2alkyl substituted with one, two or three fluorine atoms, C1-2alkoxy, and C1-2alkoxy substituted with one, two or three fluorine atoms.
In one embodiment of the invention, R5 is selected from chloro, bromo, fluoro, C1-4alkoxy, C1-4alkyl and C1-4alkyl substituted with one or more fluorine atoms.
In a further embodiment of the invention, R5 is selected from chloro, bromo, fluoro, methyl, ethyl, methoxy and trifluoromethyl. In one embodiment, R5 is selected from chloro, fluoro and trifluoromethyl.
In one embodiment, R6 is selected from hydrogen, halogen, cyano, C1-6alkyl, C1-6alkyl substituted with one, two or three fluorine atoms, C1-6alkylsulfonyl, C3-6cycloalkyl, C3-6cycloalkyl substituted with one or more fluorine atoms, C1-6alkoxy and C1-6alkoxy substituted with one, two or three fluorine atoms.
In one embodiment, R6 is selected from hydrogen, halogen, cyano, C1-4alkyl, C1-4alkyl substituted with one, two or three fluorine atoms, C1-4alkylsulfonyl, C3-6cycloalkyl, C3-6cycloalkyl substituted with one or more fluorine atoms, C1-4alkoxy and C1-4alkoxy substituted with one, two or three fluorine atoms.
In one embodiment, R6 is selected from hydrogen, halogen, cyano, C1-2alkyl, C1-2alkyl substituted with one, two or three fluorine atoms, C1-2alkylsulfonyl, C3-6cycloalkyl, C3-6cycloalkyl substituted with one or more fluorine atoms, C1-2alkoxy and C1-2alkoxy substituted with one, two or three fluorine atoms.
In one aspect of the invention, R6 is selected from chloro, bromo, fluoro, methyl, ethyl, isopropyl, methoxy, trifluoromethoxy and trifluoromethyl.
In a further aspect of the invention, R6 is selected from chloro, bromo, methyl, ethyl, isopropyl, methoxy, trifluoromethoxy and trifluoromethyl. In one embodiment, R6 is selected from methyl and bromo.
In one embodiment, R is selected from C1-6alkyl, C3-6cycloalkyl, C3-6cycloalkylC1-6alkyl and C2-6alkynyl, any alkyl or cycloalkyl group being optionally substituted with one, two or three fluorine atoms.
In one embodiment, R is selected from C1-4alkyl, C3-6cycloalkyl, C3-6cycloalkylC1-4alkyl and C2-4alkynyl, any alkyl or cycloalkyl group being optionally substituted with one, two or three fluorine atoms.
In one embodiment of the invention, R is selected from C1-6alkyl, C3-6cycloalkyl, C3-6cycloalkylC1-6alkyl, any alkyl group being optionally substituted with one or more fluorine atoms.
In a further embodiment of the invention, R is selected from C1-3alkyl and C3-6cycloalkylC1-3alkyl, any alkyl or cycloalkyl group (for example any alkyl group) being optionally substituted with one or more fluorine atoms.
In a further embodiment, R is selected from methyl, ethyl, propyl, isopropyl and cyclopropylmethyl. For example, R may be selected from methyl, ethyl and propyl.
In one embodiment of the invention Q is selected from hydrogen and C1-3alkyl. In a further embodiment, Q is selected from hydrogen, methyl, ethyl and propyl. For example, Q represents hydrogen or methyl.
In one embodiment, in formula (I) above, R5 is selected from chloro, bromo, fluoro, C1-4alkyl, C1-4alkyl substituted with one or more fluorine atoms, and C1-4alkoxy, R6 is selected from chloro, bromo, methyl, ethyl, isopropyl, methoxy, trifluoromethoxy and trifluoromethyl, R is selected from methyl, ethyl, propyl, isopropyl and, cyclopropylmethyl, and Q is selected from hydrogen and methyl.
The present invention also provides a compound of formula (Ia):
wherein:
In one embodiment the salt or solvate of the compound of formula (I) is a pharmaceutically acceptable salt or solvate. In one embodiment, the invention provides a compound of formula (I), or a pharmaceutically acceptable salt or solvate thereof.
It will be appreciated that for use in medicine the salts of formula (I) should be pharmaceutically acceptable. Suitable salts will be apparent to those skilled in the art and include for example mono- or di-basic salts formed with inorganic acids e.g. hydrochloric, hydrobromic, sulfuric, nitric, sulfamic phosphoric, hydroiodic, phosphoric or metaphosphoric acid; and with organic acids, such as tartaric, acetic, trifluoroacetic, citric, malic, lactic, fumaric, benzoic, formic, propionic, glycolic, gluconic, maleic, succinic, (1S)-(−)-10-camphorsulphonic, (1S)-(+)-10-camphorsulphonic, isothionic, mucic, gentisic, isonicotinic, saccharic, glucuronic, furoic, glutamic, ascorbic, anthranilic, salicylic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, pantothenic, stearic, sulfinilic, alginic, galacturonic and arylsulfonic, for example naphthalene-1,5-disulphonic, naphthalene-1,3-disulphonic, benzenesulfonic, and p-toluenesulfonic, acids. Other non-pharmaceutically acceptable salts e.g. oxalates, may be used, for example in the isolation of compounds of formula (I) and are included within the scope of this invention. The compounds of the present invention may be in the form of their free base or pharmaceutically acceptable salts thereof, particularly the monohydrochloride, monoformate or monotrifluoroacetate salts.
Certain of the compounds of formula (I) may form acid addition salts with less than one (for example, 0.5 equivalent of a dibasic acid) or one or more equivalents of an acid. The present invention includes within its scope all possible stoichiometric and non-stoichiometric forms thereof.
It will be appreciated that compounds of formula (I) can exist in cis or trans isomeric forms (the OR group on the cyclohexane ring in relation to the piperidine substituent).
Cis form:
It will be appreciated that the trans form may be drawn in the following different ways, although both represent the same isomeric form:
The individual isomers (cis and trans) and mixtures of these are included within the scope of the present invention. The isomers may be separated one from the other by the usual methods or by methods detailed for the example compounds below. Any given isomer may also be obtained by stereospecific or asymmetric synthesis. The invention also extends to any tautomeric forms and mixtures thereof.
In one embodiment, the compounds of formula (I) are trans isomers.
In another embodiment, the compounds of formula (I) are cis isomers.
Mixtures of cis- and trans-compounds, or compounds in which the cis/trans conformation have not been determined, are drawn herein as shown below:
Compounds according to the invention include those specifically exemplified in the Examples section and named hereinafter including, without limitation:—
Further example compounds include:
It will be appreciated by those skilled in the art that certain protected derivatives of compounds of formula (I), which may be made prior to a final deprotection stage, may not possess pharmacological activity as such, but may, in certain instances, be administered orally or parenterally and thereafter metabolised in the body to form compounds of the invention which are pharmacologically active. Such derivatives may therefore be described as “prodrugs”. Further, certain compounds of the invention may act as prodrugs of other compounds of the invention. All protected derivatives and prodrugs of compounds of the invention are included within the scope of the invention. Examples of suitable protecting groups for the compounds of the present invention are described in Drugs of Today, Volume 19, Number 9, 1983, pp 499-538 and in Topics in Chemistry, Chapter 31, pp 306-316 and in “Design of Prodrugs” by H. Bundgaard, Elsevier, 1985, Chapter 1 (the disclosures in which documents are incorporated herein by reference). It will further be appreciated by those skilled in the art, that certain moieties, known to those skilled in the art as “pro-moieties”, for example as described by H. Bundgaard in “Design of Prodrugs” (the disclosure in which document is incorporated herein by reference) may be placed on appropriate functionalities when such functionalities are present within compounds of the invention. Suitable prodrugs for compounds of the invention include: esters, carbonate esters, hemi-esters, phosphate esters, nitro esters, sulfate esters, sulfoxides, amides, carbamates, azo-compounds, phosphamides, glycosides, ethers, acetals and ketals.
In a further aspect, the invention provides a general process (A1) for preparing compounds of formula (I) in which Q=H, which process comprises:
coupling a compound of formula (II)
with a compound of formula (III)
wherein
R5′ is a group R5 as previously defined, or a group convertible to R5, R6′ is a group R6 as previously defined, or a group convertible to R6, and R′ is a group R as previously defined, or a group convertible to R.
The reaction is carried out under conditions suitable for reductive alkylation. The reductive alkylation reaction is typically carried out using sodium triacetoxyborohydride in dichloroethane, optionally in the presence of triethylamine, and optionally in the presence of titanium tetraisopropoxide. Alternatively sodium cyanoborohydride can be used as the reducing reagent in solvents such as methanol or ethanol, or the reductive alkylation can be effected under catalytic hydrogenation conditions using a palladium catalyst. In a further variation, the compounds (II) and (III) can be condensed under dehydrating conditions e.g. molecular sieves or magnesium sulfate, and the resultant imine or enamine reduced using for example sodium borohydride or by catalytic hydrogenation. This reaction can generate a mixture of cis and trans isomers which can be separated by chromatography or crystallisation.
A modification of general process (A1) is required where Q is C1-6 alkyl. Thus, in general process (A2), a compound of formula (II) can be reacted with a compound of formula (III) in the presence of a source of cyanide, e.g. acetone cyanohydrin, to form the cyano intermediate (XXXX) which can be reacted with an alkyl Grignard reagent QMgX to form compounds of formula (I) in which Q is C1-6 alkyl.
wherein
R5′ is a group R5 as previously defined, or a group convertible to R5, R6′ is a group R6 as previously defined, or a group convertible to R6, and R′ is a group R as previously defined, or a group convertible to R, Q is C1-6 alkyl, and X is bromo or iodo or chloro.
This reaction can generate a mixture of cis and trans isomers which can be separated by chromatography or crystallisation.
In a further aspect, the invention provides a general process (B) for preparing compounds of formula (I) which process comprises:
coupling a compound of formula (IV)
with a compound of formula (V)
wherein R5′ is a group R5 as previously defined, or a group convertible to R5, R6′ is a group R6 as previously defined, or a group convertible to R6, R′ is a group R as previously defined, or a group convertible to R, Q is as previously defined, and X and Y both represent leaving groups. X and Y can be the same or different and examples are Cl, PhO, EtO, imidazole. When X and Y are both Cl, i.e. phosgene, this reagent can be generated in situ e.g. from diphosgene or triphosgene.
The above reaction is carried out using standard methodology e.g. reacting the diamine (IV) with the reagent (V) in an inert solvent for example dichloromethane or toluene, optionally in the presence of a base such as triethylamine or potassium carbonate, and optionally with heating.
It will be appreciated that compounds of formula (IV) can be pure cis or trans isomers, or a mixture of isomers. If necessary, separation of pure cis and trans isomers after the reaction with (V) can be achieved by chromatography or crystallisation.
In a further aspect, the invention provides a general process (C) for preparing compounds of formula (I) which process comprises:
treatment of a compound of formula (VI)
with a palladium or copper catalyst (VII) to effect an intramolecular cyclisation
wherein R5′ is a group R5 as previously defined, or a group convertible to R5, R6′ is a group R6 as previously defined, or a group convertible to R6, R′ is a group R as previously defined, or a group convertible to R, Q is as previously defined, and Z is a leaving group such as bromo, iodo, chloro or triflate.
The cyclisation reaction can be carried out using a variety of palladium or copper reagents as described in the literature (JACS, 2003, 125, 6653, Tet. Lett., 2004, 45, 8535, or JACS, 2002, 124, 7421.)
It will be appreciated that compounds of formula (VI) can be pure cis or trans isomers, or a mixture of isomers. If necessary, separation of pure cis and trans isomers after the intramolecular cyclisation can be achieved by chromatography or crystallisation.
In a further aspect, the invention provides a general process (D) for preparing compounds of formula (I) which process comprises:
coupling a compound of formula (VIII)
with a compound of formula (IX)
wherein R5′ is a group R5 as previously defined, or a group convertible to R5, R6′ is a group R6 as previously defined, or a group convertible to R6, R′ is a group R as previously defined, or a group convertible to R, Q is as previously defined, and Ra is a C1-5 alkyl group.
The condensation and cyclisation reactions can be carried out under reaction conditions similar to those described in the literature for an analogous process (U.S. Pat. No. 3,161,645) (for example heating in an inert solvent such as xylene) followed by reduction of the piperidine double bond using for example catalytic hydrogenation over palladium or Raney nickel.
It will be appreciated that compounds of formula (IX) can be pure cis or trans isomers, or a mixture of isomers. If necessary, separation of pure cis and trans isomers after the intramolecular cyclisation can be achieved by chromatography or crystallisation.
In a further aspect, the invention provides a general process (E) for preparing compounds of formula (I) which process comprises:
reaction of a compound of formula (X)
with diphenylphosphoryl azide or other reagent/combination of reagents to effect the Curtius rearrangement of compound (X), followed by intramolecular cyclisation.
wherein R5′ is a group R5 as previously defined, or a group convertible to R5, R6′ is a group R6 as previously defined, or a group convertible to R6, R′ is a group R as previously defined, or a group convertible to R, and Q is as previously defined.
The Curtius rearrangement is typically carried out by mixing the two reactants in an inert solvent such as toluene, optionally with heating.
It will be appreciated that compounds of formula (X) can be pure cis or trans isomers, or a mixture of isomers. If necessary, separation of pure cis and trans isomers after the intramolecular cyclisation can be achieved by chromatography or crystallisation.
In a further aspect, the invention provides a general process (F) for preparing compounds of formula (I) which process comprises:
coupling a compound of formula (XI)
with a compound of formula (XII)
wherein R5′ is a group R5 as previously defined, or a group convertible to R5, R6′ is a group R6 as previously defined, or a group convertible to R6, R′ is a group R as previously defined, or a group convertible to R, Q is as previously defined, and Z is hydroxy or a leaving group such as chloro, bromo or iodo, or alkyl/aryl sulfonate.
The alkylation reaction can be carried out under classical alkylation (Z=a leaving group) or Mitsunobu reaction (Z=OH) conditions. Using classical alkylation conditions, the benzimidazolone intermediate (XI) can be deprotonated using a base such as sodium hydride in an inert solvent such as dimethylformamide, and then treated with the alkylating reagent (XII), optionally with heating. The Mitsunobu reaction with (XII) Z=OH can be carried out using standard conditions e.g. triphenylphosphine and diethylazodicarboxylate in an inert solvent such as dichloromethane or tetrahydrofuran at room temperature.
It will be appreciated that compounds of formula (X) can be pure cis or trans isomers, or a mixture of isomers. If necessary, separation of pure cis and trans isomers after the intramolecular cyclisation can be achieved by chromatography or crystallisation.
Conversion of R6′ to R6 or interconversions of R6 may be accomplished as indicated below.
For example, when R6′ is a halogen, it can be converted to an alkoxy or trifluoromethyl group by copper catalysed reaction, using an alcohol, or methyl fluorosulfonyl(difluoro)acetate, respectively. It may also be converted to an alkyl group with an organometallic reagent, for example an alkylstannane.
As another example, when R6′ is hydroxy, it may be converted to alkoxy by reaction with an alkyl halide or sulfonate, or to trifluoromethoxy by conversion to the xanthate followed by oxidation in the presence of fluoride ion.
As a further example, when R6′ is methyl, it may be converted to trifluoromethyl by chlorination or bromination followed by displacement of the introduced halogens with fluoride.
Similarly, conversion of R5′ to R5 or interconversions of R5 may be accomplished as described for R6.
Conversion of R′ to R or interconversions of R may be accomplished as indicated below. For example when R′ is benzyl, the benzyl group can be removed using standard methodology, e.g. catalytic hydrogenation over palladium on carbon, to provide the alcohol. Alkylation of the resultant alcohol using a strong base e.g. sodium hydride and a C1-6 alkylating agent e.g. methyl iodide or ethyl iodide or propyl iodide, will afford the desired product. It will be appreciated that protection of any NH functionality present in the molecule may be necessary
As another example, when R is methyl, the methyl group can be removed by treatment with a dealkylating agent such as boron tribromide to afford the alcohol intermediate, which can be alkylated in a similar manner to that described above.
Compounds of formula (II) are generally known in the literature or can be prepared by a range of different processes for example:
(a) displacement of an ortho-fluoro or ortho-chloro nitrobenzene intermediate (XIII) with the amine (XIV), wherein R5′ is a group R5 as previously defined, or a group convertible to R5, R6′ is a group R6 as previously defined, or a group convertible to R6, and P represents a nitrogen protecting group e.g. Boc, acetyl, trifluoroacetyl, ethoxycarbonyl, benzyloxycarbonyl, to give (XXIII), followed by reduction of the nitro group, cyclisation using phosgene or a phosgene equivalent, and deprotection of the piperidine nitrogen using standard literature conditions (Scheme 1).
Compounds of formula (XIII) are commercially available or can be prepared by standard methodology. The compound (XIV) in which P=Boc is commercially available
(b) metal catalysed cyclisation of an intermediate (XV) followed by deprotection of the piperidine nitrogen, wherein R5′ is a group R5 as previously defined, or a group convertible to R5, R6′ is a group R6 as previously defined, or a group convertible to R6, P represents a nitrogen protecting group e.g. Boc, acetyl, trifluoroacetyl, benzyloxycarbonyl, and Z represents a leaving group such as bromo, iodo, chloro or triflate. Reaction conditions for the metal catalysed cyclisation are summarised in Process C. The urea (XV) can be prepared using any of the classical methods for urea formation as illustrated in Scheme 2. The starting materials for this process are commercially available or can be prepared using standard methodology.
(c) Curtius rearrangement of an intermediate (XVI), wherein R5′ is a group R5 as previously defined, or a group convertible to R5, R6′ is a group R6 as previously defined, or a group convertible to R6, P represents a nitrogen protecting group e.g. Boc, acetyl, trifluoroacetyl, benzyloxycarbonyl, and Rb represents H or a C1-5 alkyl group e.g. methyl or ethyl, followed by intramolecular cyclisation and deprotection of the piperidine nitrogen (Scheme 3). The anthranilic acid or ester starting materials (XVII) are commercially available or can be made by standard methodology. The piperidone starting material (P=Boc or benzyl) is commercially available. The Curtius rearrangement can be effected using the conditions described under process E.
(d) Condensation of an orthophenylenediamine (VIII) with a 3-alkoxycarbonyl-4-piperidone (XX), wherein R5′ is a group R5 as previously defined, or a group convertible to R5, R6′ is a group R6 as previously defined, or a group convertible to R6, P represents a nitrogen protecting group e.g. Boc, acetyl, trifluoroacetyl, benzyloxycarbonyl and Rb is a C1-5 alkyl group (Scheme 4), by heating in an inert solvent at elevated temperature, to afford the tetrahydropyridine intermediate (XXI). Hydrogenation of the double bond and deprotection of the piperidine nitrogen can be accomplished separately or concomitantly dependent on the precise nature of the protecting group P, to afford the desired product (II). Compounds of formula (VIII) are commercially available or can be prepared by standard methodology. Compounds of formula (XX) are commercially available or can be prepared by standard methodology.
(e) Reductive alkylation of an ortho nitroaniline (XXII) with an N-protected 4-piperidone (XVIII), wherein R5′ is a group R5 as previously defined, or a group convertible to R5, R6′ is a group R6 as previously defined, or a group convertible to R6, and P represents a nitrogen protecting group e.g. Boc, acetyl, trifluoroacetyl, benzyloxycarbonyl, using for example sodium triacetoxyborohydride to give the intermediate (XXIII). Reduction of the nitro group, followed by cyclisation and deprotection as described hereinbefore provides the desired product (II) (Scheme 5). Compounds of formula (XXII) and (XVIII) are commercially available or can be prepared by standard methodology
(f) metal catalysed reaction between the amine (XIV) and a suitably substituted nitrobenzene compound (XXIV) wherein R5′ is a group R5 as previously defined, or a group convertible to R5, R6′ is a group R6 as previously defined, or a group convertible to R6, P represents a nitrogen protecting group e.g. Boc, acetyl, trifluoroacetyl, benzyloxycarbonyl, and Z represents a leaving group such as bromo, iodo, chloro or triflate (Scheme 6). This process generates intermediates of formula (XXIII) and subsequent reactions are similar to that for Scheme 5. Compounds of formula (XXIV) are commercially available or can be prepared by known methodology. The compound (XIV) in which P=Boc is commercially available
(g) metal catalysed reaction between the amine (XIV) and the protected aniline (XXV), wherein R5′ is a group R5 as previously defined, or a group convertible to R5, R6′ is a group R6 as previously defined, or a group convertible to R6, P and P′ independently represent a nitrogen protecting group e.g. Boc, acetyl, trifluoroacetyl, benzyloxycarbonyl, and Z represents a leaving group such as bromo, iodo, chloro or triflate, to give the intermediate (XXVI) (Scheme 7). Deprotection of the aniline followed by the same reaction sequence as in Scheme 6 affords the desired intermediate (II). Compounds of formula (XXV) are commercially available or can be prepared by known methodology e.g. halogenation ortho to the optionally protected aniline group. The compound (XIV) in which P=Boc is commercially available.
The compounds of formula (III) can be prepared by standard literature methodology.
Compounds of formula (IV) can be prepared by a number of different processes e.g.
(h) displacement of an ortho-fluoro or ortho-chloro nitrobenzene intermediate (XIII) with the amine (XXVII) wherein R5′ is a group R5 as previously defined, or a group convertible to R5, R6′ is a group R6 as previously defined, or a group convertible to R6, R′ is a group R as previously defined, or a group convertible to R, and Q is as previously defined, to afford compound (XXVIII) followed by reduction of the nitro group using standard conditions e.g. hydrogenation over palladium or Raney nickel (Scheme 8). Compounds of formula (XIII) are commercially available or can be prepared by standard methodology. It will be appreciated that separation of the cis and trans isomers can be achieved at any suitable stage in the synthesis.
(i) metal catalysed reaction of the amine (XXVII) with the ortho substituted nitrobenzene (XXIX), wherein R5′ is a group R5 as previously defined, or a group convertible to R5, R6′ is a group R6 as previously defined, or a group convertible to R6, R′ is a group R as previously defined, or a group convertible to R, and Q is as previously defined, to afford compound (XXVIII) (Scheme 9) followed by the same reactions as illustrated in Scheme 8. Compounds of formula (XXIX) are commercially available or can be prepared by standard methodology. It will be appreciated that separation of the cis and trans isomers can be achieved at any suitable stage in the synthesis.
(j) metal catalysed reaction of the amine (XXVII) with the protected aniline derivative (XXV), wherein R5′ is a group R5 as previously defined, or a group convertible to R5, R6′ is a group R6 as previously defined, or a group convertible to R6, R′ is a group R as previously defined, or a group convertible to R, and Q is as previously defined, and P′ represents a nitrogen protecting group such as acetyl, trifluoroacetyl, Boc, phthalimide, to afford compound (XXXI) (Scheme 10) followed by deprotection of the aniline group. Compounds of formula (XXV) are commercially available or can be prepared by standard methodology. It will be appreciated that separation of the cis and trans isomers can be achieved at any suitable stage in the synthesis.
(k) Reductive alkylation of an ortho nitroaniline (XXII) with the piperidone (XXXII) wherein R5′ is a group R5 as previously defined, or a group convertible to R5, R6′ is a group R6 as previously defined, or a group convertible to R6, R′ is a group R as previously defined, or a group convertible to R, and Q is as previously defined, using for example sodium triacetoxyborohydride in dichloroethane to give the intermediate (XXVIII) (Scheme 11). Reduction of the nitro group using, for example, palladium on carbon or Raney nickel affords the desired intermediate (IV). It will be appreciated that separation of the cis and trans isomers can be achieved at any suitable stage in the synthesis.
Compounds of formula (V) are commercially available e.g. carbonyl diimidazole, phosgene, phosgene solution in toluene, diphosgene, triphosgene, phenyl chloroformate, diethyl carbonate.
Compounds of formula (VI) can be prepared by a variety of processes e.g. urea formation can be achieved as shown in Scheme 12 by
Both isocyanates can be prepared from the corresponding amines using standard methodology for isocyanate formation. It will be appreciated that separation of the cis and trans isomers can be achieved at any suitable stage in the synthesis.
Palladium and copper catalysts (VII) are commercially available or can be prepared as described in the literature (see references in Process C).
Compounds of formula (VIII) are commercially available or can be prepared by known literature routes e.g. reduction of a mono or dinitrobenzene precursor.
Compounds of formula (IX) can be prepared by reductive alkylation of the 3-alkoxycarbonyl-4-piperidone with cyclohexanone.
Compounds of formula (X) can be prepared as shown in Scheme 13. Reductive alkylation of an anthranilic acid or ester (XVII) with the ketone (XXXII), followed if appropriate by hydrolysis of the ester group. It will be appreciated that separation of the cis and trans isomers can be achieved at any suitable stage in the synthesis.
Compounds of formula (XI) are commercially available or can be prepared by literature processes.
Compounds of formula (XII) where Q=H can be prepared as shown in Scheme 14, by reductive alkylation of (XXXVII) where Z′ represents Z or a group convertible to Z with the ketone (III). Conversion of a Z′ hydroxy group to Z=chloro or bromo can be accomplished using standard methodology e.g. treatment with thionyl chloride or triphenylphosphine/carbon tetrabromide. It will be appreciated that separation of the cis and trans isomers can be achieved at any suitable stage in the synthesis.
The compound (XXVII) where Q=H can be prepared as shown in Scheme 15. Reductive alkylation of the commercially available amine (XXXVIII) with cyclohexanone (III) using for example sodium triacetoxyborohydride in dichloroethane provides the intermediate (XXXIX) which is deprotected using HCl in ethanol or trifluoroacetic acid to afford the primary amine (XXVII). It will be appreciated that separation of the cis and trans isomers can be achieved at any suitable stage in the synthesis.
The compound (XXVII) where Q=alkyl can be prepared as in process A2, followed by deprotection.
Compounds of the present invention are M1 receptor agonists. Selective M1 receptor agonists are said to be useful to ameliorate positive and cognitive symptoms of psychotic disorders such as schizophrenia, schizo-affective disorders, schizophreniform diseases, psychotic depression, mania, acute mania, paranoid and delusional disorders, and cognitive impairment including memory disorders such as Alzheimer's disease without peripheral cholinergic side effects mediated predominantly through M2 and M3 receptors. M1 receptor agonists may also be suitable for combination with other typical and atypical antipsychotics and other actives such as mood stabilisers, antidepressants, anxiolytics, drugs for extrapyrimidal side effects and cognitive enhancers, to provide improved treatment of psychotic disorders.
Thus in a further aspect, the invention provides a compound of formula (I) as hereinbefore described or a salt or solvate thereof for use in therapy.
In another aspect, the invention provides a compound of formula (I) or a salt or solvate thereof for use in the treatment of a condition which requires agonism of a muscarinic M1 receptor.
The terms describing the indications used herein are classified in the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, published by the American Psychiatric Association (DSM-IV) and/or the International Classification of Diseases, 10th Edition (ICD-10). The various subtypes of the disorders mentioned herein are contemplated as part of the present invention. Numbers in brackets after the listed diseases below refer to the classification code in DSM-IV.
Within the context of the present invention, the term psychotic disorder includes Schizophrenia including the subtypes Paranoid Type (295.30), Disorganised Type (295.10), Catatonic Type (295.20), Undifferentiated Type (295.90) and Residual Type (295.60); Schizophreniform Disorder (295.40); Schizoaffective Disorder (295.70) including the subtypes Bipolar Type and Depressive Type; Delusional Disorder (297.1) including the subtypes Erotomanic Type, Grandiose Type, Jealous Type, Persecutory Type, Somatic Type, Mixed Type and Unspecified Type; Brief Psychotic Disorder (298.8); Shared Psychotic Disorder (297.3); Psychotic Disorder Due to a General Medical Condition including the subtypes With Delusions and With Hallucinations; Substance-Induced Psychotic Disorder including the subtypes With Delusions (293.81) and With Hallucinations (293.82); and Psychotic Disorder Not Otherwise Specified (298.9);
Other conditions the treatment of which require agonism of a muscarinic M1 receptor include:
Depression and mood disorders including Major Depressive Episode, Manic Episode, Mixed Episode and Hypomanic Episode; Depressive Disorders including Major Depressive Disorder, Dysthymic Disorder (300.4), Depressive Disorder Not Otherwise Specified (311); Bipolar Disorders including Bipolar I Disorder, Bipolar II Disorder (Recurrent Major Depressive Episodes with Hypomanic Episodes) (296.89), Cyclothymic Disorder (301.13) and Bipolar Disorder Not Otherwise Specified (296.80); Other Mood Disorders including Mood Disorder Due to a General Medical Condition (293.83) which includes the subtypes With Depressive Features, With Major Depressive-like Episode, With Manic Features and With Mixed Features), Substance-Induced Mood Disorder (including the subtypes With Depressive Features, With Manic Features and With Mixed Features) and Mood Disorder Not Otherwise Specified (296.90);
Anxiety disorders including Social Anxiety Disorder, Panic Attack, Agoraphobia, Panic Disorder, Agoraphobia Without History of Panic Disorder (300.22), Specific Phobia (300.29) including the subtypes Animal Type, Natural Environment Type, Blood-Injection-Injury Type, Situational Type and Other Type), Social Phobia (300.23), Obsessive-Compulsive Disorder (300.3), Posttraumatic Stress Disorder (309.81), Acute Stress Disorder (308.3), Generalized Anxiety Disorder (300.02), Anxiety Disorder Due to a General Medical Condition (293.84), Substance-Induced Anxiety Disorder and Anxiety Disorder Not Otherwise Specified (300.00); Substance-related disorders including Substance Use Disorders such as Substance Dependence, Substance Craving and Substance Abuse; Substance-Induced Disorders such as Substance Intoxication, Substance Withdrawal, Substance-Induced Delirium, Substance-Induced Persisting Dementia, Substance-Induced Persisting Amnestic Disorder, Substance-Induced Psychotic Disorder, Substance-Induced Mood Disorder, Substance-Induced Anxiety Disorder, Substance-Induced Sexual Dysfunction, Substance-Induced Sleep Disorder and Hallucinogen Persisting Perception Disorder (Flashbacks); Alcohol-Related Disorders such as Alcohol Dependence (303.90), Alcohol Abuse (305.00), Alcohol Intoxication (303.00), Alcohol Withdrawal (291.81), Alcohol Intoxication Delirium, Alcohol Withdrawal Delirium, Alcohol-Induced Persisting Dementia, Alcohol-Induced Persisting Amnestic Disorder, Alcohol-Induced Psychotic Disorder, Alcohol-Induced Mood Disorder, Alcohol-Induced Anxiety Disorder, Alcohol-Induced Sexual Dysfunction, Alcohol-Induced Sleep Disorder and Alcohol-Related Disorder Not Otherwise Specified (291.9); Amphetamine (or Amphetamine-Like)-Related Disorders such as Amphetamine Dependence (304.40), Amphetamine Abuse (305.70), Amphetamine Intoxication (292.89), Amphetamine Withdrawal (292.0), Amphetamine Intoxication Delirium, Amphetamine Induced Psychotic Disorder, Amphetamine-Induced Mood Disorder, Amphetamine-Induced Anxiety Disorder, Amphetamine-Induced Sexual Dysfunction, Amphetamine-Induced Sleep Disorder and Amphetamine-Related Disorder Not Otherwise Specified (292.9); Caffeine Related Disorders such as Caffeine Intoxication (305.90), Caffeine-Induced Anxiety Disorder, Caffeine-Induced Sleep Disorder and Caffeine-Related Disorder Not Otherwise Specified (292.9); Cannabis-Related Disorders such as Cannabis Dependence (304.30), Cannabis Abuse (305.20), Cannabis Intoxication (292.89), Cannabis Intoxication Delirium, Cannabis-Induced Psychotic Disorder, Cannabis-Induced Anxiety Disorder and Cannabis-Related Disorder Not Otherwise Specified (292.9); Cocaine-Related Disorders such as Cocaine Dependence (304.20), Cocaine Abuse (305.60), Cocaine Intoxication (292.89), Cocaine Withdrawal (292.0), Cocaine Intoxication Delirium, Cocaine-Induced Psychotic Disorder, Cocaine-Induced Mood Disorder, Cocaine-Induced Anxiety Disorder, Cocaine-Induced Sexual Dysfunction, Cocaine-Induced Sleep Disorder and Cocaine-Related Disorder Not Otherwise Specified (292.9); Hallucinogen-Related Disorders such as Hallucinogen Dependence (304.50), Hallucinogen Abuse (305.30), Hallucinogen Intoxication (292.89), Hallucinogen Persisting Perception Disorder (Flashbacks) (292.89), Hallucinogen Intoxication Delirium, Hallucinogen-Induced Psychotic Disorder, Hallucinogen-Induced Mood Disorder, Hallucinogen-Induced Anxiety Disorder and Hallucinogen-Related Disorder Not Otherwise Specified (292.9); Inhalant-Related Disorders such as Inhalant Dependence (304.60), Inhalant Abuse (305.90), Inhalant Intoxication (292.89), Inhalant Intoxication Delirium, Inhalant-Induced Persisting Dementia, Inhalant-Induced Psychotic Disorder, Inhalant-Induced Mood Disorder, Inhalant-Induced Anxiety Disorder and Inhalant-Related Disorder Not Otherwise Specified (292.9); Nicotine-Related Disorders such as Nicotine Dependence (305.1), Nicotine Withdrawal (292.0) and Nicotine-Related Disorder Not Otherwise Specified (292.9); Opioid-Related Disorders such as Opioid Dependence (304.00), Opioid Abuse (305.50), Opioid Intoxication (292.89), Opioid Withdrawal (292.0), Opioid Intoxication Delirium, Opioid-Induced Psychotic Disorder, Opioid-Induced Mood Disorder, Opioid-Induced Sexual Dysfunction, Opioid-Induced Sleep Disorder and Opioid-Related Disorder Not Otherwise Specified (292.9); Phencyclidine (or Phencyclidine-Like)-Related Disorders such as Phencyclidine Dependence (304.60), Phencyclidine Abuse (305.90), Phencyclidine Intoxication (292.89), Phencyclidine Intoxication Delirium, Phencyclidine-Induced Psychotic Disorder, Phencyclidine-Induced Mood Disorder, Phencyclidine-Induced Anxiety Disorder and Phencyclidine-Related Disorder Not Otherwise Specified (292.9); Sedative-, Hypnotic-, or Anxiolytic-Related Disorders such as Sedative, Hypnotic, or Anxiolytic Dependence (304.10), Sedative, Hypnotic, or Anxiolytic Abuse (305.40), Sedative, Hypnotic, or Anxiolytic Intoxication (292.89), Sedative, Hypnotic, or Anxiolytic Withdrawal (292.0), Sedative, Hypnotic, or Anxiolytic Intoxication Delirium, Sedative, Hypnotic, or Anxiolytic Withdrawal Delirium, Sedative-, Hypnotic-, or Anxiolytic-Persisting Dementia, Sedative-, Hypnotic-, or Anxiolytic-Persisting Amnestic Disorder, Sedative-, Hypnotic-, or Anxiolytic-Induced Psychotic Disorder, Sedative-, Hypnotic-, or Anxiolytic-Induced Mood Disorder, Sedative-, Hypnotic-, or Anxiolytic-Induced Anxiety Disorder Sedative-, Hypnotic-, or Anxiolytic-Induced Sexual Dysfunction, Sedative-, Hypnotic-, or Anxiolytic-Induced Sleep Disorder and Sedative-, Hypnotic-, or Anxiolytic-Related Disorder Not Otherwise Specified (292.9); Polysubstance-Related Disorder such as Polysubstance Dependence (304.80); and Other (or Unknown) Substance-Related Disorders such as Anabolic Steroids, Nitrate Inhalants and Nitrous Oxide;
Sleep disorders including primary sleep disorders such as Dyssomnias such as Primary Insomnia (307.42), Primary Hypersomnia (307.44), Narcolepsy (347), Breathing-Related Sleep Disorders (780.59), Circadian Rhythm Sleep Disorder (307.45) and Dyssomnia Not Otherwise Specified (307.47); primary sleep disorders such as Parasomnias such as Nightmare Disorder (307.47), Sleep Terror Disorder (307.46), Sleepwalking Disorder (307.46) and Parasomnia Not Otherwise Specified (307.47); Sleep Disorders Related to Another Mental Disorder such as Insomnia Related to Another Mental Disorder (307.42) and Hypersomnia Related to Another Mental Disorder (307.44); Sleep Disorder Due to a General Medical Condition; and Substance-Induced Sleep Disorder including the subtypes Insomnia Type, Hypersomnia Type, Parasomnia Type and Mixed Type;
Eating disorders such as Anorexia Nervosa (307.1) including the subtypes Restricting Type and Binge-Eating/Purging Type; Bulimia Nervosa (307.51) including the subtypes Purging Type and Nonpurging Type; Obesity; Compulsive Eating Disorder; and Eating Disorder Not Otherwise Specified (307.50);
Autistic Disorder (299.00); Attention-Deficit/Hyperactivity Disorder including the subtypes Attention-Deficit/Hyperactivity Disorder Combined Type (314.01), Attention-Deficit/Hyperactivity Disorder Predominantly Inattentive Type (314.00), Attention-Deficit/Hyperactivity Disorder Hyperactive-Impulse Type (314.01) and Attention-Deficit/Hyperactivity Disorder Not Otherwise Specified (314.9); Hyperkinetic Disorder; Disruptive Behaviour Disorders such as Conduct Disorder including the subtypes childhood-onset type (321.81), Adolescent-Onset Type (312.82) and Unspecified Onset (312.89), Oppositional Defiant Disorder (313.81) and Disruptive Behaviour Disorder Not Otherwise Specified; and Tic Disorders such as Tourette's Disorder (307.23);
Personality Disorders including the subtypes Paranoid Personality Disorder (301.0), Schizoid Personality Disorder (301.20), Schizotypal Personality Disorder (301.22), Antisocial Personality Disorder (301.7), Borderline Personality Disorder (301.83), Histrionic Personality Disorder (301.50), Narcissistic Personality Disorder (301.81), Avoidant Personality Disorder (301.82), Dependent Personality Disorder (301.6), Obsessive-Compulsive Personality Disorder (301.4) and Personality Disorder Not Otherwise Specified (301.9); and
Sexual dysfunctions including Sexual Desire Disorders such as Hypoactive Sexual Desire Disorder (302.71), and Sexual Aversion Disorder (302.79); sexual arousal disorders such as Female Sexual Arousal Disorder (302.72) and Male Erectile Disorder (302.72); orgasmic disorders such as Female Orgasmic Disorder (302.73), Male Orgasmic Disorder (302.74) and Premature Ejaculation (302.75); sexual pain disorder such as Dyspareunia (302.76) and Vaginismus (306.51); Sexual Dysfunction Not Otherwise Specified (302.70); paraphilias such as Exhibitionism (302.4), Fetishism (302.81), Frotteurism (302.89), Pedophilia (302.2), Sexual Masochism (302.83), Sexual Sadism (302.84), Transvestic Fetishism (302.3), Voyeurism (302.82) and Paraphilia Not Otherwise Specified (302.9); gender identity disorders such as Gender Identity Disorder in Children (302.6) and Gender Identity Disorder in Adolescents or Adults (302.85); and Sexual Disorder Not Otherwise Specified (302.9).
The compounds of formula (I) may also be useful for the enhancement of cognition, including both the treatment of cognitive impairment on its own and the treatment of cognition impairment in other diseases such as schizophrenia, bipolar disorder, depression, other psychiatric disorders and psychotic conditions associated with cognitive impairment.
Within the context of the present invention, the term cognitive impairment includes, for example, impairment of cognitive functions including attention, orientation, learning disorders, memory (i.e. memory disorders, amnesia, amnesic disorders, transient global amnesia syndrome and age-associated memory impairment) and language function; cognitive impairment as a result of stroke, Alzheimer's disease, Huntington's disease, Pick disease, Aids-related dementia or other dementia states such as Multiinfarct dementia, alcoholic dementia, hypotiroidism-related dementia, and dementia associated to other degenerative disorders such as cerebellar atrophy and amyotropic lateral sclerosis; other acute or sub-acute conditions that may cause cognitive decline such as delirium or depression (pseudodementia states) trauma, head trauma, age related cognitive decline, stroke, neurodegeneration, drug-induced states, neurotoxic agents, mild cognitive impairment, age related cognitive impairment, autism related cognitive impairment, Down's syndrome, cognitive deficit related to psychosis, and post-electroconvulsive treatment related cognitive disorders; and dyskinetic disorders such as Parkinson's disease, neuroleptic-induced parkinsonism, and tardive dyskinesias.
The therapy of the present invention may also be used as a memory and/or cognition enhancer in healthy humans with no cognitive and/or memory deficit.
In another aspect, the invention provides a compound of formula (I) as hereinbefore described or a salt or solvate thereof for use in the treatment of a psychotic disorder. In one embodiment, the invention provides a compound of formula (I) as hereinbefore described or a salt or solvate thereof for use in the treatment of schizophrenia.
The invention also provides a compound of formula (I) as hereinbefore described or a salt or solvate thereof for use in the treatment of cognitive impairment.
In another aspect, the invention provides the use of a compound of formula (I) as hereinbefore described or a salt or solvate thereof in the manufacture of a medicament for the treatment of a condition which requires agonism of a muscarinic M1 receptor.
In another aspect, the invention provides the use of a compound of formula (I) as hereinbefore described or a salt or solvate thereof in the manufacture of a medicament for the treatment of a psychotic disorder. In one embodiment, the invention provides the use of a compound of formula (I) as hereinbefore described or a salt or solvate thereof in the manufacture of a medicament for the treatment of schizophrenia.
The invention also provides the use of a compound of formula (I) as hereinbefore described or a salt or solvate thereof in the manufacture of a medicament for the treatment of cognitive impairment.
In another aspect, the invention provides a method of treating a condition which requires agonism of a muscarinic M1 receptor, which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I) as hereinbefore described or a salt or solvate thereof. In one embodiment, the mammal is a human.
In another aspect, the invention provides a method of treating a psychotic disorder which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I) as hereinbefore described or a salt or solvate thereof. In one embodiment, the invention provides a method of treating schizophrenia, which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I) as hereinbefore described or a salt or solvate thereof. In one embodiment, the mammal is a human.
The invention also provides a method of treating cognitive impairment, which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I) as hereinbefore described or a salt or solvate thereof. In one embodiment, the mammal is a human.
The compounds of formula (I) and their salts and solvates thereof may alsbo be suitable for combination with other actives, such as typical and atypical antipsychotics, mood stabilisers, antidepressants, anxiolytics, drugs for extrapyrimidal side effects and cognitive enhancers to provide improved treatment of psychotic disorders.
The combination therapies of the invention are, for example, administered adjunctively. By adjunctive administration is meant the coterminous or overlapping administration of each of the components in the form of separate pharmaceutical compositions or devices. This regime of therapeutic administration of two or more therapeutic agents is referred to generally by those skilled in the art and herein as adjunctive therapeutic administration; it is also known as add-on therapeutic administration. Any and all treatment regimes in which a patient receives separate but coterminous or overlapping therapeutic administration of the compounds of formula (I) or a salt or solvate thereof and at least one antipsychotic agent, a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects or a cognitive enhancer are within the scope of the current invention. In one embodiment of adjunctive therapeutic administration as described herein, a patient is typically stabilised on a therapeutic administration of one or more of the components for a period of time and then receives administration of another component. The compounds of formula (I) or a salt or solvate thereof may be administered as adjunctive therapeutic treatment to patients who are receiving administration of at least one antipsychotic agent, a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects or a cognitive enhancer, but the scope of the invention also includes the adjunctive therapeutic administration of at least one antipsychotic agent, a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects or a cognitive enhancer to patients who are receiving administration of compounds of formula (I) or a salt or solvate thereof.
The combination therapies of the invention may also be administered simultaneously. By simultaneous administration is meant a treatment regime wherein the individual components are administered together, either in the form of a single pharmaceutical composition or device comprising or containing both components, or as separate compositions or devices, each comprising one of the components, administered simultaneously. Such combinations of the separate individual components for simultaneous combination may be provided in the form of a kit-of-parts.
In a further aspect therefore, the invention provides a method of treatment of a psychotic disorder by adjunctive therapeutic administration of compounds of formula (I) or a salt or solvate thereof to a patient receiving therapeutic administration of at least one antipsychotic agent. In a further aspect, the invention provides the use of compounds of formula (I) or a salt or solvate thereof in the manufacture of a medicament for adjunctive therapeutic administration for the treatment of a psychotic disorder in a patient receiving therapeutic administration of at least one antipsychotic agent. The invention further provides compounds of formula (I) or a salt or solvate thereof for use for adjunctive therapeutic administration for the treatment of a psychotic disorder in a patient receiving therapeutic administration of at least one antipsychotic agent.
In a further aspect, the invention provides a method of treatment of a psychotic disorder by adjunctive therapeutic administration of at least one antipsychotic agent to a patient receiving therapeutic administration of compounds of formula (I) or a salt or solvate thereof. In a further aspect, the invention provides the use of at least one antipsychotic agent in the manufacture of a medicament for adjunctive therapeutic administration for the treatment of a psychotic disorder in a patient receiving therapeutic administration of compounds of formula (I) or a salt or solvate thereof. The invention further provides at least one antipsychotic agent for adjunctive therapeutic administration for the treatment of a psychotic disorder in a patient receiving therapeutic administration of compounds of formula (I) or a salt or solvate thereof.
In a further aspect, the invention provides a method of treatment of a psychotic disorder by simultaneous therapeutic administration of compounds of formula (I) or a salt or solvate thereof in combination with at least one antipsychotic agent. The invention further provides the use of a combination of compounds of formula (I) or a salt or solvate thereof and at least one antipsychotic agent in the manufacture of a medicament for simultaneous therapeutic administration in the treatment of a psychotic disorder. The invention further provides the use of compounds of formula (I) or a salt thereof in the manufacture of a medicament for simultaneous therapeutic administration with at least one antipsychotic agent in the treatment of a psychotic disorder. The invention further provides compounds of formula (I) or a salt thereof for use for simultaneous therapeutic administration with at least one antipsychotic agent in the treatment of a psychotic disorder. The invention further provides the use of at least one antipsychotic agent in the manufacture of a medicament for simultaneous therapeutic administration with compounds of formula (I) or a salt thereof in the treatment of a psychotic disorder.
In a further aspect, the invention provides a kit-of-parts for use in the treatment of a psychotic disorder comprising a first dosage form comprising compounds of formula (I) or a salt or solvate thereof and one or more further dosage forms each comprising a antipsychotic agent for simultaneous therapeutic administration.
In another aspect, the invention provides a method of treatment of a psychotic disorder by adjunctive therapeutic administration of a compound of the present invention to a patient receiving therapeutic administration of an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer.
In a further aspect, the invention provides the use of a compound of the present invention in the manufacture of a medicament for adjunctive therapeutic administration for the treatment of a psychotic disorder in a patient receiving therapeutic administration of an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer.
The invention also provides the use of a compound of the present invention in adjunctive therapeutic administration for the treatment of a psychotic disorder in a patient receiving therapeutic administration of an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer.
The invention further provides the use of a compound of the present invention for use for adjunctive therapeutic administration for the treatment of a psychotic disorder in a patient receiving therapeutic administration of an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer.
In a further aspect, the invention provides a method of treatment of a psychotic disorder by adjunctive therapeutic administration of an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer to a patient receiving therapeutic administration of a compound of the present invention.
In a further aspect, the invention provides the use of an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer in the manufacture of a medicament for adjunctive therapeutic administration for the treatment of a psychotic disorder in a patient receiving therapeutic administration of a compound of the present invention.
The invention also provides the use of an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer for adjunctive therapeutic administration for the treatment of a psychotic disorder in a patient receiving therapeutic administration of a compound of the present invention
In a further aspect, the invention provides a method of treatment of a psychotic disorder by simultaneous therapeutic administration of a compound of the present invention in combination with an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer.
The invention further provides the use of a combination of a compound of the present invention and an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer in the manufacture of a medicament for simultaneous therapeutic administration in the treatment of a psychotic disorder.
The invention further provides the use of a combination of a compound of the present invention and an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer for simultaneous therapeutic administration in the treatment of a psychotic disorder.
The invention further provides the use of a compound of the present invention in the manufacture of a medicament for simultaneous therapeutic administration with an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer in the treatment of a psychotic disorder.
The invention further provides the use of a compound of the present invention for simultaneous therapeutic administration with an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer in the treatment of a psychotic disorder.
The invention further provides a compound of the present invention for use for simultaneous therapeutic administration with an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer in the treatment of a psychotic disorder.
The invention further provides the use of an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer in the manufacture of a medicament for simultaneous therapeutic administration with a compound of the present invention in the treatment of a psychotic disorder.
The invention further provides the use of an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer for simultaneous therapeutic administration with a compound of the present invention in the treatment of a psychotic disorder.
In a further aspect, the invention provides a kit-of-parts for use in the treatment of a psychotic disorder comprising a first dosage form comprising a compound of the present invention and one or more further dosage forms each comprising an active ingredient selected from the group consisting of: a mood stabiliser, an antidepressant, an anxiolytic, a drug for extrapyrimidal side effects and a cognitive enhancer for simultaneous therapeutic administration.
In one embodiment, the patient is a human.
Examples of antipsychotic drugs that may be useful in the present invention include, but are not limited to: sodium channel blockers; mixed 5HT/dopamine receptor antagonists; mGluR5 positive modulators; D3 antagonists; 5HT6 angatonists; nicotinic alpha-7 modulators; glycine transporter GIyT1 inhibitors; D2 partial agonist/D3 antanogist/H3 antagonists; AMPA modulators; NK3 antagonists such as osanetant and talnetant; an atypical antipsychotic, for example clozapine, olanzapine, risperidone, quetiapine, aripirazole, ziprasidone and amisulpride; butyrophenones, such as haloperidol, pimozide, and droperidol; phenothiazines, such as chlorpromazine, thioridazine, mesoridazine, trifluoperazine, perphenazine, fluphenazine, thiflupromazine, prochlorperazine, and acetophenazine; thioxanthenes, such as thiothixene and chlorprothixene; thienobenzodiazepines; dibenzodiazepines; benzisoxazoles; dibenzothiazepines; imidazolidinones; benzisothiazolyl-piperazines; triazine such as lamotrigine; dibenzoxazepines, such as loxapine; dihydroindolones, such as molindone; aripiprazole; and derivatives thereof that have antipsychotic activity.
Examples of tradenames and suppliers of selected antipsychotic drugs that may be suitable for use in the present invention are as follows: clozapine (available under the tradename CLOZARIL®, from Mylan, Zenith Goldline, UDL, Novartis); olanzapine (available under the tradename ZYPREXA®, from Lilly; ziprasidone (available under the tradename GEODON®, from Pfizer); risperidone (available under the tradename RISPERDAL®, from Janssen); quetiapine fumarate (available under the tradename SEROQUEL®, from AstraZeneca); sertindole (available under the tradename SERLECT®); amisulpride (available under the tradename SOLION®, from Sanofi-Synthelabo); haloperidol (available under the tradename HALDOL®, from Ortho-McNeil); haloperidol decanoate (available under the tradename HALDOL Decanoate®); haloperidol lactate (available under the tradenames HALDOL® and INTENSOL®); chlorpromazine (available under the tradename THORAZINE®, from SmithKline Beecham (GSK); fluphenazine (available under the tradename PROLIXIN®, from Apothecon, Copley, Schering, Teva, and American Pharmaceutical Partners, Pasadena); fluphenazine decanoate (available under the tradename PROLIXIN Decanoate®); fluphenazine enanthate (available under the tradename PROLIXIN®); fluphenazine hydrochloride (available under the tradename PROLIXIN®); thiothixene (available under the tradename NAVANE®; from Pfizer); thiothixene hydrochloride (available under the tradename NAVANE®); trifluoperazine (10-[3-(4-methyl-1-piperazinyl)propyl]-2-(trifluoromethyl)phenothiazine dihydrochloride, available under the tradename STELAZINE®, from SmithKline Beckman; perphenazine (available under the tradename TRILAFON®; from Schering); perphenazine and amitriptyline hydrochloride (available under the tradename ETRAFON TRILAFON®); thioridazine (available under the tradename MELLARIL®; from Novartis, Roxane, HiTech, Teva, and Alpharma); molindone (available under the tradename MOBAN®, from Endo); molindone hydrochloride (available under the tradename MOBAN®); loxapine (available under the tradename LOXITANE®; from Watson); loxapine hydrochloride (available under the tradename LOXITANE®); and loxapine succinate (available under the tradename LOXITANE®). Furthermore, benperidol (Glianimon®), perazine (Taxilan®) or melperone (Eunerpan®)) may be used.
Other suitable antipsychotic drugs include promazine (available under the tradename SPARINE®), triflurpromazine (available under the tradename VESPRIN®), chlorprothixene (available under the tradename TARACTAN®), droperidol (available under the tradename INAPSINE®), acetophenazine (available under the tradename TINDAL®), prochlorperazine (available under the tradename COMPAZINE®), methotrimeprazine (available under the tradename NOZINAN®), pipotiazine (available under the tradename PIPOTRIL®), iloperidone, pimozide and flupenthixol.
The antipsychotic drugs listed above by Tradename may also be available from other suppliers under a different Tradename.
In one further aspect of the invention, suitable antipsychotic agents include olanzapine, risperidone, quetiapine, aripiprazole, haloperidol, clozapine, ziprasidone, talnetant and osanetant.
Mood stabilisers which may be used in the therapy of the present invention include lithium, sodium valproate/valproic acid/divalproex, carbamazepine, lamotrigine, gabapentin, topiramate, oxcarbazepine and tiagabine.
Antidepressant drugs which may be used in the therapy of the present invention include serotonin antagonists, CRF-1 antagonists, Cox-2 inhibitor/SSRI dual antagonists; dopamine/noradrenaline/serotonin triple reuptake inhibitors; NK1 antagonists; NK1 and NK2 dual antagonists; NK1/SSRI dual antagonists; NK2 antagonists; serotonin agonists (such as rauwolscine, yohimbine and metoclopramide); serotonin reuptake inhibitors (such as citalopram, escitalopram, fluoxetine, fluvoxamine, femoxetine, indalpine, zimeldine, paroxetine and sertraline); dual serotonin/noradrenaline reuptake inhibitors (such as venlafaxine, reboxetine, duloxetine and milnacipran); Noradrenaline reuptake inhibitors (such as reboxetine); tricyclic antidepressants (such as amitriptyline, clomipramine, imipramine, maprotiline, nortriptyline and trimipramine); monoamine oxidase inhibitors (such as isocarboxazide, moclobemide, phenelzine and tranylcypromine); 5HT3 antagonists (such as example ondansetron and granisetron); and others (such as bupropion, amineptine, radafaxine, mianserin, mirtazapine, nefazodone and trazodone).
Anxiolytics which may be used in the therapy of the present invention include V1b antagonists, 5HT7 antagonists and benzodiazepines such as alprazolam and lorazepam.
Drugs for extrapyramidal side effects which may be used in the therapy of the present invention include anticholinergics (such as benztropine, biperiden, procyclidine and trihexyphenidyl), antihistamines (such as diphenhydramine) and dopaminergics (such as amantadine).
Cognitive enhancers which may be used in the therapy of the present invention include example cholinesterase inhibitors (such as tacrine, donepezil, rivastigmine and galantamine), H3 antagonists and muscarinic M1 agonists (such as cevimeline).
In one embodiment, the active ingredient for use in combination with a compound of the present invention, is an atypical antipsychotic, for example clozapine, olanzapine, risperidone, quetiapine, aripirazole, ziprasidone or amisulpride.
In one embodiment, the active ingredient for use in combination with a compound of the present invention is a typical antipsychotic, for example chlorpromazine, thioridazine, mesoridazine, fluphenazine, perphenazine, prochlorperazine, trifluoperazine, thiothixine, haloperidol, thiflurpromazine, pimozide, droperidol, chlorprothixene, molindone or loxapine.
In another embodiment, the active ingredient for use in combination with a compound of the present invention is a mood stabiliser, for example lithium, sodium valproate/valproic acid/divalproex, carbamazepine, lamotrigine, gabapentin, topiramate, oxcarbazepine or tiagabine.
In another embodiment, the active ingredient for use in combination with a compound of the present invention is an antidepressant, for example a serotonin agonist (such as rauwolscine, yohimbine or metoclopramide); a serotonin reuptake inhibitor (such as citalopram, escitalopram, fluoxetine, fluvoxamine, femoxetine, indalpine, zimeldine, paroxetine or sertraline); a dual serotonin/noradrenaline reuptake inhibitor (such as venlafaxine, reboxetine, duloxetine or milnacipran); a noradrenaline reuptake inhibitors (such as reboxetine); a tricyclic antidepressants (such as amitriptyline, clomipramine, imipramine, maprotiline, nortriptyline or trimipramine); a monoamine oxidase inhibitor (such as isocarboxazide, moclobemide, phenelzine or tranylcypromine); or other (such as bupropion, amineptine, radafaxine, mianserin, mirtazapine, nefazodone or trazodone).
In another embodiment, the active ingredient for use in combination with a compound of the present invention is an anxiolytic, for example a benzodiazepine such as alprazolam or lorazepam.
For use in medicine, the compounds of the present invention are usually administered as a standard pharmaceutical composition. The present invention therefore provides in a further aspect a pharmaceutical composition comprising a compound of formula (I) as hereinbefore described or a salt or solvate thereof and a pharmaceutically acceptable carrier. The pharmaceutical composition can be for use in the treatment of any of the conditions described herein.
The compounds of formula (I) may be administered by any convenient method, for example by oral, parenteral (e.g. intravenous), buccal, sublingual, nasal, rectal or transdermal administration and the pharmaceutical compositions adapted accordingly.
The compounds of formula (I) as hereinbefore described and their salts or solvates which are active when given orally can be formulated as liquids or solids, for example syrups, suspensions or emulsions, tablets, capsules and lozenges.
A liquid formulation will generally consist of a suspension or solution of the compound or salt or solvate in a suitable liquid carrier(s) for example an aqueous solvent such as water, ethanol or glycerine, or a non-aqueous solvent, such as polyethylene glycol or an oil. The formulation may also contain a suspending agent, preservative, flavouring or colouring agent.
A composition in the form of a tablet can be prepared using any suitable pharmaceutical carrier(s) routinely used for preparing solid formulations. Examples of such carriers include magnesium stearate, starch, lactose, sucrose and cellulose.
A composition in the form of a capsule can be prepared using routine encapsulation procedures. For example, pellets containing the active ingredient can be prepared using standard carriers and then filled into a hard gelatin capsule; alternatively, a dispersion or suspension can be prepared using any suitable pharmaceutical carrier(s), for example aqueous gums, celluloses, silicates or oils and the dispersion or suspension then filled into a soft gelatin capsule.
Typical parenteral compositions consist of a solution or suspension of the compound or salt or solvate in a sterile aqueous carrier or parenterally acceptable oil, for example polyethylene glycol, polyvinyl pyrrolidone, lecithin, arachis oil or sesame oil. Alternatively, the solution can be lyophilised and then reconstituted with a suitable solvent just prior to administration.
Compositions for nasal administration may conveniently be formulated as aerosols, drops, gels and powders. Aerosol formulations typically comprise a solution or fine suspension of the active substance in a pharmaceutically acceptable aqueous or non-aqueous solvent and are usually presented in single or multidose quantities in sterile form in a sealed container, which can take the form of a cartridge or refill for use with an atomising device. Alternatively the sealed container may be a unitary dispensing device such as a single dose nasal inhaler or an aerosol dispenser fitted with a metering valve which is intended for disposal once the contents of the container have been exhausted. Where the dosage form comprises an aerosol dispenser, it will contain a propellant which can be a compressed gas such as compressed air or an organic propellant such as a fluorochloro-hydrocarbon. The aerosol dosage forms can also take the form of a pump-atomiser.
Compositions suitable for buccal or sublingual administration include tablets, lozenges and pastilles, wherein the active ingredient is formulated with a carrier such as sugar and acacia, tragacanth, or gelatin and glycerin.
Compositions for rectal administration are conveniently in the form of suppositories containing a conventional suppository base such as cocoa butter.
Compositions suitable for transdermal administration include ointments, gels and patches. The composition may be in unit dose form such as a tablet, capsule or ampoule.
Each dosage unit for oral administration contains, for example, from 1 to 250 mg (and for parenteral administration contains, for example, from 0.1 to 25 mg) of a compound of the formula (I) or a salt thereof calculated as the free base.
The antipsychotic agent component or components used in the adjunctive therapy of the present invention may also be administered in their basic or acidic forms as appropriate or, where appropriate, in the form of a salt or other derivative. All solvates and all alternative physical forms of the antipsychotic agent or agents or their salts or derivatives as described herein, including but not limited to alternative crystalline forms, amorphous forms and polymorphs, are also within the scope of this invention. In the case of the antipsychotic agent or agents, the forms and derivatives are, for example, those which are approved for therapeutic administration as monotherapies, including those mentioned above, but all references to antipsychotic agents herein include all salts or other derivatives thereof, and all solvates and alternative physical forms thereof.
For adjunctive therapeutic administration according to the invention, compounds of formula (I) or salts or solvates and the antipsychotic agent or agents or their salts, derivatives or solvates may each be administered in pure form, but each of the components will, for example, be formulated into any suitable pharmaceutically acceptable and effective composition which provides effective levels of the respective component in the body. The choice of the most appropriate pharmaceutical compositions for each component is within the skill of the art, and may be the same form or different forms for each of the components. Suitable formulations include, but are not limited to tablets, capsules, powders, granules, lozenges, suppositories, reconstitutable powders, or liquid preparations such as oral or sterile parenteral solutions or suspensions.
For simultaneous administration as a combined composition of compounds of formula (I) and the antipsychotic agent or agents according to the invention, compounds of formula (I) or their salts or solvates and the antipsychotic agent or agents and their salts, derivatives or solvates may be administered together in pure form, but the combined components will, for example, be formulated into any suitable pharmaceutically acceptable and effective composition which provides effective levels of each of the components in the body. The choice of the most appropriate pharmaceutical compositions for the combined components is within the skill of the art. Suitable formulations include, but are not limited to tablets, sub-lingual tablets, buccal compositions, capsules, powders, granules, lozenges, suppositories, reconstitutable powders, or liquid preparations such as oral or sterile parenteral solutions or suspensions.
In order to obtain consistency of adjunctive administration, the compositions of each of the components, or of the combination of the components is, for example, in the form of a unit dose.
The term “treatment” includes prophylaxis, where this is appropriate for the relevant condition(s).
Compounds of the invention were characterized in a functional assay to determine their ability to activate the intracellular calcium pathway in CHO cells with stable expression of human muscarinic receptors using FLIPR (Fluorometric Imaging Plate Reader) technology. Briefly, CHO-M1 cells were plated (20,000/well) and allowed to grow overnight at 37 degrees. Media was removed and 30 uL loading buffer (HBSS with 20 mM HEPES, pH 7.4) containing FLIPR Calcium 3 dye (Molecular Devices Co., Sunnyvale, Calif.) was added according to manufacturer's instructions. After incubation at 37 degrees for 45-60 minutes, 10 uL of the assay buffer (HBSS with 20 mM HEPES and 2.5 mM probenecid, pH 7.4) containing test compounds was added to each well on FLIPR instrument. Calcium response was monitored to determine agonism. Plates were then incubated for another 30 minutes before 10 uL of assay buffer containing acetylcholine was added at an EC80, as the agonist challenge. Calcium response was then monitored again to determine compound's antagonism to acetylcholine. Concentration-response curves of both agonism and antagonism on M1 receptors were performed for each compound. Results were imported into ActivityBase data analysis suite (ID Business Solution Inc., Parsippany, N.J.) where the curves were analysed by non-linear curve fitting and the resulting pEC50/pIC50 were calculated. The intrinsic activities of agonist compounds were calculated as percentage of maximum FLIPR response induced by acetylcholine (ie using acetylcholine at EC100 as the control).
Compounds of the invention were characterized in a functional assay to determine their ability to activate the intracellular calcium pathway in CHO cells with stable expression of human muscarinic receptors using FLIPR (Fluorometric Imaging Plate Reader) technology. Briefly, CHO-M1 cells were plated (15,000/well) and allowed to grow overnight at 37 degrees. Media was removed and 30 uL loading buffer (HBSS with 2.5 mM probenicid, 2 uM Fluo-4, 500 uM Brilliant Black, pH 7.4) was added. After incubation at 37 degrees for 90 minutes, 10 uL of the assay buffer (HBSS with 2.5 mM probenecid, pH 7.4) containing test compounds was added to each well on the FLIPR instrument. Calcium response was monitored to determine agonism. Plates were then incubated for another 30 minutes before 10 uL of assay buffer containing acetylcholine was added at an EC80, as the agonist challenge. Calcium response was then monitored again to determine compound's antagonism to acetylcholine. Concentration-response curves of both agonism and antagonism on M1 receptors were performed for each compound. Results were imported into ActivityBase data analysis suite (ID Business Solution Inc., Parsippany, N.J.) where the curves were analysed by non-linear curve fitting and the resulting pEC50/fpKi were calculated. The intrinsic activities of agonist compounds were calculated as percentage of maximum FLIPR response induced by acetylcholine added as control on the same compound plates, and converted to a fraction between 0 and 1 (ie calculated using a 100% max response from a fitted acetylcholine standard curve, containing multiple concentrations, as control).
Examples 1-32 below were tested in one or both of the above assays and were found to have a pEC50 value of >6.0 at the muscarinic M1 receptor, and intrinsic activity >50%.
To determine the intrinsic activities of M1 agonist compounds, compounds of the invention were characterized in FLIPR experiments on U2OS cells with transient expression of human muscarinic M1 receptors. Briefly, U2OS cells were transduced with M1 BacMam virus (Ames, R S; Fornwald, J A; Nuthulaganti, P; Trill, J J; Foley, J J; Buckley, P T; Kost, T A; Wu, Z and Romanos, M A. (2004) Use of BacMam recombinant baculoviruses to support G protein-coupled receptor drug discovery. Receptors and Channels 10 (3-4): 99-109) in 2×10e5/mL cell suspension with 0.1% virus/cell ratio (v/v). The virus to cell ratio was determined in separate experiments by functional titration to be most appropriate to measure intrinsic activities of partial agonists. After mixing with virus in suspension, cells were then plated (10,000/well) and allowed to grow overnight at 37 degrees. FLIPR experiment was then carried out next day using the same protocol as described above for CHO-M1 cells. Results were imported into ActivityBase data analysis suite where the curves were analysed by non-linear curve fitting and the resulting pEC50 values were calculated. The intrinsic activities of agonist compounds were calculated as percentage of maximum FLIPR response induced by acetylcholine added as control on the same compound plates, and converted to a fraction between 0 and 1 (ie calculated using a 100% max response from a fitted acetylcholine standard curve, containing multiple concentrations, as control).
To determine the intrinsic activities of M1 agonist compounds, compounds of the invention were characterized in FLIPR experiments on CHO cells with transient expression of human muscarinic M1 receptors. Briefly, CHO cells were transduced with M1 BacMam virus (Ames, R S; Fornwald, J A; Nuthulaganti, P; Trill, J J; Foley, J J; Buckley, P T; Kost, T A; Wu, Z and Romanos, M A. (2004) Use of BacMam recombinant baculoviruses to support G protein-coupled receptor drug discovery. Receptors and Channels 10 (3-4): 99-109) at a multiplicity of infection of 6. The virus to cell ratio was determined in separate experiments by functional titration to be most appropriate to measure intrinsic activities of partial agonists. After mixing with virus in suspension, cells were then plated (15,000/well) and allowed to grow overnight at 37 degrees.
Alternatively, cells were then frozen in 1 ml vials at a concentration of 4.8×10e7 cells/ml in 90% dialysed Foetal Bovine Serum, 10% DimethylSulphoxide at −140 degrees. Cells could then be thawed on the day prior to assay, plated (15,000/well) and allowed to grow overnight at 37 degrees.
The FLIPR experiment was carried out on the day following plating using the same protocol as described above for CHO-M1 cells. Results were imported into ActivityBase data analysis suite where the curves were analysed by non-linear curve fitting and the resulting pEC50 values were calculated. The intrinsic activities of agonist compounds were calculated as percentage of maximum FLIPR response induced by acetylcholine added as control on the same compound plates, and converted to a fraction between 0 and 1 (ie calculated using a 100% max response from a fitted acetylcholine standard curve, containing multiple concentrations, as control).
Examples 1-32 below were tested in one or both of the above assays, and were found to have a pEC50 value of >6.0 at the muscarinic M1 receptor, and intrinsic activity of greater than or equal to 0.3.
To determine selectivity of compounds of the invention against other muscarinic receptor subtypes, compounds were characterized in FLIPR experiments in CHO cells with stable expression of human muscarinic receptors, M2, M3, M4 or M5. In the case of M2 and M4 receptors, chimeric G-protein Gqi5 was also co-expressed to couple receptors to the calcium signaling pathway. Briefly, cells were plated (20,000/well) and allowed to grow overnight at 37 degrees. FLIPR experiment was then carried out next day using the same protocol as described above for CHO-M1 cells. Results were imported into ActivityBase data analysis suite where the curves were analysed by non-linear curve fitting and the resulting pEC50/pIC50 values were calculated.
To determine selectivity of compounds of the invention against other muscarinic receptor subtypes, compounds were characterized in FLIPR experiments in CHO cells with stable expression of human muscarinic receptors, M2, M3, M4 or M5. In the case of M2 and M4 receptors, chimeric G-protein Gqi5 was also co-expressed to couple receptors to the calcium signaling pathway. Briefly, cells were plated (15,000/well) and allowed to grow overnight at 37 degrees. The FLIPR experiment was then carried out on the next day using the same protocol as described above for CHO-M1 cells. Results were imported into ActivityBase data analysis suite where the curves were analysed by non-linear curve fitting and the resulting pEC50/fpKi values were calculated.
Examples 1-32 below were tested in one or both of the above assays and were found to be selective for the M1 receptor over M2, M3, M4 and M5 receptors, with typical selectivity (ratio of pEC50's) of ≧10-fold, and in certain cases ≧100-fold.
The invention is further illustrated by the following non-limiting examples. In the procedures that follow, after each starting material, reference to a Description by number is typically provided. This is provided merely for assistance to the skilled chemist. The starting material may not necessarily have been prepared from the batch referred to. SCX refers to a sulfonic acid ion exchange resin supplied by Varian. MDAP refers to purification by HPLC, wherein fraction collection is by reverse phase chromatography on C18 stationary phase eluted with acetonitrile/water/0.1% formic acid, and is triggered by detection of the programmed mass ion for the compound of interest. All reactions were either done under argon or can be done under argon, unless stated otherwise (for example hydrogenation reactions). All 1H NMR are consistent with the structures shown.
1-Chloro-4-fluoro-2-methylbenzene (10 mmol, 1.44 g) was dissolved in concentrated sulphuric acid under argon and cooled to 0° C. KNO3 (10 mmol, 1.01 g, 1 eq) was then added cautiously while keeping the temperature around 0° C. The mixture was then allowed to stir for 2 h while warming up to room temperature, then it was poured cautiously onto ice and extracted twice with ether. The organics were combined, dried on MgSO4 and concentrated under reduced pressure to give an oil (9.1 mmol, 1.73 g, 91% yield), which was chromatographed (0-25% ethyl acetate/petrol ether) to give the title compound as a transparent oil (7 mmol, 1.3 g, 70% total yield).
1H NMR (CDCl3): 8.09 (1H, d), 7.19 (1H, d), 2.46 (3H, s).
A stirred solution of 2-bromo-4-fluorobenzotrifluoride (1.0 g, 4.1 mmole) in concentrated sulphuric acid (10 ml) at 0° C. was treated portionwise with KNO3 (0.46 g, 4.6 mmole) and maintained at 0° C. for 0.5 hr before warming to room temp. over 2 hr. The mixture was added to well stirred ice/water (100 ml) and then extracted with ethyl acetate. The extract was dried and concentrated under vacuum to afford the title compound as a yellow solid (1.2 g, 100%).
1H NMR (400 MHz, CDCl3): 7.75 (1H, d), 8.45 (1H, d).
1,4-Dioxaspiro[4.5]decan-8-one (64 mmol, 10 g) was dissolved in ethanol (125 ml) and treated with NaBH4 (1.2 eq., 76.8 mmol, 2.9 g), at 0° C. and the mixture was stirred at room temperature for 1 hour. Reaction was quenched with NaOH (25 ml, 2N aqueous solution). The aqueous solution was extracted with dichloromethane (2×). The organics were combined, dried over Na2SO4, filtered and the solvent was evaporated to afford the title compound, 8.3 g, 82%, as a colourless oil.
1HNMR (d6DMSO, 400 MHz) 1.443 (4H, m), 1.645 (4H, m), 3.549 (1H, d broad), 3.827 (4H, m), 4.480 (1H, d).
1,4-dioxaspiro[4.5]decan-8-ol (D3, 52.5 mmol, 8.3 g) was dissolved in dimethylformamide (200 ml) and NaH (2 eq., 105 mmol, 4.2 g) was added at 0° C. portionwise. The mixture was stirred at 0° C. for 10 minutes and iodomethane (2 eq., 6.5 ml) was added at room temperature. The mixture was stirred at room temperature for 2 hours, then it was quenched with methanol, partitioned between ethyl acetate and water and the two phases were separated. The aqueous phase was extracted with ethyl acetate (2×), the combined organics were washed with brine, dried over Na2SO4, filtered and the solvent was evaporated to afford the crude compound. Chromatography (ethyl acetate/n-hexane) afforded title compound, 7.3 g, 80%, as a colourless oil.
1HNMR (d6DMSO, 400 MHz) 1.462 (2H, m), 1.557 (2H, m), 1.642 (2H, m), 1.732 (2H, m), 3.210 (3H, s), 3.242 (1H, m), 3.834 (4H, m)
8-(Methyloxy)-1,4-dioxaspiro[4.5]decane (D4, 62.2 mmol, 11.9 g) was dissolved in 10 ml of tetrahydrofuran and HCl (50 ml of 5M aqueous solution) was added at room temperature; the mixture was stirred at room temperature overnight. Tetrahydrofuran was then evaporated, mixture was basified to pH=10 and it was extracted with ethyl acetate (3×); the organic phases were combined and washed with brine, dried over Na2SO4, filtered and the solvent was evaporated to afford the title compound, 8.2 g, complete conversion.
1HNMR (d6DMSO, 400 MHz) 1.920 (4H, m), 2.199 (2H, m), 2.348 (2H, m), 3.287 (3H, s), 3.531 (1H, m)
A solution of 4-methoxycyclohexanone (D5, 4.5 g) in dichloromethane (200 ml) at room temperature under argon was treated with 1,1-dimethylethyl 4-piperidinylcarbamate (9.0 g) and sodium triacetoxyborohydride (16.0 g) then stirred at room temperature for 18 h, then partitioned between dichloromethane and water at pH9. Drying, evaporation and chromatography (50 g silica, 0-10% methanol in dichloromethane) gave the title compound as a mixture of cis and trans isomers, 7.0 g.
A solution of 1,1-dimethylethyl[1-(4-methoxycyclohexyl)-4-piperidinyl]carbamate (D6, 7.0 g) in dichloromethane (50 ml) at room temperature was treated with 4M HCl in dioxane (25 ml). After 4 h evaporation gave the title compound, 6.3 g.
A stirred solution of 2,5-difluoro-4-nitrotoluene (0.7 g) in dimethylformamide (15 ml) at room temperature under argon was treated with diisopropylethylamine (2.0 ml) and 1-[4-(methoxy)cyclohexyl]-4-piperidinamine dihydrochloride (D7, cis:trans mixture, 0.85 g) and heated at 80° C. for 18 h. The cooled reaction was diluted with ethyl acetate and washed three times with water then dried, evaporated and chromatographed on Biotage KP-NH™ (NH-silica column eluting with 0-25% ethyl acetate/hexane) to give the separate cis (D8a, 370 mg) and trans (D8b, 180 mg) isomers of the title compound.
A stirred solution of N-(4-fluoro-5-methyl-2-nitrophenyl)-1-[cis-4-(methyloxy)cyclohexyl]-4-piperidinamine (D8a, 0.38 g, 1.09 mmole) in ethanol (30 ml) at room temperature under argon was treated with Raney Nickel (˜50 mg) followed by a dropwise addition of hydrazine hydrate (1.5 ml, 50.4 mmole). The mixture was heated at 50° C. for 7 h then cooled and filtered through a Kieselguhr pad to remove the catalyst and the solution was concentrated under vacuum to afford the title compound as a pale yellow oil (0.33 g, 95% yield).
MH+=336, 337 and 338.
A stirred solution of N-(4-fluoro-5-methyl-2-nitrophenyl)-1-[trans-4-(methyloxy)cyclohexyl]-4-piperidinamine (D8b, 0.29 g, 0.83 mmole) in ethanol (30 ml) at room temperature under argon was treated with Raney Nickel (˜50 mg) followed by a dropwise addition of hydrazine hydrate (1.1 ml, 36.96 mmole). The mixture was maintained overnight then filtered through a Kieselguhr pad to remove the catalyst and the solution was concentrated under vacuum to afford the title compound as a pale yellow oil (0.25 g, 95% yield).
MH+=336 and 337.
A stirred solution of 2-chloro-5-difluoro-4-nitrotoluene (D1, 0.8 g) in dimethylformamide (15 ml) at room temperature under argon was treated with diisopropylethylamine (2.0 ml) and 1-[4-(methoxy)cyclohexyl]-4-piperidinamine dihydrochloride (D7, cis:trans mixture, 0.85 g) and heated at 80° C. for 18 h. The cooled reaction was diluted with ethyl acetate and washed three times with water then dried, evaporated and was repeatedly chromatographed on a Biotage KP-NH™ column eluted with ethyl acetate and hexane using a gradient from 0 to 25% ethyl acetate to give the separate cis and trans isomers.
N-(4-chloro-5-methyl-2-nitrophenyl)-1-[cis-4-(methyloxy)cyclohexyl]-4-piperidinamine (D11a, 0.236 g) was isolated as the fast running isomer. 1H NMR (CDCl3, 400 MHz): 1.42 (2H, m), 1.65 (obs, m), 2.05 (4H, m), 2.36 (3H, s), 2.45 (3H, m), 3.90 (2H, m), 3.30 (3H, s), 3.39 (1H, m), 3.51 (1H, m), 6.70 (1H, s), 8.09 (1H, d), 8.16 (1H, s).
N-(4-chloro-5-methyl-2-nitrophenyl)-1-[trans-4-(methyloxy)cyclohexyl]-4-piperidinamine (D11b, 0.140 g) was isolated as the slow running isomer. 1H NMR (CDCl3, 400 MHz): 1.24 (4H, m), 1.65 (2H, m), 1.90 (2H, m), 2.1 (4H, m), 2.4 (6H, m), 2.85 (2H, m), 3.10 (1H, m), 3.30 (3H, s), 3.53 (1H, m), 6.70 (1H, s), 8.08 (1H, d), 8.16 (1H, s).
A stirred solution of N-(4-chloro-5-methyl-2-nitrophenyl)-1-[cis-4-(methyloxy)cyclohexyl]-4-piperidinamine (D11a, 0.25 g, 0.65 mmole) in ethanol (50 ml) at room temperature under argon was treated with Raney Nickel (˜50 mg) followed by a dropwise addition of hydrazine hydrate (1 ml, 33.6 mmole). The mixture was maintained for 30 minutes then filtered through a Kieselguhr pad to remove the catalyst and the solution was concentrated under vacuum to afford the title compound as a yellow oil (0.22 g, 95% yield). MH+=352 and 354.
A stirred solution of N-(4-chloro-5-methyl-2-nitrophenyl)-1-[trans-4-(methyloxy)cyclohexyl]-4-piperidinamine (D11b, 0.14 g, 0.37 mmole) in ethanol (35 ml) at room temperature under argon was treated with Raney Nickel (˜20 mg) followed by a dropwise addition of hydrazine hydrate (0.8 ml, 36.88 mmole). The mixture was maintained for 30 minutes then filtered through a Kieselguhr pad to remove the catalyst and the solution was concentrated under vacuum to afford the title compound as a pale yellow oil (0.13 g, 99% yield).
MH+=352 and 354.
A stirred solution of 2-fluoro-5-trifluoromethyl-4-bromonitrobenzene (D2, 1.2 g) in dimethylformamide (15 ml) at room temperature under argon was treated with diisopropylethylamine (2.0 ml) and 1-[4-(methoxy)cyclohexyl]-4-piperidinamine dihydrochloride (D7, cis:trans mixture, 0.85 g) and stirred at room temperature for 18 h. The cooled reaction was diluted with dichloromethane and washed twice with water then dried, evaporated and repeatedly chromatographed on a Biotage KP-NH™ column eluted with ethyl acetate and hexane using a gradient from 0 to 25% ethyl acetate to give the separate cis and trans isomers.
N-[5-bromo-2-nitro-4-(trifluoromethyl)phenyl]-1-[cis-4-(methyloxy)cyclohexyl]-4-piperidinamine (D14a, 0.508 g) was isolated as the fast running isomer. 1H NMR (CDCl3, 400 MHz): 1.40 (2H, m), 1.60 (obs, m), 2.06 (4H, m), 2.38 (1H, m), 2.50 (2H, m), 2.90 (2H, m), 3.30 (3H, s), 3.40 (1H, m), 3.55 (1H, m), 7.18 (1H, s), 8.29 (1H, d), 8.49 (1H, s).
N-[5-bromo-2-nitro-4-(trifluoromethyl)phenyl]-1-[trans-4-(methyloxy)cyclohexyl]-4-piperidinamine (D14b, 0.236 g) was isolated as the slow running isomer. 1H NMR (CDCl3, 400 MHz): 1.24 (4H, m), 1.65 (2H, m), 1.90 (2H, m), 2.12 (4H, m), 2.38 (1H, m), 2.45 (2H, m), 2.90 (2H, m), 3.10 (1H, m), 3.35 (3H, s), 3.55 (1H, m), 7.17 (1H, s), 8.28 (1H, d), 8.49 (1H, s).
A stirred solution of N-[5-bromo-2-nitro-4-(trifluoromethyl)phenyl]-1-[cis-4-(methyloxy)cyclohexyl]-4-piperidinamine (D14a, 508 mg, 1.06 mmole) in ethanol (40 ml) at room temperature under argon was treated with Raney Nickel (˜20 mg) followed by a dropwise addition of hydrazine hydrate (0.75 ml, 25.2 mmole). The mixture was maintained for 18 h then filtered through a Kieselguhr pad to remove the catalyst and the solution was concentrated under vacuum to afford the title compound as a pale yellow oil (0.480 g, 99% yield).
MH+=451, 452, 453 and 454.
A stirred solution of N-[5-bromo-2-nitro-4-(trifluoromethyl)phenyl]-1-[trans-4-(methyloxy)cyclohexyl]-4-piperidinamine (D14b, 236 mg, 0.5 mmole) in ethanol (30 ml) at room temperature under argon was treated with Raney Nickel (˜20 mg) followed by a dropwise addition of hydrazine hydrate (0.35 ml, 11.8 mmole). The mixture was maintained for 18 h then filtered through a Kieselguhr pad to remove the catalyst and the solution was concentrated under vacuum to afford the title compound (212 mg, 97% yield). MH+=451, 452, 453 and 454.
A stirred solution of 1,4-dioxaspiro[4.5]decan-8-ol (D3, 4.0 g, 0.025 mole) in N-methylpyrrolidinone (35 ml) at 10° C. under argon was treated portionwise with NaH (1.1 g of 60% oil dispersion, 0.028 mole) and maintained for 1 h, then iodoethane (2.6 ml, 0.032 mole) was added. The mixture was allowed to warm to room temperature and stir for 18 h. Further NaH (0.5 g of 60% oil dispersion) was added and the mixture stirred for 0.5 h, then more iodoethane (2.0 ml) was added and the mixture maintained at room temperature for 3 h. The mixture was cautiously treated with ethanol (1 ml) to destroy excess NaH and then water (300 ml) was added and the mixture extracted with hexane (2×200 ml). The combined extract as washed with water (2×200 ml), then dried (Na2SO4) and concentrated under vacuum to afford a colourless oil (4.7 g) containing the title compound contaminated with mineral oil residues.
1HNMR (CDCl3, 400 MHz): 1.20 (3H, t), 1.50-1.60 (2H, m), 1.63-1.77 (2H, m), 1.77-1.90 (4H, m), 3.35-3.43 (1H, m), 3.49 (2H, q), 3.90-4.00 (4H, m).
A solution of 8-(ethyloxy)-1,4-dioxaspiro[4.5]decane (D17, 4.7 g, 0.025 mole) in tetrahydrofuran (10 ml) at room temperature under argon was treated with 5M HCl acid (40 ml) and stirred for 18 h, at which stage conc. HCl acid (5 ml) was added and the mixture heated at 40° C. for 3.5 h to complete the reaction. The resulting mixture was diluted with water (75 ml) and extracted with dichloromethane (2×80 ml). The combined extract was dried (Na2SO4) and carefully concentrated under partial vacuum at <20° C. to afford the title compound as a pale yellow oil (3.8 g, ˜90% purity).
1HNMR (CDCl3, 400 MHz): 1.25 (3H, t), 1.90-2.00 (2H, m), 2.01-2.13 (2H, m), 2.20-2.32 (2H, m), 2.53-2.65 (2H, m), 3.55 (2H, q), 3.58-3.70 (1H, m).
A stirred solution of 4-(ethyloxy)cyclohexanone (D18, 3.5 g, 0.025 mole) in dichloromethane (100 ml) at room temperature under argon was treated with 1,1-dimethylethyl 4-piperidinylcarbamate (5.0 g, 0.025 mole), followed by portionwise addition over 5 minutes of sodium triacetoxyborohydride (7.4 g, 0.035 mole), then the resulting mixture stirred well at room temperature for 20 h. The reaction mixture was treated with methanol (8 ml) and the resulting solution allowed to stand for 3 days, then 5% Na2CO3 solution (100 ml) was added and the mixture extracted with dichloromethane (200 ml). The extract was washed with brine, then dried (Na2SO4) and concentrated under vacuum. The residual yellow oil was dissolved in 60-80 petrol ether (100 ml) and allowed to stand at room temperature overnight whereupon the crystals which had formed were filtered off, washed with petrol and dried to give 1.7 g of ˜45:55 mixture of title compound trans isomer and starting 1,1-dimethylethyl 4-piperidinylcarbamate. Purification by column chromatography on silica gel eluting with 0-5% methanol/dichloromethane afforded the pure title compound trans isomer (D19b) as a white solid (0.93 g).
1H NMR (CDCl3, 400 MHz): 1.15-1.50 (6H, m), 1.18 (3H, t), 1.44 (9H, s), 1.82-2.00 (4H, m), 2.04-2.14 (2H, m), 2.20-2.32 (3H, m), 2.85 (2H, br d), 3.10-3.20 (1H, m), 3.38-3.50 (1H, m), 3.50 (2H, q), 4.40 (1H, br d).
Concentration under vacuum of the mother liquors from the crystallisation afforded 6 g of a yellow oil containing the title compound cis isomer (D19a) as ˜4:1 mixture with the trans isomer.
1,1-Dimethylethyl {1-[trans-4-(ethyloxy)cyclohexyl]-4-piperidinyl}carbamate (D19b, 920 mg, 5.0 mmol) was dissolved in dichloromethane (6 ml) and treated with HCl (21 ml of a 4M solution in 1,4-dioxane) at room temperature. The mixture was stirred at room temperature for 1 hour and the solvent was evaporated. The crude was passed through an SCX cartridge to yield the free base title compound as a pale brown powder (865 mg, 4.0 mmol, 89%). M++H=227.
A mixture of trans-1-(4-ethoxyclohexyl)-4-piperidone (D50, 13.2 g), 2M ammonia in methanol (300 ml), and 10% palladium on carbon paste (4 g) was hydrogenated at 50 psi at room temperature for 18 h, then filtered and evaporated to give the title compound (9.5 g) as a oil.
A stirred mixture of 2,5-difluoro-4-nitrotoluene (168 mg, 0.972 mmole), diisopropylethylamine (1.5 eqs, 0.21 ml, 1.21 mmole) and 1-(trans-4-ethoxycyclohexyl)piperidin-4-amine (D20, 183 mg, 0.810 mmole) in dimethylformamide (3 ml) was heated at 80° C. over one weekend. The mixture was concentrated under vacuum and the residue treated with 10% Na2CO3 solution and extracted with dichloromethane. The extract was dried (Na2SO4) and concentrated under vacuum. The residue was chromatographed on silica gel (20 g) eluting with 0-10% methanol/dichloromethane to afford the title compound as an orange solid (90 mg, 29%).
1H NMR (CDCl3, 400 MHz): 1.17-1.40 (7H including 4H, m and 3H, t), 1.58-1.72 (2H, m), 1.85-2.00 (2H, m), 2.02-2.17 (4H, m), 2.30 (3H, s), 2.30-2.50 (3H, m), 2.82-2.92 (2H, m), 3.12-3.22 (1H, m), 3.47-3.57 (3H including 1H, m and 2H, q), 6.63 (1H, d), 7.82 (1H, d), 8.06 (1H, d).
A stirred suspension of 1-[trans-4-(ethyloxy)cyclohexyl]-N-(4-fluoro-5-methyl-2-nitrophenyl)-4-piperidinamine (D21, 90 mg, 0.24 mmole) in ethanol (10 ml) at room temperature under argon was treated with Raney nickel (˜12 mg) followed by dropwise addition of hydrazine hydrate (0.073 ml, 2.4 mmole), then maintained for 1 h. The catalyst was removed by filtration through Kieselguhr and the filtrate concentrated under vacuum to afford the title compound as a pale grey solid (74 mg, 89%).
1H NMR (CDCl3, 400 MHz): 1.16-1.40 (7H including 4H, m and 3H, t), 1.48-1.62 (2H, m), 1.90-2.18 (5H, m), 2.13 (3H, s), 2.32-2.43 (3H, m), 2.88-3.00 (2H, m), 3.08-3.22 (3H, br m), 3.40-3.60 (4H including 2H, q), 6.38-6.48 (2H, m). 1H not discernible.
A stirred solution of 1,4-dioxaspiro[4.5]decan-8-ol (D3, 10 g, 0.063 mole) in N-methylpyrrolidin-2-one (100 ml) at 10° C. under argon was treated portionwise over 15 minutes with NaH (2.78 g of 60% oil dispersion, 0.069 mole), then maintained at 10° C. for 20 minutes before warming to room temperature over 1 h. The mixture was re-cooled to 5° C. and treated dropwise over 10 minutes with 1-bromopropane (8.6 ml, 0.095 mole), then maintained at 5-10° C. for 1 h, before warming to room temperature and stirring for 3 days. The mixture was cautiously treated with methanol (5 ml) to destroy remaining NaH, then water (1200 ml) was added and the mixture extracted with n-hexane (3×300 ml). The combined extract was washed with water (2×250 ml), dried (Na2SO4) and concentrated under vacuum to afford the title compound as a colourless oil (9.96 g, 79%).
1H NMR δ (CDCl3 400 MHz): 0.91 (3H, t), 1.48-1.62 (4H, m), 1.62-1.90 (6H, m), 3.35-3.42 (3H, m), 3.90-4.00 (4H, m).
A stirred solution of 8-(propyloxy)-1,4-dioxaspiro[4.5]decane (D23, 9.96 g, 0.050 mole) in tetrahydrofuran (20 ml) at room temperature under argon was treated with 5M HCl acid (100 ml) and maintained for 18 h. The mixture was diluted with water (300 ml) and extracted with dichloromethane (2×250 ml). The combined extract was washed with dil. brine, then dried (Na2SO4) and concentrated under vacuum at ˜15° C. to leave the title compound as a colourless oil (7.8 g, 100%).
1H NMR δ (CDCl3 400 MHz): 0.95 (3H, t), 1.57-1.69 (2H, m), 1.87-2.00 (2H, m), 2.04-2.14 (2H, m), 2.20-2.32 (2H, m), 2.52-2.63 (2H, m), 3.46 (2H, t), 3.67-3.72 (1H, m).
A stirred solution of 4-(propyloxy)cyclohexanone (D24, 7.8 g, 0.050 mole) in dichloromethane (200 ml) at room temperature under argon was treated with 1,1-dimethylethyl 4-piperidinylcarbamate (10.0 g, 0.050 mole), followed by portionwise addition over 10 minutes of sodium triacetoxyborohydride (14.8 g, 0.070 mole). The resulting mixture was diluted with further dichloromethane (50 ml) and stirred well at room temperature for 18 h. The reaction mixture was carefully treated with methanol (10 ml) and the resulting solution stirred for 1 h, then 2% Na2CO3 solution (200 ml) was added and the mixture extracted with dichloromethane (2×200 ml). The combined extract was washed with water (200 ml), then dried (Na2SO4) and concentrated under vacuum. The residual yellow oil was dissolved in 60-80 petrol ether (120 ml) and allowed to stand at room temperature overnight whereupon the crystals which had formed were filtered off, washed with petrol and dried to give 0.95 g of title compound trans isomer (D25b) (>90% purity) as a white solid. Concentration of the mother liquors and a second crystallisation of the residue from 60-80 petrol (80 ml) over 4 h afforded a further 0.65 g of trans isomer (˜90% purity) as a white solid.
1H NMR (CDCl3, 400 MHz): 0.91 (3H, t), 1.15-1.33 (4H, m), 1.33-1.50 (2H, m), 1.44 (9H, s), 1.56 (2H, m), 1.85-2.00 (4H, m), 2.05-2.14 (2H, m), 2.20-2.35 (3H, m), 2.80-2.90 (2H, m), 3.10-3.20 (1H, m), 3.40 (2H, t), 3.4-3.50 (1H, m), 4.40 (1H, br d).
Concentration under vacuum of the mother liquors from the second crystallisation afforded 13.9 g of a yellow oil containing the title compound cis isomer (D25a) as ˜3:1 mixture with the trans isomer.
A solution of 1,1-dimethylethyl{1-[trans-4-(propyloxy)cyclohexyl]-4-piperidinyl}carbamate (D25b, 0.95 g, 2.8 mmole) in dichloromethane (20 ml) at room temperature under argon was treated with 1M HCl/diethyl ether (25 ml) and allowed to stand for 18 h when a white solid had formed, however reaction was only partially complete. The mixture was concentrated under vacuum and the residue dissolved in methanol (20 ml) and treated with a concentrated solution of HCl in methanol. After 3 h the solution was concentrated under vacuum and the residual gum treated with toluene and then concentrated under vacuum to remove water, however no solid was obtained. The gum was therefore treated with ethyl acetate and excess 10% Na2CO3 solution, shaken well and the ethyl acetate layer separated, dried (Na2SO4) and concentrated under vacuum to afford the title compound as a white semi-solid (0.50 g, 75%).
1H NMR (CDCl3, 400 MHz): 0.90 (3H, t), 1.15-1.45 (8H, m), 1.57 (2H, m), 1.82 (2H, br d), 1.87-1.95 (2H, m), 2.03-2.12 (2H, m), 2.21 (2H, dt), 2.22-2.32 (1H, m), 2.56-2.66 (1H, m), 2.86 (2H, br d), 3.10-3.20 (1H, m), 3.40 (2H, t).
A stirred solution of 1,1-dimethylethyl{1-[trans-4-(propyloxy)cyclohexyl]-4-piperidinyl}carbamate (D25b, 0.65 g, 1.9 mmole) in dichloromethane (15 ml) at room temperature under argon was treated with 4M HCl/dioxane (5 ml) and maintained for 3 days. The mixture containing a white precipitate was concentrated under vacuum and then dried at 50° C. under vacuum to afford the title compound as a white solid (0.60 g, 100%).
A mixture of trans-1-(4-propoxycyclohexyl)-4-piperidone (D53, 7.5 g), 2M ammonia in methanol (100 ml), and 10% palladium on carbon paste (100 mg) was hydrogenated at 50 psi at room temperature for 18 h then filtered and evaporated. The residue was converted to the dihydrochloride salt to give the title compound, crystallised from diethyl ether, 7.5 g.
A stirred solution of cis/trans-1,1-dimethylethyl{1-[cis-4-(propyloxy)cyclohexyl]-4-piperidinyl}carbamate (D25a, ˜3:1 cis:trans, 7.0 g, 0.021 mole) in dichloromethane (50 ml) at room temperature under argon was treated with 4M HCl/dioxane (25 ml) and maintained for 3 days. The mixture containing a white precipitate was concentrated under vacuum and then dried at 50° C. under vacuum for 1 h to afford the title compound (˜3:1 mixture of cis:trans isomers) as a white solid (6.7 g, 100%).
A stirred suspension of cis/trans-1-[4-(propyloxy)cyclohexyl]-4-piperidinamine dihydrochloride (D28, ˜3:1 cis:trans mixture, 1.5 g, 4.8 mmole) in dimethylformamide (12 ml) at room temperature under argon was treated with diisopropylethylamine (3.0 ml, 17 mmole) and 2-chloro-5-fluoro-4-nitrotoluene (D1, 1.05 g, 5.5 mmole) and heated at 80° C. for 18 h. The resulting solution was concentrated under vacuum and the residue treated with 10% Na2CO3 solution (40 ml) and extracted with dichloromethane. The extract was dried, concentrated under vacuum to ˜5 ml and loaded onto a SCX cartridge (10 g), which was eluted with dichloromethane followed by methanol to remove non-basic contaminants, then with 2M NH3/methanol to remove the product. The product solution was concentrated under vacuum and the residue chromatographed on NH-silica column (100 g) eluting with 0-20% ethyl acetate/hexane to obtain the title compound as the fastest eluting isomer. This was obtained as an orange solid (0.68 g, 35%).
1H NMR (CDCl3, 400 MHz): 0.94 (3H, t), 1.33-1.45 (2H, m), 1.50-1.75 (8H, m), 1.93-2.03 (2H, m), 2.03-2.13 (2H, m), 2.32-2.41 (1H, m and 3H, s), 2.41-2.51 (2H, m), 2.84-2.94 (2H, m), 3.34 (2H, t), 3.45-3.57 (2H, m), 6.71 (1H, s), 8.08 (1H, d), 8.16 (1H, s).
Latter fractions contained a small amount of the pure trans isomer (112 mg).
A stirred suspension of N-(4-chloro-5-methyl-2-nitrophenyl)-1-[cis-4-(propyloxy)cyclohexyl]-4-piperidinamine (D29, 680 mg, 1.66 mmole) in ethanol (40 ml) at room temperature under argon was treated with Raney nickel (˜20 mg) followed by dropwise addition of hydrazine hydrate (0.50 ml, 16 mmole). The mixture was maintained for 3 days then filtered through Kieselguhr to remove the catalyst and the filtrate concentrated under vacuum to afford the title compound as a pale purple oil (630 mg, 100%).
1H NMR (CDCl3, 400 MHz): 0.94 (3H, t), 1.30-1.45 (2H, m), 1.45-1.75 (8H, m), 1.92-2.02 (2H, m), 2.02-2.12 (2H, m), 2.25 (3H, s), 2.32-2.45 (3H, m), 2.89-2.98 (2H, m), 3.00-3.40 (4H, br), 3.33 (2H, t), 3.45-3.50 (1H, m), 6.47 (1H, s), 6.70 (1H, s).
A stirred solution of 1-[trans-4-(propyloxy)cyclohexyl]-4-piperidinamine (D26, 250 mg, 1.0 mmole) and diisopropylethylamine (0.43 ml, 2.4 mmole) in dimethylformamide (4 ml) at room temperature under argon was treated with 2-chloro-5-fluoro-4-nitrotoluene (D1, 227 mg, 1.2 mmole) and heated at 70° C. for 18 h. The resulting solution was concentrated under vacuum and the residue treated with 10% Na2CO3 solution (20 ml) and extracted with dichloromethane. The extract was dried, concentrated under vacuum to ˜4 ml and loaded onto a SCX cartridge (5 g), which was eluted with dichloromethane followed by methanol to remove non-basic contaminants, then with 2M NH3/methanol to remove the product. The product solution was concentrated under vacuum and the residue crystallised from methanol to afford the title compound as a crystalline orange solid (310 mg, 76%).
1H NMR (CDCl3, 400 MHz): 0.93 (3H, t), 1.17-1.37 (4H, m), 1.52-1.70 (4H, m), 1.88-1.95 (2H, m), 2.01-2.15 (4H, m), 2.29-2.49 (3H, m), 2.37 (3H, s), 2.83-2.92 (2H, m), 3.10-3.20 (1H, m), 3.40 (2H, t), 3.46-3.58 (1H, m), 6.70 (1H, s), 8.08 (1H, d), 8.17 (1H, s).
A stirred suspension of N-(4-chloro-5-methyl-2-nitrophenyl)-1-[trans-4-(propyloxy)cyclohexyl]-4-piperidinamine (D31, 420 mg, 1.02 mmole) in ethanol (15 ml) at room temperature under argon was treated with Raney nickel (˜20 mg) followed by dropwise addition of hydrazine hydrate (0.30 ml, 9.6 mmole). The mixture was stirred at room temperature for 2 h followed by 45° C. for 1 h, then filtered through Kieselguhr to remove the catalyst and the filtrate concentrated under vacuum to afford the title compound as a pale purple solid (360 mg, 93%).
1H NMR (CDCl3, 400 MHz): 0.91 (3H, t), 1.18-1.38 (4H, m), 1.40-1.52 (2H, m), 1.52-1.62 (2H, m), 1.88-1.96 (2H, m), 2.00-2.15 (4H, m), 2.25 (3H, s), 2.28-2.40 (3H, m), 2.85-2.95 (2H, m), 3.10-3.30 (5H, br m), 3.40 (2H, t), 6.47 (1H, s), 6.70 (1H, s).
A stirred solution of 2,5-difluoro-4-nitrotoluene (0.95 g, 5.5 mmole) in dimethylformamide (12 ml) at room temperature under argon was treated with diisopropylethylamine (3.0 ml, 17 mmole) and cis/trans-1-[4-(propyloxy)cyclohexyl]-4-piperidinamine dihydrochloride (D28, ˜3:1 cis:trans mixture, 1.5 g, 4.8 mmole) and heated at 80° C. for 24 h. The resulting solution was concentrated under vacuum and the residue treated with 10% Na2CO3 solution (40 ml) and extracted with dichloromethane (40 ml). The extract was dried, concentrated under vacuum to ˜5 ml and loaded onto a SCX cartridge (10 g), which was eluted with dichloromethane followed by methanol to remove non-basic contaminants, then with 2M NH3/methanol to remove the product. The product solution was concentrated under vacuum and the residue chromatographed on NH-silica column (100 g) eluting with 0-20% ethyl acetate/hexane to obtain the title compound as the fastest eluting isomer. This was obtained as an orange solid (0.675 g, 36%).
1H NMR (CDCl3, 400 MHz): 0.94 (3H, t), 1.34-1.44 (2H, m), 1.53-1.80 (8H, m), 1.92-2.02 (2H, m), 2.02-2.12 (2H, m), 2.29 (3H, s), 2.30-2.40 (1H, m), 2.40-2.50 (2H, m), 2.82-2.92 (2H, m), 3.35 (2H, t), 3.45-3.55 (2H, m), 6.64 (1H, d), 7.82 (1H, d), 8.06 (1H, d).
Latter fractions afforded some of the trans isomer (190 mg, >90% purity).
A stirred suspension of N-(4-fluoro-5-methyl-2-nitrophenyl)-1-[cis-4-(propyloxy)cyclohexyl]-4-piperidinamine (D33, 330 mg, 0.84 mmole) in ethanol (25 ml) at room temperature under argon was treated with Raney nickel (˜20 mg) followed by dropwise addition of hydrazine hydrate (0.25 ml, 8.4 mmole). The mixture was maintained for 4 h, then filtered through Kieselguhr to remove the catalyst and the filtrate concentrated under vacuum to afford the title compound as a pale purple oil (290 mg, 95%).
1H NMR (CDCl3, 400 MHz): 0.92 (3H, t), 1.30-1.42 (2H, m), 1.50-1.75 (8H, m), 1.95-2.10 (4H, m), 2.15 (3H, s), 2.35-2.50 (3H, m), 2.90 (1H, vbr), 2.90-3.02 (2H, m), 3.08-3.18 (1H, m), 3.33 (2H, t), 3.47 (3H, br s), 6.42 (1H, d), 6.45 (1H, d).
A stirred solution of 1-[trans-4-(propyloxy)cyclohexyl]-4-piperidinamine (D26, 250 mg, 1.0 mmole) and diisopropylethylamine (0.43 ml, 2.4 mmole) in dimethylformamide (4 ml) at room temperature under argon was treated with 2,5-difluoro-4-nitrotoluene (208 mg, 1.2 mmole) and heated at 70° C. for 18 h. The resulting solution was concentrated under vacuum and the residue treated with 10% Na2CO3 solution (20 ml) and extracted with dichloromethane (25 ml). The extract was dried, concentrated under vacuum to ˜4 ml and loaded onto a SCX cartridge (5 g), which was eluted with dichloromethane followed by methanol to remove non-basic contaminants, then with 2M NH3/methanol to remove the product. The product solution was concentrated under vacuum and the residue crystallised from methanol to afford the title compound as a dark orange solid (190 mg, 48%).
1H NMR (CDCl3, 400 MHz): 0.91 (3H, t), 1.18-1.38 (4H, m), 1.50-1.72 (4H, m), 1.88-1.98 (2H, m), 2.00-2.15 (4H, m), 2.25-2.38 (1H, m), 2.30 (3H, s), 2.38-2.50 (2H, m), 2.83-2.93 (2H, m), 3.10-3.22 (1H, m), 3.41 (2H, t), 3.45-3.58 (1H, m), 6.63 (1H, d), 7.82 (1H, d), 8.06 (1H, d).
A stirred suspension of N-(4-fluoro-5-methyl-2-nitrophenyl)-1-[trans-4-(propyloxy)cyclohexyl]-4-piperidinamine (D35, 190 mg, 0.46 mmole) in ethanol (15 ml) at room temperature under argon was treated with Raney nickel (˜15 mg) followed by dropwise addition of hydrazine hydrate (0.14 ml, 4.6 mmole). The mixture was stirred at room temperature for 3 h, then filtered through Kieselguhr to remove the catalyst and the filtrate concentrated under vacuum to afford the title compound as a grey semi-solid (158 mg, 90%).
1H NMR (CDCl3, 400 MHz): 0.91 (3H, t), 1.17-1.37 (4H, m), 1.40-1.52 (2H, m), 1.52-1.65 (2H, m), 1.88-1.97 (2H, m), 1.98-2.14 (4H, m), 2.16 (3H, s), 2.25-2.38 (3H, m), 2.3-3.0 (1H, vbr), 2.85-2.95 (2H, m), 3.04-3.20 (2H, m), 3.40 (2H, t), 3.45 (2H, br s), 6.41 (1H, d), 6.44 (1H, d).
A stirred suspension of cis/trans-1-[4-(propyloxy)cyclohexyl]-4-piperidinamine dihydrochloride (D28, ˜3:1 cis:trans mixture, 1.0 g, 3.2 mmole) in dimethylformamide (10 ml) at room temperature under argon was treated with diisopropylethylamine (2.0 ml, 11 mmole) and 1-bromo-5-fluoro-4-nitro-2-(trifluoromethyl)benzene (D2, 1.10 g, 3.8 mmole) and heated at 80° C. for 2 h. The resulting solution was concentrated under vacuum and the residue treated with 10% Na2CO3 solution (40 ml) and extracted with dichloromethane. The extract was dried, concentrated under vacuum to ˜5 ml and loaded onto a SCX cartridge (10 g), which was eluted with dichloromethane followed by methanol to remove non-basic contaminants, then with 2M NH3/methanol to remove the product. The product solution was concentrated under vacuum and the residue chromatographed on NH-silica column (100 g) eluting with 0-20% ethyl acetate/hexane to obtain the title compound as the fastest eluting isomer. This was obtained as an orange solid (0.744 g, 38%).
1H NMR (CDCl3, 400 MHz): 0.93 (3H, t), 1.33-1.45 (2H, m), 1.50-1.75 (8H, m), 1.94-2.02 (2H, m), 2.03-2.14 (2H, m), 2.33-2.42 (1H, m), 2.43-2.53 (2H, m), 2.85-2.95 (2H, m), 3.35 (2H, t), 3.45-3.60 (2H, m), 7.18 (1H, s), 8.30 (1H, d), 8.49 (1H, s).
Latter fractions contained a small amount of the trans isomer (108 mg; >95% purity).
A stirred suspension of N-[5-bromo-2-nitro-4-(trifluoromethyl)phenyl]-1-[cis-4-(propyloxy)cyclohexyl]-4-piperidinamine (D37, 744 mg, 1.46 mmole) in ethanol (35 ml) at room temperature under argon was treated with Raney nickel (˜30 mg) followed by dropwise addition of hydrazine hydrate (0.39 ml, 12.5 mmole). The mixture was maintained at room temperature for 18 h, then filtered through Kieselguhr to remove the catalyst and the filtrate concentrated under vacuum to leave a pale red solid (700 mg). A portion of this material (350 mg) was purified by mass-directed automated HPLC to afford the title compound as a pale grey solid (190 mg, 54%).
1H NMR (CDCl3, 400 MHz): 0.94 (3H, t), 1.33-1.43 (2H, m), 1.43-1.75 (8H, m), 1.93-2.02 (2H, m), 2.02-2.12 (2H, m), 2.30-2.45 (3H, m), 2.88-2.98 (2H, m), 3.25 (3H, br s), 3.33 (2H, t), 3.48 (1H, m), 3.70 (1H, d), 6.81 (1H, s), 6.98 (1H, s).
A stirred solution of 1-[trans-4-(propyloxy)cyclohexyl]-4-piperidinamine dihydrochloride
(D27, 400 mg, 1.3 mmole) and diisopropylethylamine (0.81 ml, 4.5 mmole) in dimethylformamide (5 ml) at room temperature under argon was treated with 1-bromo-5-fluoro-4-nitro-2-(trifluoromethyl)benzene (D2, 430 mg, 1.5 mmole) and heated at 70° C. for 18 h. The resulting solution was concentrated under vacuum and the residue treated with 10% Na2CO3 solution (20 ml) and extracted with dichloromethane. The extract was dried, concentrated under vacuum to ˜4 ml and loaded onto a SCX cartridge (5 g), which was eluted with dichloromethane followed by methanol to remove non-basic contaminants, then with 2M NH3/methanol to remove the product. The product solution was concentrated under vacuum and the residue chromatographed on NH-silica column (100 g) eluting with 0-20% ethyl acetate/hexane to obtain the title compound a yellow solid (238 mg, 47%).
1H NMR (CDCl3, 400 MHz): 0.92 (3H, t), 1.20-1.40 (4H, m), 1.52-1.80 (4H, m), 1.88-1.98 (2H, m), 2.02-2.16 (4H, m), 2.30-2.40 (1H, m), 2.40-2.52 (2H, m), 2.84-2.94 (2H, m), 3.12-3.20 (1H, m), 3.40 (2H, m), 3.50-3.60 (1H, m), 7.18 (1H, s), 8.29 (1H, d), 8.50 (1H, s).
N-[5-bromo-2-nitro-4-(trifluoromethyl)phenyl]-1-[trans-4-(propyloxy)cyclohexyl]-4-piperidinamine (D39, 138 mg, 0.3 mmole) was dissolved in ethanol (3 ml) and an aqueous suspension of Raney Nickel (1 ml) was added at room temperature. The mixture was stirred for 30 minutes before adding hydrazine monohydrate (0.12 ml, 15 eq., 4.0 mmole) over 30 minutes. The reaction was left overnight. The reaction mixture was filtered through celite and the solvent was evaporated to yield the title compound as a brown solid (175 mgs, 100%). M++H=480.
A mixture of 1,4-dioxaspiro[4.5]decan-8-ol (D3, 5.0 g, 0.032 mole), 2-iodopropane (25 ml) and silver (I) oxide (14 g, 0.060 mole) at room temperature under argon was stirred in the dark for 6 days, followed by 6 days standing. The mixture was treated with diethyl ether (40 ml) and filtered through Kieselguhr washing well with diethyl ether. The filtrate was concentrated under vacuum and the residue dissolved in hexane (150 ml), washed with water (150 ml), then dried (Na2SO4) and concentrated under vacuum to afford a colourless oil (4.89 g) containing approx. 80% of the title compound together with 4-[(1-methylethyl)oxy]cyclohexanone from ketal hydrolysis. This mixture was used in the next step without purification.
1H NMR (CDCl3, 400 MHz): 1.13 (6H, d), 1.5-1.59 (2H, m), 1.60-1.74 (2H, m), 1.75-1.88 (4H, m), 3.43-3.50 (1H, m), 3.62-3.72 (1H, m), 3.90-4.00 (4H, m).
A solution of the mixture of 8-[(1-methylethyl)oxy]-1,4-dioxaspiro[4.5]decane and 4-[(1-methylethyl)oxy]cyclohexanone (˜4:1) (D41, 4.89 g, ˜0.025 mole) in tetrahydrofuran (10 ml) at room temperature under argon was treated with 5M HCl acid (50 ml) and stirred well for 18 h. The reaction mixture was treated with water (150 ml) and extracted with dichloromethane (2×80 ml). The combined extract was washed with brine, dried (Na2SO4) and concentrated under vacuum to afford the title compound as a colourless oil (3.9 g, 100%).
1H NMR (CDCl3, 400 MHz): 1.19 (6H, d), 1.88-2.08 (4H, m), 2.22-2.32 (2H, m), 2.54-2.65 (2H, m), 3.70-3.84 (2H, m).
A stirred solution of 4-[(1-methylethyl)oxy]cyclohexanone (D42, 3.9 g, 0.025 mole) in dichloromethane (100 ml) at room temperature under argon was treated with 1,1-dimethylethyl 4-piperidinylcarbamate (5.0 g, 0.025 mole), followed by portionwise addition over 10 minutes of sodium triacetoxyborohydride (7.4 g, 0.035 mole). Further dichloromethane (50 ml) was added to aid stirring which was continued at room temperature for 18 h. The reaction mixture was carefully treated with methanol (5 ml) and stirred for 20 minutes, then 2% Na2CO3 solution (200 ml) was added and the mixture extracted with dichloromethane (2×150 ml). The combined extract was washed with brine, then dried (Na2SO4) and concentrated under vacuum. The residual yellow oil (8.6 g) was triturated with 60-80 petrol ether (80 ml) which caused immediate crystallisation of a white solid. This was filtered off, washed with 60-80 petrol ether and dried, then recrystallised from 9:1 60-80 petrol ether/dichloromethane to afford the title compound trans isomer (D43b) as a white solid (0.85 g).
1H NMR (CDCl3, 400 MHz): 1.12 (6H, d), 1.18-1.50 (6H, m), 1.44 (9H, s), 1.80-2.05 (6H, m), 2.20-2.32 (3H, m), 2.80-2.90 (2H, m), 3.15-3.26 (1H, m), 3.38-3.50 (1H, m), 3.64-3.73 (1H, m), 4.37-4.47 (1H, m).
Concentration under vacuum of the mother liquors from the first crystallisation afforded 7.3 g of a yellow oil containing the title compound cis isomer (D43a) as ˜4:1 mixture with the trans isomer.
A stirred solution of 1,1-dimethylethyl (1-{trans-4-[(1-methylethyl)oxy]cyclohexyl}-4-piperidinyl)carbamate (D43b, 0.85 g, 2.5 mmole) in dichloromethane (10 ml) at room temperature under argon was treated with 4M HCl/dioxane (5 ml) and maintained for 18 h, then concentrated under vacuum. The residue was treated with diethyl ether (20 ml), stirred for 5 minutes, then the solid filtered off, washed with diethyl ether and then dried to afford the title compound as a white solid (0.73 g, 93%).
1H NMR (d6DMSO, 400 MHz): 1.05 (6H, d), 1.08-1.22 (2H, m), 1.43-1.60 (2H, m), 1.93-2.20 (8H, m), 2.98-3.15 (3H, m), 3.20-3.55 (5H, m), 3.62-3.72 (1H, m), 8.46 & 8.60 (together 3H, 2×brs), 10.84 & 10.95 (together 1H, 2×brs).
N-Ethoxycarbonylphthalimide (100 g) was added to a mixture of trans-4-hydroxycyclohexylamine hydrochloride (69 g), potassium carbonate (158 g) and water (1 l) at room temperature. After 3 h the title compound was isolated by filtration, washing with water then ethyl acetate, 95 g.
Tert-butyldimethylsilyl chloride (60 g) was added in portions to a mixture of trans-N-(4-hydroxycyclohexyl)phthalimide (D45, 95 g), imidazole (55 g), and dimethylformamide (200 ml) at 20-30° C. (internal, ice cooling). After stirring for 3 h more at 40° C. the mixture was partitioned water/hexane. Drying and evaporation of the organic layer gave the title compound crystallised from pentane, 92 g.
Acetaldehyde (10 ml) in acetonitrile (50 ml) was added over 30 minutes to a solution of 2-(trans-4-{[(1,1-dimethylethyl)(dimethyl)silyl]oxy}cyclohexyl)-1H-isoindole-1,3(2H)-dione (D46, 50.0 g), bismuth tribromide (6.7 g), triethylsilane (27 ml) in acetonitrile (500 ml) stirred at ice bath temperature and the mixture was allowed to warm to room temperature overnight. The mixture was filtered and the resulting grey solid and filtrate were worked up separately. The filtrate was evaporated and treated with hexane to give the title compound as a white solid (16.35 g). The grey solid washed with dichloromethane, the dichloromethane extract was evaporated and the residue was stirred with hexane (200 ml) to give a second crop of the title compound as a white solid (17.47 g).
A solution of trans-N-(4-ethoxycyclohexyl)phthalimide (16.35 g), hydrazine hydrate (12 ml) in ethanol (300 ml) and methanol (200 ml) was stirred at reflux for 3 hours. The solvent was removed to give a slurry, which was treated with diethyl ether and filtered. The filtrate was evaporated to afford the title compound as a viscous oil contaminated with ether (8.16 g).
Iodomethane (65 ml) was added in portions to a solution of 1-ethyl-4-piperidone (100 g) in acetone (1 l) at 20-30° C. (internal, ice cooling). After stirring for 3 h more the title compound was obtained by filtration, 189 g.
A mixture of 1-ethyl-4-piperidone methiodide (D49, 27 g), trans-4-ethoxycyclohexylamine (D48, 8.16 g), potassium carbonate (13.5 g), water (100 ml), and ethanol (200 ml) was heated for 3 hours at 80° C., then cooled overnight. The mixture was partitioned with aqueous sodium bicarbonate and dichloromethane. The dichloromethane layer was separated, washed with brine and solvent removed to give the title compound as an amber coloured oil (13.2 g).
A solution of trans-N-(4-tert-butyldimethylsilyloxycyclohexyl)phthalimide (D46, 45 g) in acetonitrile (500 ml) at room temperature was treated sequentially with triethylsilane (24 ml), bismuth tribromide (6 g), and (dropwise) propanal (11 ml) at 20-30° C. (internal, ice cooling). After 30 min more the solution was partitioned between aqueous sodium bicarbonate/ethyl acetate. Drying and evaporation of the organic layer gave the title compound crystallised from pentane, 20 g.
A mixture of trans-N-(4-propoxycyclohexyl)phthalimide (D51, 20 g), hydrazine hydrate (15 ml), and ethanol (400 ml) was heated at 80° C. for 2 h then cooled and filtered. The filtrate was evaporated and the resulting residue redissolved in diethyl ether, filtered and again evaporated to give the title compound, 11 g.
1-Ethyl-4-piperidone methiodide (D49, 26 g) was added to a refluxing mixture of trans-4-propoxycyclohexylamine (D52, 11 g), potassium carbonate (1 g), water (75 ml), and ethanol (150 ml) over 30 min, and the mixture was then heated for another 30 min at 80° C., then cooled, partitioned between aqueous sodium bicarbonate/dichloromethane, and purified by chromatography (40+M Biotage silica column, 0 to 10% methanol in dichloromethane containing 0.2M ammonia) to give the title compound, 8 g.
A stirred solution of diisopropylamine (16.1 ml, 115 mmol, 2.1 eq.) in tetrahydrofuran (200 ml) at 0° C. under argon was treated with 2.5M n-butyllithium in hexane (1.05 eq., 110 mmol, 44 ml) and it was then stirred at the same temperature for 10 minutes. The mixture was then treated with a solution of 4-(methyloxy)cyclohexanecarboxylic acid (1 eq., 55 mmol, 8.7 g) in 50 ml of dry tetrahydrofuran. The resulting yellow solution was heated at 50° C. for 2.0 hrs, then cooled to 0° C. and treated with iodomethane (3 eq., 12 ml). The mixture was allowed to warm to room temperature and stir for 2 hrs. The mixture was partitioned between citric acid (10% aqueous solution) and Et2O, the two phases were separated and the aqueous was extracted with Et2O (2×). Organics were combined, dried (Na2SO4), filtered and concentrated under vacuum to leave a yellow solid (9.8 g) a mixture of cis:trans isomers.
1H NMR δ (d6DMSO, 400 MHz): 1.078-2.018 (11H, cis/trans isomers), 3.074 (1H, m single isomer), 3.193 (3H, s single isomer), 3.213 (3H, s single isomer), 3.606 (1H, s broad, single isomer), >12.5 (1H, s broad, cis/trans isomers).
cis/trans-1-methyl-4-(methyloxy)cyclohexanecarboxylic acid (D54, 41.3 mmol, 7.7 g) was dissolved in thionyl chloride (15.3 eq., 631 mmol, 46 ml). The mixture was refluxed at 90° C. for 4 hours. The solvent was evaporated and the crude product treated with toluene and concentrated in vacuo. The residual brown oil was treated with 5% Na2CO3 solution (400 ml) and tetrahydrofuran (40 ml) and the mixture was stirred at room temperature for minutes. The aqueous solution was washed with Et2O (2×) and the aqueous phase was acidified with 2M HCl acid and extracted with ethyl acetate (2×). The combined organics were dried over Na2SO4, filtered and the solvent was evaporated to afford the titled compound, 2.8 g, 40%.
1H NMR δ (d6DMSO, 400 MHz): 1.085 (3H, s), 1.419 (2H, m), 1.485 (4H, m), 1.701 (2H, m), 3.225 (4H, m), 3.342 (1H, s).
To a solution of trans-1-methyl-4-(methyloxy)cyclohexanecarboxylic acid (D55, 15.0 mmol, 2.8 g) in dry toluene (70 ml), Et3N (1.3 eq., 19.6 mmol, 2.7 ml), and diphenylphosphoryl azide (1.0 eq., 15.0 mmol, 3.2 ml) were added at room temperature. The mixture was refluxed at 80° C. for 2 hours. The mixture was cooled room temperature and poured onto 1M NaOH (70 ml); the aqueous solution was extracted with EtOAc (2×). The organics were combined dried over Na2SO4, filtered and the solvent was evaporated to afford the crude compound. The crude product was then purified by chromatography (EtOAc-nhex) on silica column to afford the title compound, 1.33 g, 48%.
1H NMR δ (d6DMSO, 400 MHz): 1.327 (3H, s), 1.61 (8H, m), 3.197 (3H, s) 3.355 (1H, m).
To a solution of trans-1-isocyanato-1-methyl-4-(methyloxy)cyclohexane (D56, 7.27 mmol, 1.33 g) in THF (30 ml), concentrated HCl (6 ml) was added at room temperature. The mixture was stirred for 4 hours at room temperature and concentrated HCl (a few drops) was added. The reaction was left overnight and the solvent evaporated to afford the titled compound, 0.9 g, 69%.
1H NMR δ (d6DMSO, 400 MHz): 1.260 (3H, s), 1.39 (2H, m), 1.632 (4H, m), 1.87 (2H, m), 3.157 (1H, m), 3.217 (3H, s).
Trans-1-methyl-4-(methyloxy)cyclohexanamine monohydrochloride (D57, 7.69 mmol, 1.1 g), 1-ethyl-1-methyl-4-oxopiperidinium iodide (D49, 1.7 eq., 13.1 mmol), 3.5 g, K2CO3 (1.5 eq., 11.5 mmol, 1.5 g), water (40 ml) and ethanol (80 ml) were refluxed at 80° C. until the starting material was not observed on TLC. The mixture was partitioned between NaHCO3 and dichloromethane. Some product was lost due to mechanical spillage. The work up was repeated. The crude product was then purified by chromatography (MeOH—NH3-dichloromethane) on silica column to afford the title compound, 650 mg, 35%.
1H NMR δ (d6DMSO, 400 MHz) 0.85 (3H, s), 1.50 (8H, m) 1.762 (2H, t), 2.301 (4H, t), 2.725 (4H, t), 3.207 (3H, s), 3.274 (1H, m).
To a solution of 1-[trans-1-methyl-4-(methyloxy)cyclohexyl]-4-piperidinone (D58, 2.67 mmol, 650 mg) in 2M NH3 in methanol (15.0 eq., 40.0 mmol, 20 ml), 10% Pd/C paste (65 mg) was added. The mixture hydrogenated at 50 psi for 24 hours at room temperature. The mixture filtered through kieselguhr and washed with ethanol (100 ml). The solvent was evaporated to afford the crude product. The reaction was repeated on the crude product and left for 24 hours. The mixture was filtered through celite and washed with ethanol and the solvent was evaporated to afford the titled compound, 390 mg, 68%, M++H=227.
Chloro(1,1-dimethylethyl)dimethylsilane (115 g) was added in portions over 1 hour to a solution of ethyl 4-hydroxycyclohexanecarboxylate (118 g), imidazole (103 g) and dimethylformamide (400 ml) stirred under an atmosphere of argon. A small exotherm was observed resulting in the reaction mixture temperature increasing to −40° C. The mixture was stirred at room temperature overnight then poured into 10% citric acid solution (2000 ml) and extracted with diethyl ether (2×800 ml). The ether extracts were washed with water, brine and then dried (Na2SO4) and the solvent was removed to give the title compound as a oil (198.4 g)
1H NMR (CDCl3, 400 MHz): 0.01 (6H, m), 0.85 (9H, s), 1.2 (3H, m), 1.3-1.5 (2H, m), 1.6 (2H, m), 1.85-2 (3H, m), 2.15-2.3 (1H, m) 3.5 (0.4H, m) 3.86 (1H, m) 4.1 (1H, m).
cis/trans-Ethyl 4-{[(1,1-dimethylethyl)(dimethyl)silyl]oxy}cyclohexanecarboxylate (D60, 35 g, 122 mmol) was dissolved in acetonitile (250 ml) and Et3SiH (1.2 eq., 0.146 mol, 23 ml), BiBr3 (4% mol, 4.9 mmol, 2.2 g) were added at room temperature followed by acetaldehyde (1.2 eq., 8.2 ml) that was slowly added at 25° C. The mixture was stirred at room temperature for 1 hour. The mixture was subsequently poured onto an aqueous saturated solution of NaHCO3 and the mixture obtained was then extracted with EtOAc (3×). Organics were combined, dried over Na2SO4, filtered and the solvent was evaporated to afford the crude mixture that was purified by silica chromatography (65i column, EtOAc-nhexane) to afford the title compound, 21 g, 87%.
1H NMR (DMSO, 400 MHz): 1.1 (3H, m), 1.15 (3H, m), 1.492-3.212 (assume 10H, set of broad signals and multiplets), 3.312 (2H, m), 4.041 (2H, m).
cis/trans-Ethyl 4-(ethyloxy)cyclohexanecarboxylate (D61, 21 g, 105 mmol) was dissolved in MeOH-tetrahydrofuran (100 ml-100 ml) and NaOH (5 eq., 0.5 mol, 40 ml, 12.5N aqueous solution) was slowly added at room temperature. The mixture was stirred at room temperature overnight; tetrahydrofuran/MeOH was then evaporated and the crude was washed with Et2O. The aqueous was acidified and extracted with EtOAc (2×); organics were dried over Na2SO4, filtered and the solvent was evaporated to afford the title compound as a pale-yellow oil, 17.3 g, 96%.
1H NMR (DMSO, 400 MHz): 1.1 (3H, m), 1.3-3.201 (assume 10H, set of broad signals and multiplets), 3.417 (2H, m), 12.1 (1H, s broad).
A stirred solution of diisopropylamine (2.3 eq., 0.231 mol, 33 ml) in tetrahydrofuran (300 ml) at −20° C. under argon was treated over 10 min with 2.5M n-butyllithium in hexane (2.3 eq., 93 ml), then allowed to warm to 0° C. and stir for 15 mins. The mixture was recooled to −10° C. and treated over 10 min with a solution of cis/trans-4-(ethyloxy)cyclohexanecarboxylic acid (D62, 17.3 g, 0.1 mol) in 50 ml of tetrahydrofuran. The resulting yellow solution was heated at 50° C. for 2.5 hrs, then cooled to 0° C. and treated with iodomethane (3 eq., 0.3 mol, 19 ml). The mixture was allowed to warm to room temperature and stir for 20 hrs when a yellow precipitate had formed. The mixture was cooled to 10° C., treated with 10% citric acid solution (200 ml), and then concentrated under vacuum. The residual mixture was diluted with water (200 ml) and extracted with Et2O (2×). The combined extracts were dried (Na2SO4) and concentrated under vacuum to leave the title compound as a yellow oil, 16.2 g, 87%, a mixture of cis:trans isomers.
1H NMR (DMSO, 400 MHz): 1.086 (assume 8H, m), 1.510 (3H, m), 1.698 (1H, m), 1.781 (1H, m), 2.005 (1H, m), 3.191 (1/2H, m), 3.392 (2H, m), 3.606 (1/2H, m), 12.2 (1H, s br)
cis/trans-4-(Ethyloxy)-1-methylcyclohexanecarboxylic acid (D63, 16.2 g, 87.1 mmol) was dissolved in thionyl chloride (15 eq., 1.31 mol, 95 ml) at room temperature and it was subsequently heated to 85° C. for 4 hrs. The mixture was then allowed to cool to room temperature and the thionyl chloride was azeotropically evaporated with toluene. The residue was dissolved in THF (100 ml), treated with a 5% aqueous solution of Na2CO3 (500 ml) and stirred well at room temperature for 20 minutes. The aqueous residue washed with Et2O (2), then acidified and extracted with EtOAc (3×). The combined extracts were dried (Na2SO4), filtered and concentrated under vacuum to leave the title compound, 6.5 g, 40%
1H NMR (DMSO, 400 MHz): 1.076 (6H, m), 1.505 (6H, m), 1.693 (2H, m), 3.331 (1H, m), 3.394 (2H, q), 12.1 (1H, s br).
A stirred solution of trans-4-(ethyloxy)-1-methylcyclohexanecarboxylic acid (D64, 5.5 g, 29.5 mmol) in toluene (120 ml) at room temperature under argon was treated with triethylamine (1.3 eq., 37.7 mmol, 5.3 ml) and diphenylphosphoryl azide (1 eq., 29.5 mmol, 6.4 ml) and heated at 85° C. for 1 hr. The mixture was allowed to cool to room temperature, then treated with 1M NaOH solution (300 ml) and extracted with Et2O (3×). The combined extract was dried (Na2SO4), filtered and concentrated under vacuum to leave the title compound, 5 g, 94%.
1H NMR (DMSO, 400 MHz): 1.092 (3H, t), 1.330 (3H, s), 1.487-1.691 (8H, m), 3.392 (2H, q), 3.477 (1H, m).
A solution of trans-4-(ethyloxy)-1-isocyanato-1-methylcyclohexane (D65, 5.0 g, 27.3 mmol) in THF (100 ml) was treated with 5M aqueous HCl acid (5.5 eq., 150 mmol, 30 ml) and stirred at room temperature under argon overnight, then concentrated under vacuum. The residual semi-solid was triturated with Et2O to give a first batch of title compound as a white solid, 2.8 g. The mother liquors were evaporated, dissolved in THF again (50 ml) and treated with 5M aqueous HCl acid (15 ml) and the mixture stirred for over the weekend at room temperature. The solvent was then evaporated and the solid obtained was dried in the oven at 50° C. before trituration with Et2O. This final trituration afforded further 646 mg of title compound. The two batches were combined to afford 3.4 g, 66%.
1H NMR (DMSO, 400 MHz): 1.084 (3H, t), 1.256 (3H, s), 1.378 (2H, m), 1.619 (4H, m), 1.847 (2H, m), 3.243 (1H, m), 3.424 (2H, q), 8.090 (3H, br s).
A stirred solution of [trans-4-(ethyloxy)-1-methylcyclohexyl]amine mono hydrochloride (D66, 3.4 g, 17.8 mmol) in a mixture of ethanol (216 ml) and water (108 ml) at room temperature under argon was treated with potassium carbonate (1.1 eq., 19.6 mmol, 2.7 g) followed by 1-ethyl-1-methyl-4-oxopiperidinium iodide (D49, 1.5 eq., 26.7 mmol, 7.1 g), then heated at 80° C. for 2 hours. The mixture was allowed to cool to room temperature then the aqueous residue was treated with sat. NaHCO3 solution and extracted with dichloromethane (3×). The combined extracts were dried (Na2SO4) and concentrated under vacuum to leave the crude compound which was chromatographed on silica gel (65i column) eluting with 0-10% MeOH/DCM to afford the title compound, 2.3 g 54%.
1H NMR (DMSO, 400 MHz): 0.855 (3H, s), 1.099 (3H, t), 1.421 (2H, m), 1.544 (4H, m), 1.793 (2H, m), 2.297 (4H, t), 2.726 (4H, t), 3.377-3.430 (3H, t+m).
A solution of 1-[trans-4-(ethyloxy)-1-methylcyclohexyl]-4-piperidinone (D67, 2.3 g, 9.62 mmol) in 2M NH3/MeOH (200 ml) was treated with 10% Pd/C (510 mg) and shaken under hydrogen atmosphere at 50 psi initial pressure overnight at room temperature. The mixture was filtered through Kieselguhr to remove catalyst and the filtrate concentrated under vacuum to leave the free base of the title compound. This was dissolved in MeOH (20 ml) and treated with 10 ml of HCl (1M solution of in Et2O) for 10 min. Solvent was subsequently evaporated to afford the title compound as a white solid 2.8 g, complete conversion.
1H NMR (DMSO, 250 MHz, at 352.2K): 1.091 (6H, m br), 1.336 (2H, m), 1.695-1.865 (7H, m), 2.067 (2H, d br), 2.531 (1H, br), 3.187-3.317 (assume 6H, set of broad signals and multiplets), 3.434 (2H, q), 8.496 (2H, s br).
Propionaldehyde (6.4 g) in acetonitrile (50 ml) was added over 30 minutes to a solution of cis/trans-ethyl 4-{[(1,1-dimethylethyl)(dimethyl)silyl]oxy}cyclohexanecarboxylate (D60, 25.2 g), bismuth tribromide (4.4 g), triethylsilane (17.5 ml) in acetonitrile (300 ml) and the mixture was stirred for a further 1.5 hours. The solvent was partially removed then the residue was treated with ethyl acetate and saturated sodium bicarbonate solution. The organic layer was separated, washed with brine, dried with anhydrous sodium sulphate and the solvent was removed to give the title compound contaminated with silicone residues (39.1 g).
The product from Description 69 (39.1 g) containing cis/trans-ethyl 4-(propyloxy)cyclohexanecarboxylate, 40% w/w sodium hydroxide solution (150 ml) tetrahydrofuran (200 ml) and methanol (150 ml) was stirred for approx. 72 hours. The solvent was partially removed then the resulting mixture was treated with ethyl acetate and water. The aqueous layer was separated, acidified with concentrated hydrochloric acid and extracted with diethyl ether. The ether layer was washed with brine, dried with anhydrous sodium sulphate and the solvent was removed to give the title compound as a oil (15.42 g).
A stirred solution of diisopropylamine (24 ml, 0.17 mole) in tetrahydrofuran (300 ml) at −20° C. under argon was treated over 10 mins with 2.5M n-butyllithium in hexane (68 ml, 0.17 mole), then allowed to warm to 0° C. and stir for 15 mins. The mixture was recooled to −10° C. and treated over 10 mins with a solution of 4-(propyloxy)cyclohexanecarboxylic acid (D70, 13.8 g, 0.074 mole) in tetrahydrofuran. The resulting yellow solution was heated at 50° C. for 2.5 hrs, then cooled to 0° C. and treated with iodomethane (13.8 ml, 0.22 mole). The mixture was allowed to warm to room temperature and stir for 20 hrs when a yellow precipitate had formed. The mixture was cooled to 10° C., treated with 10% citric acid solution (200 ml), then concentrated under vacuum to approx. 250 ml volume. The residual mixture was diluted with water (200 ml) and extracted with Et2O (3×250 ml). The combined extract was dried (Na2SO4) and concentrated under vacuum to leave a yellow oil (15.0 g) which was approx. 60:40 mixture of cis:trans isomers.
cis/trans-1-Methyl-4-(propyloxy)cyclohexanecarboxylic acid (D71, 13 g, 0.070 mole) was added to stirred thionyl chloride (50 ml), 0.68 mole) at 10° C. and then allowed to warm to room temperature, followed by heating at 85° C. for 3 hrs. The mixture was concentrated under vacuum and the residue concentrated twice with toluene to remove excess thionyl chloride. The residue was dissolved in THF (100 ml), treated with dil. NaHCO3 solution (250 ml) and stirred well at room temperature for 24 hrs, followed by standing at room temperature for 3 days. The mixture from the same stage of a smaller scale reaction on 2 g of cis/trans-1-methyl-4-(propyloxy)cyclohexanecarboxylic acid was combined at this time. The combined mixture was concentrated under vacuum to approx. 300 ml and the aqueous residue washed with Et2O (2×120 ml), then acidified with 2M HCl acid and extracted with EtOAc (2×150 ml). The combined extract was dried (Na2SO4) and concentrated under vacuum to leave the title compound as a pale yellow solid (5.1 g, 34%).
1H NMR (CDCl3, 400 MHz): 0.92 (3H, t), 1.24 (3H, s), 1.54-1.74 (8H, m), 1.78-1.88 (2H, m), 3.33-3.40 (3H, m). 1H not discernible from spectrum.
A stirred solution of trans-1-methyl-4-(propyloxy)cyclohexanecarboxylic acid (D72, 5.1 g, 0.027 mole) in toluene (120 ml) at room temperature under argon was treated with triethylamine (4.9 ml, 0.035 mole) and diphenylphosphoryl azide (5.8 ml, 0.027 mole) and heated at 85° C. for 1 hr. The mixture was allowed to cool to room temperature, then treated with 1M NaOH solution (200 ml) and extracted with Et2O (2×150 ml). The combined extract was dried (Na2SO4) and concentrated under vacuum to leave the title compound as a yellow oil (5.0 g, 100%).
1H NMR (CDCl3, 400 MHz): 0.91 (3H, t), 1.36 (3H, s), 1.50-1.60 (4H, m), 1.65-1.80 (6H, m), 3.33 (2H, t), 3.46-3.52 (1H, m).
A solution of trans-1-isocyanato-1-methyl-4-(propyloxy)cyclohexane (D73, 5.0 g, 0.027 mole) in THF (100 ml) was treated with 5M HCl acid (25 ml) and stirred at room temperature under argon for 20 hrs, then concentrated under vacuum and the residue azeotroped with toluene to remove traces of water. The residual semi-solid was triturated with Et2O (120 ml) to give a solid, which was filtered off, washed with Et2O and dried at 50° C. under vacuum to afford the title compound as a white solid (4.5 g, 85%).
1H NMR (CDCl3, 400 MHz): 0.91 (3H, t), 1.47 (3H, s), 1-45-1.70 (4H, m), 1.75-2.00 (6H, m), 3.52 (2H, t), 3.40-3.48 (1H, m), 8.38 (3H, br s).
A stirred solution of [trans-1-methyl-4-(propyloxy)cyclohexyl]amine hydrochloride (D74, 4.5 g, 0.022 mole) in a mixture of ethanol (100 ml) and water (60 ml) at room temperature under argon was treated with potassium carbonate (3.31 g, 0.024 mole) followed by 1-ethyl-1-methyl-4-oxopiperidinium iodide (D49, 8.91 g, 0.033 mole), then heated at 80° C. for 2.5 hrs. The mixture was allowed to cool, concentrated under vacuum to approx. 60 ml, then the aqueous residue was treated with sat. NaHCO3 solution and extracted with dichloromethane (3×80 ml). The combined extract was dried (Na2SO4) and concentrated under vacuum to leave an orange oil (6.1 g), which was chromatographed on silica gel eluting with 0-10% MeOH/dichloromethane to afford the title compound as a yellow oil (3.45 g, 63%).
1H NMR (CDCl3, 400 MHz): 0.93 (3H, s+3H, t), 1.48-1.72 (8H, m), 1.80-1.92 (2H, m), 2.41 (4H, t), 2.82 (4H, t), 3.35-3.45 (3H, t+m).
A solution of 1-[trans-1-methyl-4-(propyloxy)cyclohexyl]-4-piperidinone (D75, 2.0 g, 0.0079 mole) in 2M NH3/MeOH (60 ml) was treated with 10% Pd/C (150 mg) and shaken under hydrogen atmosphere at 55 psi initial pressure for 3.5 days at room temperature. The mixture was filtered through Kieselguhr to remove catalyst and the filtrate concentrated under vacuum to leave the title compound as a white solid (1.82 g, 91%).
1H NMR (CDCl3, 400 MHz): 0.91 (3H, t), 1.08 (3H, br s), 1.32-1.45 (2H, m), 1.5-1-60 (2H, m), 1.62-2.60 (assume 12H, set of broad signals), 2.70-3.10 (1H, br), 34.10-3.25 (2H, br), 3.30-3.45 (3H, m), 3.40-4.40 (2H, v br).
4,5-Dimethyl-1,2-benzenediamine (409 mg, 3 mmole) and ethyl 4-oxo-1-(phenylmethyl)-3-piperidinecarboxylate (784 mg, 3 mmole) were dissolved in xylene (20 ml) and heated under argon under reflux for 8 h, then allowed to stand at room temperature overnight. The mixture was concentrated under reduced pressure, and the residue was recrystallised from ethyl acetate containing a trace of methanol to give the title compound as white crystals (463 mg, 46%). M+H=334.3.
A solution of 5,6-dimethyl-1-[1-(phenylmethyl)-1,2,3,6-tetrahydro-4-pyridinyl]-1,3-dihydro-2H-benzimidazol-2-one (D77) (333 mg, 1.0 mmole) in ethanol (10 ml) and acetic acid (2 ml), was treated with Pd/charcoal (90 mg) and shaken under 50 PSI of hydrogen pressure for 45 hr. The catalyst was filtered off and the filtrate was concentrated under reduced pressure to leave a thick oil, which crystallised using a small amount of methanol. As material was a 1:1 mixture containing title compound and 5,6-dimethyl-1-(1,2,3,6-tetrahydro-4-pyridinyl)-1,3-dihydro-2H-benzimidazol-2-one, the solid was dissolved in ethanol and acetic acid, treated with 10% Pd/C catalyst and shaken under 50 PSI hydrogen pressure over a weekend. After work-up the material still contained some 5,6-dimethyl-1-(1,2,3,6-tetrahydro-4-pyridinyl)-1,3-dihydro-2H-benzimidazol-2-one. This was used without purification.
A solution of 2-bromo-5-fluorotoluene (3.8 g) in concentrated sulfuric acid (40 ml) was treated portionwise with potassium nitrate (2.0 g) at 0-20° C. (internal). After 2 h more at the same temperature the mixture was poured onto ice and extracted with hexane. Drying and evaporation gave the title compound, 4.0 g.
A stirred solution of 1-bromo-4-fluoro-2-methyl-5-nitrobenzene (D79, 0.23 g) in dimethylformamide (5 ml) at room temperature under argon was treated with diisopropylethylamine (0.7 ml) and trans-1-[4-(ethoxy)cyclohexyl]-4-piperidinamine dihydrochloride (D20, 0.3 g) and heated at 80° C. for 18 h. The cooled reaction was diluted with ethyl acetate and washed three times with water then dried, evaporated and chromatographed (Biotage KP-NH™-silica column eluting with 0-15% ethyl acetate/hexane) to give the title compound (0.15 g).
A stirred suspension of trans-N-(4-bromo-5-methyl-2-nitrophenyl)-1-(4-ethoxycyclohexyl)-4-piperidinamine (D80,150 mg) in ethanol (10 ml) at 50° C. was treated with Raney nickel (2.0 ml of 10% aqueous suspension) followed by dropwise addition of hydrazine hydrate (0.17 ml). The mixture was heated at the same temperature for 1 h, then filtered through Kieselguhr and the filtrate evaporated and re-evaporated from toluene to afford the title compound, 130 mg.
A stirred mixture of 1-chloro-4-fluoro-2-methyl-5-nitrobenzene (D1, 310 mg, 1.6 mmole) in dimethylformamide (7 ml) at room temperature under argon was treated with diisopropylethylamine (0.71 ml, 4.0 mmole) and 1-(trans-4-ethoxycyclohexyl)piperidin-4-amine dihydrochloride (D20, 400 mg, 1.34 mmole) and heated at 85° C. for 3 hrs. The mixture was concentrated under vacuum and the residue treated with 10% Na2CO3 solution and extracted with dichloromethane. The extract was dried, concentrated under vacuum and the residue chromatographed on silica gel eluting with 0-10% methanol/dichloromethane to afford the title compound as an orange solid (425 mg, 80%). Recrystallisation from methanol (˜15 ml) afforded a crystalline orange solid (320 mg). MH+396.
1H NMR (CDCl3, 400 MHz): 1.17-1.38 (4H, m), 1.20 (3H, t), 1.59-1.71 (2H, m), 1.90-1.97 (2H, m), 2.03-2.17 (4H, m), 2.30-2.50 (3H, m), 2.36 (3H, s), 2.83-2.93 (2H, m), 3.13-3.23 (1H, m), 3.48-3.59 (3H, m), 6.70 (1H, s), 8.08 (1H, d), 8.16 (1H, s).
A stirred solution of N-(4-chloro-5-methyl-2-nitrophenyl)-1-[trans-4-(ethyloxy)cyclohexyl]-4-piperidinamine (D82, 0.32 g, 0.81 mmole) in ethanol (20 ml) at room temperature under argon was treated with Raney Nickel (˜20 mg) followed by a dropwise addition of hydrazine hydrate (0.25 ml, 8.4 mmole) and the mixture stirred at room temperature for 3 hrs. The Raney Nickel was removed by filtration through Kieselguhr and the filtrate concentrated under vacuum to afford the title compound as a pale green solid (0.295 g, 100% yield). MH+=366.
1H NMR δ (CDCl3, 400 MHz): 1.15-1.88 (4H, m), 1.19 (3H, t), 1.40-1.53 (2H, m), 1.90-1.98 (2H, m), 2.00-2.15 (4H, m), 2.25 (3H, s), 2.25-2.40 (3H, m), 2.89 (2H, br d), 3.05-3.35 (5H, m), 3.51 (2H, q), 6.47 (1H, s), 6.70 (1H, s).
A solution of 2-chloro-4-fluorotoluene (4.0 g) in concentrated sulfuric acid (30 ml) was treated portionwise with potassium nitrate (2.8 g) at <20° C. (internal). After 1 h more stirring with ice cooling the mixture was poured onto ice and extracted with diethyl ether. Drying and evaporation gave the title compound, 4.5 g.
A stirred solution of 1-chloro-5-fluoro-2-methyl-4-nitrobenzene (D84, 0.20 g) in dimethylformamide (5 ml) at room temperature under argon was treated with diisopropylethylamine (0.7 ml) and trans-1-[4-(ethoxy)cyclohexyl]-4-piperidinamine dihydrochloride (D20, 0.3 g) and heated at 50° C. for 18 h. The cooled reaction was diluted with ethyl acetate and washed three times with water then dried, evaporated and the residue crystallised from diethyl ether to give the title compound (0.10 g).
A stirred suspension of trans-N-(5-chloro-4-methyl-2-nitrophenyl)-1-(4-ethoxycyclohexyl)-4-piperidinamine (D85,100 mg) in ethanol (10 ml) at 50° C. was treated with Raney nickel (1.0 ml of 10% aqueous suspension) followed by dropwise addition of hydrazine hydrate (0.5 ml). The mixture was heated at the same temperature for 1 h, then filtered through Kieselguhr and the filtrate evaporated and re-evaporated from toluene then diethyl ether to afford the title compound, 95 mg.
To a solution of 1,5-dichloro-2-nitro-4-(trifluoromethyl)benzene (1.0 eq., 460 mg) in dry dimethylformamide (4 ml), diisopropylethylamine (2 eq., 3.54 mmol, 0.604 ml) and 1-[trans-4-(ethyloxy)cyclohexyl]-4-piperidinamine dihydrochloride (D20, 1 eq., 1.77 mmol, 400 mgs) were added at room temperature and the mixture was stirred at 45° C. for 24 hours. The crude mixture was then cooled to room temperature and the crude was poured onto water/brine; the aqueous solution was extracted with EtOAc (3×); organics were alternatively washed with brine and water (1×). The organics were combined dried over Na2SO4, filtered and the solvent was evaporated to afford the crude product. The crude product was passed through an SCX cartridge and then purified by chromatography (EtOAc-nhex) on silica column followed by another column chromatography (20% EtOAc-80% nhex) on Biotage KP-NH™-silica column to yield the title compound, 184 mgs, 23%. M++H=450.
N-[5-Chloro-2-nitro-4-(trifluoromethyl)phenyl]-1-[trans-4-(ethyloxy)cyclohexyl]-4-piperidinamine (D87, 0.409 mmol, 184 mgs) was dissolved in EtOH (15 ml) and an aqueous suspension of Raney Nickel (0.6 ml of a 50% suspension) was added at room temperature. The mixture was stirred at 40° C. before adding hydrazine monohydrate (15 eq., 6.132 mmol, 0.30 ml) over 20 minutes. The reaction mixture was filtered through a celite and the solvent was evaporated to yield the title compound, 128 mgs, 75%. W+H=420.
A stirred solution of 1-bromo-4-fluoro-2-methyl-5-nitrobenzene (D79, 0.23 g) in dimethylformamide (5 ml) at room temperature under argon was treated with diisopropylethylamine (0.7 ml) and trans-1-[4-(propoxy)cyclohexyl]-4-piperidinamine dihydrochloride (D27, 0.31 g) and heated at 80° C. for 18 h. The cooled reaction was diluted with ethyl acetate and washed three times with water then dried, evaporated and chromatographed (Biotage KP-NH™-silica column eluting with 0-15% ethyl acetate/hexane) to give the title compound (0.14 g).
A stirred suspension of trans-N-(4-bromo-5-methyl-2-nitrophenyl)-1-(4-propoxycyclohexyl)-4-piperidinamine (D89,140 mg) in ethanol (10 ml) at 50° C. was treated with Raney nickel (1.9 ml of 10% aqueous suspension) followed by dropwise addition of hydrazine hydrate (0.16 ml). The mixture was heated at the same temperature for 1 h, then filtered through Kieselguhr and the filtrate evaporated and re-evaporated from toluene to afford the title compound, 140 mg.
To a solution of 1,5-dichloro-2-nitro-4-(trifluoromethyl)benzene (1.0 eq., 430 mg) in dry dimethylformamide (4 ml), diisopropylethylamine (2 eq., 3.34 mmol, 0.60 ml) and 1-[trans-4-(propyloxy)cyclohexyl]-4-piperidinamine dihydrochloride (D27, 1 eq., 1.67 mmol, 400 mgs) were added at room temperature and the mixture was stirred at 45° C. for 24 hours. The crude mixture was then cooled to room temperature and the crude was poured onto water/brine; the aqueous solution was extracted with EtOAc (3×); organics were alternatively washed with brine and water. The organics were combined dried over Na2SO4, filtered and the solvent was evaporated to afford the crude product. The crude product was passed through an SCX cartridge and then purified by chromatography (MeOH—NH3-dichloromethane) on silica column followed by another column chromatography (20% EtOAc-80% nhex) on Biotage KP-NH™-silica column to yield the title compound; 174 mgs, 23%. M++H=464.
N-[5-Chloro-2-nitro-4-(trifluoromethyl)phenyl]-1-[trans-4-(propyloxy)cyclohexyl]-4-piperidinamine (D91, 0.375 mmol, 174 mgs) was dissolved in EtOH (15 ml) and an aqueous suspension of Raney Nickel (0.7 ml of a 50% suspension) was added at room temperature. The mixture was stirred at 40° C. before adding hydrazine monohydrate (15 eq., 5.625 mmol, 0.175 ml) over 20 minutes. The reaction was left overnight. The reaction mixture was filtered through a celite and the solvent was evaporated to yield the title compound; 158 mgs, 98%. M++H=434.
A stirred suspension of 1-{trans-4-[(1-methylethyl)oxy]cyclohexyl}-4-piperidinamine dihydrochloride (D44, 250 mg, 0.80 mmole) in dimethylformamide (4 ml) at room temperature under argon was treated with diisopropylethylamine (0.62 ml, 3.5 mmole) followed by 2,5-difluoro-4-nitrotoluene (173 mg, 1.0 mmole) and heated at 80° C. for 20 hrs. The mixture was concentrated under vacuum and the residue treated with 10% Na2CO3 solution (25 ml) and extracted with EtOAc (25 ml). The extract was dried (Na2SO4), concentrated under vacuum and the residue chromatographed on silica gel (20 g) eluting with 0-10% methanol/dichloromethane to afford the title compound as an orange solid (220 mg, 70%). MH+ 394.
1H NMR (CDCl3, 400 MHz): 1.14 (6H, d), 1.20-1.38 (4H, m), 1.60-1.72 (2H, m), 1.89-1.96 (2H, m), 2.00-2.12 (4H, m), 2.29 (3H, s), 2.30-2.50 (3H, m), 2.83-2.93 (2H, m), 3.20-3.30 (1H, m), 3.47-3.59 (1H, m), 3.66-3.76 (1H, m), 6.63 (1H, d), 7.82 (1H, d), 8.06 (1H, d).
A stirred solution of N-(4-fluoro-5-methyl-2-nitrophenyl)-1-{trans-4-[(1-methylethyl)oxy]cyclohexyl}-4-piperidinamine (D93, 220 mg, 0.56 mmole) in ethanol (15 ml) at room temperature under argon was treated with Raney Nickel (˜20 mg) followed by hydrazine hydrate (0.18 ml, 6.0 mmole) and maintained for 3 hrs. The mixture was filtered through Kieselguhr and the filtrate concentrated under vacuum to afford the title compound as a pale yellow solid (205 mg, 100% yield).
1H NMR δ (CDCl3, 400 MHz): 1.13 (6H, d), 1.20-1.38 (4H, m), 1.43-1.60 (2H, m), 1.90-1.96 (2H, m), 2.04 (4H, br d), 2.15 (3H, s), 2.30-2.42 (3H, m), 2.50-3.00 (1H, v br), 3.47 (2H, br d), 3.05-3.17 (1H, m), 3.19-3.30 (1H, m), 3.47 (2H, br s), 3.65-3.75 (1H, m), 6.40-6.48 (2H, m).
To a solution of 1,4-difluoro-2-methyl-5-nitrobenzene (2.6 eq., 2.19 mmol, 380 mg) in dry dimethylformamide (12 ml), diisopropylethylamine (2 eq., 1.68 mmol, 0.29 ml) and 1-[trans-1-methyl-4-(methyloxy)cyclohexyl]-4-piperidinamine (D59, 1 eq., 0.841 mmol, 190 mgs) were added at room temperature and the mixture was refluxed at 80° C. for 24 hours. The crude mixture was then cooled to room temperature and the crude was poured onto water (50 ml) and basified with 2M NaOH to pH 10. The aqueous solution was extracted with EtOAc (3×) and the organics were combined, dried over Na2SO4, filtered and the solvent was evaporated to afford the crude product. The crude product was passed through an SCX cartridge and then purified by chromatography (MeOH—NH3-dichloromethane) on silica column afford the title compound, 125 mgs, 40%, M++H=380.
N-(4-Fluoro-5-methyl-2-nitrophenyl)-1-[trans-1-methyl-4-(methyloxy)cyclohexyl]-4-piperidinamine (D95, 0.329 mmol, 125 mg) was dissolved in EtOH (3 ml) and an aqueous suspension of Raney Nickel (1 ml of a 50% suspension) was added at room temperature. The mixture was stirred for 30 minutes at 50° C. before adding hydrazine monohydrate (15 eq., 4.93 mmol, 0.15 ml). The reaction was left for 1 hour and then the mixture was filtered through a celite and the solvent was evaporated to afford the crude compound. The crude product was purified by chromatography (MeOH—NH3-dichloromethane) on silica column to afford the title compound, 66 mgs, 60%, M++H=350.
A stirred suspension of 1-[trans-4-(ethyloxy)-1-methylcyclohexyl]-4-piperidinamine (D68 free base, 160 mg, 0.67 mmole) in dimethylformamide (3 ml) at room temperature under argon was treated with diisopropylethylamine (0.18 ml, 1.0 mmole) followed by 2,5-difluoro-4-nitrotoluene (147 mg, 0.85 mmole) and heated at 80° C. for 16 hrs. The mixture was concentrated under vacuum and the residue treated with 10% Na2CO3 solution and extracted with dichloromethane. The extract was dried (Na2SO4), concentrated under vacuum and the residue chromatographed on silica gel (10 g) eluting with 0-10% methanol/dichloromethane. The title compound crystallised from MeOH as an orange solid (107 mg, 41%). MH+ 394.
1H NMR (CDCl3, 400 MHz): 0.93 (3H, s), 1.21 (3H, t), 1.42-1.72 (8H, m), 1.80-1.90 (2H, m), 2.02-2.12 (2H, m), 2.28-2.40 (2H, m), 2.29 (3H, s), 2.90-3.00 (2H, m), 3.35-3.43 (1H, m), 3.43-3.53 (3H, m), 6.64 (1H, d), 7.82 (1H, d), 8.05 (1H, d).
A stirred solution of 1-[trans-4-(ethyloxy)-1-methylcyclohexyl]-N-(4-fluoro-5-methyl-2-nitrophenyl)-4-piperidinamine (D97, 107 mg, 0.28 mmole) in ethanol (10 ml) at room temperature under argon was treated with Raney Nickel (˜20 mg) followed by hydrazine hydrate (0.10 ml, 3.2 mmole) and maintained for 2 hrs. The mixture was filtered through Kieselguhr to remove catalyst and the filtrate concentrated under vacuum to afford the title compound as a pale yellow oil (90 mg, 91% yield). MH+ 364.
1H NMR δ (CDCl3, 400 MHz): 0.91 (3H, s), 1.20 (3H, t), 1.34-1.58 (6H, m), 1.60-1.70 (2H, m), 1.80-1.90 (2H, m), 2.02 (2H, br d), 2.15 (3H, s), 2.18-2.28 (2H, m), 2.40-2.90 (1H, vbr), 2.95 (2H, br d), 3.04-3.14 (1H, m), 3.3-3.53 (5H, m), 6.40-6.50 (2H, m).
A stirred solution of 1-[trans-4-(ethyloxy)-1-methylcyclohexyl]-4-piperidinamine (D68 free base, 170 mg, 0.71 mmole) in dimethylformamide (4 ml) at room temperature under argon was treated with diisopropylethylamine (0.18 ml, 1.0 mmole) followed by 1-chloro-4-fluoro-2-methyl-5-nitrobenzene (D84, 190 mg, 1.0 mmole) and heated at 80° C. for 20 hrs. The mixture was concentrated under vacuum and the residue treated with 10% Na2CO3 solution and extracted with dichloromethane. The extract was dried, concentrated under vacuum and the residue chromatographed on silica gel (10 g) eluting with 0-10% methanol/dichloromethane to afford the title compound as an orange solid (210 mg, 72%). MH+ 410.
1H NMR (CDCl3, 400 MHz): 0.94 (3H, s), 1.20 (3H, t), 1.40-1.70 (8H, m), 1.80-1.90 (2H, m), 2.07 (2H, br d), 2.28-2.40 (2H, m), 2.37 (3H, s), 2.90-3.00 (2H, m), 3.35-3.42 (1H, m), 3.42-3.55 (3H, m), 6.71 (1H, s), 8.06 (1H, d), 8.16 (1H, s).
A stirred solution of N-(4-chloro-5-methyl-2-nitrophenyl)-1-[trans-4-(ethyloxy)-1-methylcyclohexyl]-4-piperidinamine (D99, 210 mg, 0.51 mmole) in ethanol (15 ml) at room temperature under argon was treated with Raney Nickel (˜20 mg) followed by hydrazine hydrate (0.17 ml, 3.5 mmole) and maintained for 1 hr. The mixture was filtered through Kieselguhr to remove catalyst and the filtrate concentrated under vacuum to afford the title compound as a pale yellow oil (195 mg, 100% yield). MH+ 380.
1H NMR δ (CDCl3, 400 MHz): 0.94 (3H, s), 1.20 (3H, t), 1.40-1.60 (6H, m), 1.60-1.72 (2H, m), 1.80-1.92 (2H, m), 2.00-2.12 (2H, m), 2.20-2.35 (2H, m), 2.25 (3H, s), 2.90-3.03 (2H, m), 3.10-3.30 (3H, m), 3.32-3.40 (1H, m), 3.48 (2H, q), 6.47 (1H, s), 6.70 (1H, s). 1H not discernible from spectrum.
A microwave vessel was charged with 2,5-difluoro-4-nitrotoluene (0.254 g), 1-[cis-1-methyl-4-(propyloxy)cyclohexyl]-4-piperidinamine (D119, 0.2 g), dimethylformamide (3 ml) and diisopropylethylamine (1.0 ml) and heated at 200° C. for 20 minutes in a microwave reactor. The cooled reaction was diluted with dichloromethane and washed with saturated sodium bicarbonate solution then the solvent was removed and the residue was chromatographed on silica gel eluted with 0-5% dichloromethane-methanolic ammonia to give the title as a yellow orange solid (0.274 g). MH+=408, 409.
A solution of N-(4-fluoro-5-methyl-2-nitrophenyl)-1-[cis-1-methyl-4-(propyloxy)cyclohexyl]-4-piperidinamine (D101, 0.274 g) in ethanol (15 ml) was added over 10 min to a solution of tin (II) chloride (0.8 g) in conc hydrochloric acid (8 ml) stirred at 60° C. The mixture was heated at 60° C. for 2 hr then poured into a mixture of dilute sodium hydroxide solution and dichloromethane. The dichloromethane layer was separated, washed with brine and dried with hydromatrix and the solvent was removed to give the title compound as a gum (0.15 g). MH+=378.
A stirred mixture of 1,4-difluoro-2-methyl-5-nitrobenzene (170 mg, 0.98 mmole), 1-[trans-1-methyl-4-(propoxy)cyclohexyl]-4-piperidinamine (D76 free base, 250 mg, 0.98 mmole) and diisopropylethylamine (0.2 ml, 1.17 mmole) in dimethylformamide (20 ml) was heated at 80° C. overnight under an argon atmosphere. The mixture was washed with sat. NaHCO3 solution then extracted with dichloromethane. The organic phase was eluted through an SCX cartridge, washed with methanol and the compound was collected by elution with 2M NH3 in MeOH. The solvent was removed under vacuum to leave the title compound as an orange solid (313 mg, 78.5%). MH+=408.
A stirred solution of N-(4-fluoro-5-methyl-2-nitrophenyl)-1-[trans-1-methyl-4-(propyloxy)cyclohexyl]-4-piperidinamine (D103, 313 mg, 0.77 mmole) in ethanol (30 ml) at room temperature under argon was treated with Raney Nickel (100 mg) and dropwise addition of hydrazine hydrate (1 ml) and maintained for 1 hr. The solution was filtered through Kieselguhr and the filtrate concentrated under vacuum to leave the title compound as a colourless oil (280 mg, 96%). MH+=378.
A microwave vessel was charged with 2-chloro-5-fluoro-4-nitrotoluene (0.22 g), 1-[cis-1-methyl-4-(propyloxy)cyclohexyl]-4-piperidinamine (D119, 0.254 g), dimethylformamide (3 ml) and diisopropylethylamine (1.0 ml) and heated at 200° C. for 20 minutes in a microwave reactor. The cooled reaction was diluted with dichloromethane and washed with saturated sodium bicarbonate solution then the solvent was removed and the residue was chromatographed on silica gel eluted with 0-5% dichloromethane-methanolic ammonia to give the title as a yellow solid (0.18 g). MH+=424, 426.
To a solution of N-(4-chloro-5-methyl-2-nitrophenyl)-1-[cis-1-methyl-4-(propyloxy)cyclohexyl]-4-piperidinamine (D105, 0.18 g) in ethanol (30 ml) and methanol (20 ml), stirred at 40° C. was added Raney-nickel (˜1 ml) and hydrazine hydrate (1 ml). The mixture was stirred for 20 min, filtered and the filtrate was evaporated to give the title compound as a gum (0.167 g). MH+=394.
A stirred mixture of 1-chloro-4-fluoro-2-methyl-5-nitrobenzene (185 mg, 0.98 mmole), 1-[trans-1-methyl-4-(propoxy)cyclohexyl]-4-piperidinamine (D76 free base, 250 mg, 0.98 mmole) and diisopropylethylamine (0.2 ml, 1.17 mmole) in dimethylformamide (20 ml) was heated at 80° C. for 1.5 hrs under an argon atmosphere. The mixture was washed with sat. NaHCO3 solution then extracted with dichloromethane. The organic phase was eluted through an SCX cartridge, washed with methanol and the compound was collected by elution with 2M NH3 in MeOH. The solvent was removed under vacuum to leave the title compound as an orange solid (340 mg, 82%). MH+=424.
A stirred solution of N-(4-chloro-5-methyl-2-nitrophenyl)-1-[trans-1-methyl-4-(propyloxy)cyclohexyl]-4-piperidinamine (D107, 340 mg, 0.8 mmole) in ethanol (30 ml) at room temperature under argon was treated with Raney Nickel (50 mg) and dropwise addition of hydrazine hydrate (1 ml) and maintained for 1 hr. The solution was filtered through Kieselguhr and the filtrate concentrated under vacuum to leave the title compound as a pale yellow oil (300 mg, 95%). MH+=394.
A stirred mixture of 1-bromo-5-fluoro-4-nitro-2-(trifluoromethyl)benzene (282 mg, 0.98 mmole), 1-[trans-1-methyl-4-(propoxy)cyclohexyl]-4-piperidinamine (D76 free base, 250 mg, 0.98 mmole) and diisopropylethylamine (0.2 ml, 1.17 mmole) in dimethylformamide (20 ml) was heated at 50° C. for 1 hr under an argon atmosphere. The mixture was washed with sat. NaHCO3 solution then extracted with dichloromethane. The organic phase was eluted through an SCX cartridge, washed with methanol and the compound was collected by elution with 2M NH3 in MeOH. The solvent was removed under vacuum to leave the title compound as a pale yellow solid (450 mg, 88%). MH+=523, 524.
1H NMR δ (CDCl3, 400 MHz): 0.90-0.97 (6H, s+t), 1.4-1.70 (assume 10H, m), 1.78-1.86 (2H, m), 2.02-2.13 (2H, m), 2.30-2.40 (2H, m), 2.90-3.00 (2H, m), 3.30-3.40 (3H, q+m), 3.45-3.58 (1H, m), 7.19 (1H, s), 8.28 (1H, d), 8.50 (1H, s).
A stirred solution of N-[5-bromo-2-nitro-4-(trifluoromethyl)phenyl]-1-[trans-1-methyl-4-(propyloxy)cyclohexyl]-4-piperidinamine (D109, 450 mg, 0.86 mmole) in ethanol (50 ml) at room temperature under argon was treated with Raney Nickel (50 mg) and dropwise addition of hydrazine hydrate (1 ml) and maintained for 45 mins. The solution was filtered through Kieselguhr and the filtrate concentrated under vacuum to leave the title compound as a red oil (420 mg, 91% purity). MH+=493, 494.
cis/trans-4-(Propyloxy)cyclohexanecarboxylic acid (D70, 13.3 g), concentrated sulfuric acid (10 ml) and methanol (100 ml) was heated at reflux for 3 hours then allowed to cool overnight. The solvent was partially removed, then the residue was poured onto a mixture of ice and dichloromethane. The organic layer was separated, washed consecutively with saturated sodium bicarbonate and brine, then dried with anhydrous sodium sulphate and the solvent was removed to give the title compound as an oil (13.42 g).
A stirred solution of diisopropylamine (11.2 ml) in tetrahydrofuran (180 ml) at −78° C. under argon was treated over 10 mins with 2.5M n-butyllithium in hexane (32 ml), then stirred for a further 30 minutes when a solution of cis/trans-methyl 4-(propyloxy)cyclohexane carboxylate (D111, 13.4 g) in tetrahydrofuran (30 ml) was added over 10 minutes. The mixture was stirred at −78° C. for 1 hour when methyl iodide (4.9 ml) was added and the mixture was stirred for 2 hours then allowed to warm to room temperature overnight. The mixture was poured into 10% citric acid solution then extracted with hexane. The hexane layer was washed with saturated sodium bicarbonate solution, brine then dried (Na2SO4) and the solvent was removed to give the title compound as an oil (13.7 g), mainly the cis isomer.
cis/trans-Methyl 1-methyl-4-(propyloxy)cyclohexanecarboxylate (D112, 13.7 g), 50% w/w sodium hydroxide solution (25 ml), tetrahydrofuran (75 ml) and methanol (25 ml) was refluxed for 4 hours then allowed to cool to room temperature overnight. The solvent was partially removed then the resulting mixture was poured onto ice and extracted with hexane. The aqueous layer was separated, acidified with concentrated hydrochloric acid and extracted with diethyl ether. The ether layer was washed with brine, dried with anhydrous sodium sulphate and the solvent was removed to give the title compound as an oil (12.13 g).
A solution of chloro(1,1-dimethylethyl)diphenylsilane (12.8 g), cis/trans-1-methyl-4-(propyloxy)cyclohexanecarboxylic acid (D113, 9.2 g) and imidazole (6.25 g) in dimethylformamide (50 ml) was stirred at 80° C. for 2 hours, then at room temperature over the weekend. The mixture was then poured into 10% citric acid solution and extracted with hexane. The extracts were washed with water, brine and then dried (Na2SO4) and the solvent was removed and the residue was chromatographed on silica gel eluted with 0-5% ethyl acetate/hexane to give the title compound (8.59 g).
A solution of cis-(1,1-dimethylethyl)(diphenyl)silyl 1-methyl-4-(propyloxy)cyclohexanecarboxylate (D114, 8.59 g), tetrabutylammonium fluoride solution in tetrahydrofuran (1M, 30 ml) and tetrahydrofuran (100 ml) was stirred at room temperature for 2 days. The mixture was then treated with citric acid solution and extracted twice with diethyl ether. The organic extracts were combined and extracted twice with sodium hydroxide solution (2M). These extracts were washed with ether and the ether was discarded. The aqueous was acidified and extracted with ether. The ether layer was dried (Na2SO4) and solvent removed to leave the title compound as a white solid (3.76 g).
A stirred solution of cis-1-methyl-4-(propyloxy)cyclohexanecarboxylic acid (D115, 3.76 g) in toluene (50 ml) at room temperature under argon was treated with triethylamine (3.8 ml) and diphenylphosphoryl azide (3.9 ml) and heated at 100° C. for 20 minutes. The mixture was allowed to cool to room temperature, washed with sodium bicarbonate solution, brine and dried hydromatrix to give the title compound as a oil (3.82)
A solution of cis-1-isocyanato-1-methyl-4-(propyloxy)cyclohexane (D116, 3.82 g), water (20 ml) and 4M hydrogen chloride in dioxane (20 ml) was stirred at room temperature for 4 hours, then the solvent was removed to give the title compound as a sticky solid (3.36 g).
A solution of [cis-1-methyl-4-(propyloxy)cyclohexyl]amine hydrochloride (D117, 3.36 g) in ethanol (50 ml) and water (25 ml) together with potassium carbonate (3.8 g) and 1-ethyl-1-methyl-4-oxopiperidinium iodide (D49, 6.7) was heated at reflux for 2 hours. The solvent was partially removed and then the aqueous residue was treated with sat. NaHCO3 solution and extracted twice with dichloromethane. The combined extracts were washed with brine, dried hydromatrix and the solvent was removed to afford the title compound as a oil (2.92 g).
A solution of 1-[cis-1-methyl-4-(propyloxy)cyclohexyl]-4-piperidinone (D118, 2.92 g) in 2M NH3/MeOH (150 ml) was treated with 10% Pd/C (2 g) and shaken under hydrogen atmosphere at 50 psi initial pressure for 1 overnight. The mixture was filtered to remove catalyst and the filtrate concentrated under vacuum to leave the title compound as an oil (2.81 g).
4,5-Dimethyl-1,2-benzenediamine (100 mg, 0.74 mmol) and 1-[trans-4-(ethyloxy)-1-methylcyclohexyl]-4-piperidinone (D67, 176 mg, 0.74 mmol) were dissolved in isopropyl acetate (5 ml) at room temperature under argon. Trifluoroacetic acid (0.1 ml, 1.48 mmol) was added, followed by the addition of sodium triacetoxyborohydride (188 mg, 0.89 mmol) over approximately one minute. The mixture was stirred at room temperature under argon for 2 hours. Further sodium triacetoxyborohydride (188 mg, 0.89 mmol) added and stirring continued for 30 minutes. More isopropyl acetate (2 ml) was added, followed by sodium triacetoxyborohydride (313 mg, 1.48 mmol) and the mixture was then stirred under argon at room temperature overnight. Aqueous sodium hydroxide (0.5M) was added until solution reached pH 10, then the layers were separated. The aqueous layer was extracted with ethyl acetate, and the combined organic layers were washed with brine, dried over Na2SO4 and concentrated under vacuum to give orange crystals (200 mg). These crystals were purified by silica chromatography (Biotage 12s column, gradient 0-10% NH3/MeOH/DCM over 10 column volumes followed by 10 column volumes at 10%) to afford the title compound (35 mg). MH+=360.
4,5-Difluoro-1,2-benzenediamine (380 mg, 2.6 mmol) and 1-[trans-4-(ethyloxy)-1-methylcyclohexyl]-4-piperidinone (D67, 500 mg, 2.1 mmol) were dissolved in isopropyl acetate (20 ml) under argon at room temperature. Trifluoroacetic acid (0.3 ml, 4.44 mmol) was added, followed by addition of sodium triacetoxyborohydride 2.3 g, 10.5 mmol). The mixture was stirred under argon at room temperature for 30 minutes, followed by a further 3 hours of the same. Water (≈10 ml) was added, followed by portionwise addition of sodium hydroxide until the mixture reached a pH of approximately 10. The layers were separated and the aqueous layer was extracted with ethyl acetate. The combined organic layers were washed with brine, dried over sodium sulphate and concentrated under vacuum to give the title compound as brown/yellow solid (1.3 g). MH+=368.
Diisopropylethylamine (0.52 mL, 3.06 mmole) and 5-chloro-2-fluoro-1-nitrobenzene (359 mg, 2.05 mmole) were added to a solution of 1-[trans-4-(methyloxy)-1-methylcyclohexyl]-4-piperidinamine dihydrochloride (diHCl salt of D59, 302 mg, 1.01 mmole) in N,N-dimethylformamide (5 ml) at r.t. The reaction was heated at 110° C. in a microwave reactor for 30 min and then the mixture was poured on to sat. NaHCO3 solution (50 mL) and extracted with EtOAc (3×). The combined organics were washed sequentially with brine, H2O and brine, dried (Na2SO4) and concentrated via rotary evaporation. The crude residue was purified by SCX (5 g) and then chromatographed (silica, CH2Cl2-0.5% NH3/9.5% MeOH/90% CH2Cl2) to yield the title compound (190 mg, 49%) as an orange solid. M(Cl-35)+ 382, M(Cl-37)H+ 384.
N-(4-Chloro-2-nitrophenyl)-1-[trans-1-methyl-4-(methyloxy)cyclohexyl]-4-piperidinamine (D122, 190 mg, 0.50 mmole) was suspended in EtOH (10 mL) under argon. The reaction was stirred vigorously and Raney Nickel (0.25 mL, 10% sol. in H2O) was added, followed by the hydrazine hydrate (150 μL, 4.82 mmole). A second portion of Raney Nickel (0.25 mL, 10% sol. in H2O) was added and the reaction was stirred vigorously for 30 min. The mixture was filtered through Kieselguhr using EtOH followed by MeOH and EtOAc and concentrated by rotary evaporation. The crude residue was taken up in EtOH and concentrated twice and then in CH2Cl2 and concentrated twice to give the title compound (84 mg, 48%) as a brown solid. M(Cl-35)+ 352, M(Cl-37)H+ 354.
Diisopropylethylamine (0.52 mL, 3.06 mmole) and 5-chloro-2-fluoro-1-nitrobenzene (365 mg, 2.08 mmole) were added to a solution of 1-[trans-4-(ethyloxy)-1-methylcyclohexyl]-4-piperidinamine dihydrochloride (D68, 317 mg, 1.01 mmole) in N,N-dimethylformamide (5 ml) at r.t. The reaction was heated at 110° C. in a microwave reactor for 30 min and then the mixture was poured on to sat. NaHCO3 solution (50 mL) and extracted with EtOAc (3×). The combined organics were washed sequentially with brine, H2O and brine, dried (Na2SO4) and concentrated via rotary evaporation. The crude residue was purified by SCX (5 g) and then chromatographed (silica, CH2Cl2-0.5% NH3/9.5% MeOH/90% CH2Cl2) to yield the title compound (117 mg, 29%) as an orange solid. M(Cl-35)+ 396, M(Cl-37)H+ 398.
N-(4-Chloro-2-nitrophenyl)-1-[trans-4-(ethyloxy)-1-methylcyclohexyl]-4-piperidinamine (D124, 117 mg, 0.29 mmole) was suspended in EtOH (10 mL) under argon. The reaction was stirred vigorously and Raney Nickel (0.25 mL, 10% sol. in H2O) was added, followed by the hydrazine hydrate (90 μL, 2.89 mmole). A second portion of Raney Nickel (0.25 mL, 10% sol. in H2O) was added and the reaction was stirred vigorously for 30 min. The mixture was filtered through Kieselguhr using EtOH and concentrated by rotary evaporation. The crude residue was azeotroped with toluene (2×) to give the title compound (102 mg, 96%) as a pale brown solid. M(Cl-35)+ 366, M(Cl-37)H+ 368.
A stirred solution of 4-amino-2-chloro-5-iodobenzonitrile (J. Med. Chem. 2001, 44 (23), 3866) (440 mg, 1.60 mmole) in dioxane (5 ml) at room temperature under argon was treated with solid triphosgene (160 mg, 0.54 mmole), maintained at room temperature for 15 minutes, then heated at 95° C. for 20 minutes. The mixture was allowed to cool, concentrated under vacuum and the residue dissolved in dichloromethane (10 ml) and treated with a solution of 1-(trans-4-ethoxycyclohexyl)piperidin-4-amine (D20, 360 mg, 1.60 mmole) in dichloromethane (5 ml). The mixture was stirred at room temperature for 18 hrs when a precipitate had formed. This was filtered off and dried to give a white solid (560 mg). The material proved very insoluble in MeOH, so it was dissolved in DMSO and loaded on to an SCX cartridge (2 g) which was washed with MeOH and then eluted with 2M NH3/MeOH to remove part of the relatively insoluble material. The ammonia solution was concentrated under vacuum to leave the title compound as a white solid (300 mg). MH+ 531.
1H NMR δ (d6DMSO, 400 MHz): 1.06 (3H, t), 1.04-1.40 (6H, m), 1.73 (2H, br d), 1.82 (2H, br d), 1.99 (2H, br d), 2.18-2.30 (3H, m), 2.75 (2H, br d), 3.08-3.18 (1H, m), 3.37-3.48 (3H, m+q), 7.64 (1H, d), 7.93 (1H, s), 8.37 (2H, s).
A stirred solution of (2-amino-4-fluoro-5-methylphenyl){1-[cis-4-(methyloxy)cyclohexyl]-4-piperidinyl}amine (D9, 0.33 g, 1.04 mmole) and diisopropylethylamine (0.28 ml, 1.56 mmole) in dichloromethane (30 ml) at 0° C. under argon was treated with solid triphosgene (123 mg, 0.42 mmole) and maintained at 0° C. for 2 h. The mixture was treated with water followed by dil. NaHCO3 solution and extracted with dichloromethane (3×20 ml). The combined extract was dried with Na2SO4 and concentrated under vacuum to leave the title compound as a white solid (337 mg, 95% yield). A portion of this material (260 mg) was dissolved in methanol/diethyl ether (1:3 mixture, 10 ml), treated with 1M HCl/diethyl ether (5 ml) and concentrated under vacuum to give the hydrochloride salt as a white solid (300 mg). MH+=362 and 363.
1H NMR (HCl salt) δ (CD3OD, 400 MHz): 1.55 (2H, m), 1.8-1.9 (4H, m), 2.1-2.2 (4H, m), 2.3 (3H, s), 2.8-2.9 (2H, m), 3.3-3.4 (6H, m), 3.5 (1H, s), 3.65 (2H, m), 4.5 (1H, m), 6.8 (1H, d), 7.2 (1H, m).
A stirred solution of (2-amino-4-fluoro-5-methylphenyl){1-[trans-4-(methyloxy)cyclohexyl]-4-piperidinyl}amine (D10, 0.25 g, 0.78 mmole) and diisopropylethylamine (0.21 ml, 1.17 mmole) in dichloromethane (25 ml) at 0° C. under argon was treated with solid triphosgene (92 mg, 0.31 mmole) and maintained at 0° C. for 2 h. The mixture was treated with water followed by dil. NaHCO3 solution and extracted with dichloromethane. The combined extract was dried with Na2SO4 and concentrated under vacuum to leave the title compound as a white solid (173 mg, 62% yield). This material was dissolved in methanol/diethyl ether (1:3 mixture, 10 ml), treated with 1M HCl/diethyl ether (5 ml) and concentrated under vacuum to give the hydrochloride salt as a white solid (190 mg).
1H NMR (HCl salt) δ (CD3OD, 400 MHz): 1.3-1.4 (2H, m), 1.6-1.7 (2H, m), 2.1-2.3 (6H, m), 2.3 (3H, s), 2.8-2.9 (2H, m), 3.3-3.4 (7H, m), 3.65 (2H, m), 4.5 (1H, m), 6.8 (1H, d), 7.2 (1H, d).
MH+=362 and 363.
A stirred solution of (2-amino-4-chloro-5-methylphenyl){1-[cis-4-(methyloxy)cyclohexyl]-4-piperidinyl}amine (D12, 0.22 g, 0.63 mmole) and diisopropylethylamine (0.17 ml, 0.95 mmole) in dichloromethane (20 ml) at 0° C. under argon was treated with solid triphosgene (76 mg, 0.25 mmole) and maintained at 0° C. for 30 minutes. The mixture was treated with water followed by dil. NaHCO3 solution and extracted with dichloromethane (3×20 ml). The combined extract was dried with Na2SO4 and concentrated under vacuum to leave the title compound as a white solid (227 mg, 96% yield). This material was dissolved in dichloromethane (10 ml), treated with 1M HCl/diethyl ether (5 ml) and concentrated under vacuum to give the hydrochloride salt as a pale yellow solid.
1H NMR (HCl salt) δ (CD3OD, 400 MHz): 1.5 (2H, m), 1.8-2.0 (4H, m), 2.1-2.2 (4H, m), 2.4 (3H, s), 2.8-2.9 (2H, m), 3.3-3.4 (6H, m), 3.5 (1H, s), 3.7 (2H, m), 4.5-4.6 (1H, m), 7.1 (1H, s), 7.3 (1H, s).
MH+=378, 379, 380 and 381.
A stirred solution of (2-amino-4-chloro-5-methylphenyl){1-[trans-4-(methyloxy)cyclohexyl]-4-piperidinyl}amine (D13, 0.13 g, 0.36 mmole) and diisopropylethylamine (0.1 ml, 0.54 mmole) in dichloromethane (15 ml) at 0° C. under argon was treated with solid triphosgene (43 mg, 0.14 mmole) and maintained at 0° C. for 30 min. The mixture was treated with water followed by dil. NaHCO3 solution and extracted with dichloromethane (3×20 ml). The combined extract was dried with Na2SO4 and concentrated under vacuum to leave a white solid. Residue was a mixture of benzimidazolone (80%) and starting material (20%): residue was chromatographed on silica (5 g of silica for 150 mg of crude: 0% to 5% 0.4M NH3 in methanol/dichloromethane 8CV) to afford 80 mg of title compound, (59% yield). This material was dissolved in dichloromethane (10 ml), treated with 1M HCl/diethyl ether (5 ml) and concentrated under vacuum to give the hydrochloride salt as a white solid.
1H NMR (HCl salt) δ (CD3OD, 400 MHz): 1.3-1.4 (2H, m), 1.6-1.7 (2H, m), 2.1 (2H, m), 2.2-2.3 (4H, m), 2.4 (3H, s), 2.8-2.9 (2H, m), 3.2-3.4 (7H, m), 3.65 (2H, m), 4.55 (1H, m), 7.0 (1H, s), 7.3 (1H, s). MH+=378, 379, 380 and 381.
A stirred solution of 2-amino-5-bromo-4-(trifluoromethyl)phenyl]{1-[cis-4-(methyloxy)cyclohexyl]-4-piperidinyl}amine (D15, 480 mg, 1.04 mmole) and diisopropylethylamine (0.29 ml, 1.59 mmole) in dichloromethane (35 ml) at 0° C. under argon was treated with solid triphosgene (127 mg, 0.42 mmole) and maintained at 0° C. for 1 h. The mixture was treated with water followed by dil. NaHCO3 solution and extracted with dichloromethane (3×20 ml). The combined extract was dried with Na2SO4 and concentrated under vacuum to leave a beige solid (mix: 40% of compound+impurity). The residue was chromatographed on silica column (550 mg of crude for 2×40 g of silica: 3CV 5% to 5%, 10CV 5% to 15%, 3CV 15% to 15% 0.4M NH3 in methanol/dichloromethane) to give the title compound as a white solid (130 mg). This material was dissolved in dichloromethane (10 ml), treated with 1M HCl/diethyl ether (5 ml) and concentrated under vacuum to give the hydrochloride salt as a white solid (150 mg, 29% yield).
1H NMR (HCl salt) δ (CD3OD, 400 MHz): 1.5-1.6 (2H, m), 1.8-1.9 (4H, m), 2.1-2.2 (4H, m), 2.65-2.9 (2H, m), 3.2-3.4 (6H, m), 3.5 (1H, s), 3.7 (2H, m), 4.55 (1H, m), 7.4 (1H, s), 7.8 (1H, s). MH+=477, 478 and 479.
A stirred solution of [2-amino-5-bromo-4-(trifluoromethyl)phenyl]{1-[trans-4-(methyloxy)cyclohexyl]-4-piperidinyl}amine (D16, 212 g, 0.47 mmole) and diisopropylethylamine (0.13 ml, 0.7 mmole) in dichloromethane (20 ml) at 0° C. under argon was treated with solid triphosgene (60 mg, 0.19 mmole) and maintained at 0° C. for 1 h. The mixture was treated with water followed by dil. NaHCO3 solution and extracted with dichloromethane. The combined extract was dried with Na2SO4 and concentrated under vacuum to leave a pale yellow solid (220 mg: mixture of compound (55%) and subcompounds). The residue was purified with MDAP to afford the title compound as a white solid (60 mg, 27% yield). This material was dissolved in dichloromethane (5 ml), treated with 1M HCl/diethyl ether (1 ml) and concentrated under vacuum to give the hydrochloride salt as a white solid.
1H NMR (HCl salt) δ (CD3OD, 400 MHz): 1.3-1.4 (2H, m), 1.6-1.7 (2H, m), 2.1-2.2 (4H, m), 2.3 (2H, m), 2.75-2-85 (2H, m), 3.2-3.3 (4H, m), 3.4 (3H, s), 3.7 (2H, m), 4.6 (1H, m), 7.4 (1H, s), 7.7 (1H, s).
MH+=477, 478 and 479.
A stirred solution of N-{1-[trans-4-(ethyloxy)cyclohexyl]-4-piperidinyl}-4-fluoro-5-methyl-1,2-benzenediamine (D22, 74 mg, 0.212 mmole) and diisopropylethylamine (0.061 ml, 0.337 mmole) in dichloromethane (10 ml) at 0° C. under argon was treated with solid triphosgene (25 mg, 0.085 mmole) and maintained at 0° C. for 1 h. The mixture was treated with water (10 ml) followed by NaHCO3 solution (10 ml) and extracted with dichloromethane (2×10 ml). The combined extract was dried (Na2SO4) and concentrated under vacuum. The residue was triturated with 1:1 ethyl acetate/diethyl ether (5 ml), allowed to stand for 20 minutes, then the solid filtered off, washed with cold 1:1 ethyl acetate/diethyl ether and dried to afford the title compound as a white solid (57 mg, 72%). This was dissolved in dichloromethane (2 ml) and methanol (0.4 ml), treated with 1M HCl/diethyl ether (0.25 ml) and concentrated under vacuum. The residue was triturated with diethyl ether and the solid obtained filtered off, washed with diethyl ether and dried to afford the hydrochloride salt as a white solid.
1H NMR (HCl salt) (d6DMSO, 400 MHz): 1.09 (3H, t), 1.12-1.28 (2H, m), 1.47-1.62 (2H, m), 1.80-1.90 (2H, m), 2.03-2.22 (4H, m), 2.24 (3H, s), 2.80-2.98 (2H, m), 3.13-3.30 (4H, m), 3.40-3.68 (4H, m), 4.50-4.65 (1H, m), 6.79 (1H, d), 7.70 (1H, d), 10.80 (1H, br m), 10.98 (1H, s).
A stirred solution of 4-chloro-5-methyl-N-{1-[cis-4-(propyloxy)cyclohexyl]-4-piperidinyl}-1,2-benzenediamine (D30, 630 mg, 1.66 mmole) and diisopropylethylamine (0.44 ml, 2.49 mmole) in dichloromethane (40 ml) at 0° C. under argon was treated with solid triphosgene (198 mg, 0.66 mmole) and maintained at 0° C. for 40 minutes. The mixture was treated with water (20 ml) followed by dil. NaHCO3 solution (25 ml) and extracted with dichloromethane (2×30 ml). The combined extract was dried (Na2SO4) and concentrated under vacuum to leave a yellow oil, which crystallised from ethyl acetate (15 ml) to afford the title compound as a beige solid (347 mg, 52%). A portion of this material (300 mg) was dissolved in dichloromethane (7 ml), treated with 1M HCl/diethyl ether (1 ml) and concentrated under vacuum to give the hydrochloride salt as a white solid.
1H NMR (HCl salt) (d6DMSO, 400 MHz): 0.90 (3H, t), 1.38-1.58 (4H, m), 1.62-1.77 (2H, m), 1.80-2.05 (6H, m), 2.34 (3H, s), 2.82-2.97 (2H, m), 3.17-3.40 (6H, m), 3.45-3.55 (2H, m), 4.50-4.62 (1H, m), 7.00 (1H, s), 7.83 (1H, s), 10.78 (1H, br s), 11.00 (1H, s).
A stirred solution of 4-chloro-5-methyl-N-{1-[trans-4-(propyloxy)cyclohexyl]-4-piperidinyl}-1,2-benzenediamine (D32, 360 mg, 0.95 mmole) and diisopropylethylamine (0.25 ml, 1.42 mmole) in dichloromethane (25 ml) at 0° C. under argon was treated with solid triphosgene (113 mg, 0.38 mmole) and maintained at 0° C. for 45 minutes. The mixture was treated with water (15 ml) followed by sat. NaHCO3 solution (10 ml) and extracted with dichloromethane. The extract was dried (Na2SO4) and concentrated under vacuum. Trituration of the residue with 1:1 ethyl acetate/diethyl ether produced a solid which was filtered off, washed with 1:1 ethyl acetate/diethyl ether and dried at 50° C. under vacuum to afford the title compound as a white solid (260 mg, 68%). A portion of this material (210 mg) was dissolved in dichloromethane (5 ml), treated with 1M HCl/diethyl ether (0.7 ml) and concentrated under vacuum to give the hydrochloride salt as a white solid.
1H NMR (HCl salt) (d6DMSO, 400 MHz): 0.86 (3H, t), 1.15-1.28 (2H, m), 1.42-1.62 (4H, m), 1.80-1.90 (2H, m), 2.05-2.25 (4H, m), 2.34 (3H, s), 2.84-3.00 (2H, m), 3.12-3.30 (4H, m), 3.30-3.40 (2H, m), 3.45-3.52 (2H, m), 4.53-4.66 (1H, m), 6.70 (1H, s), 7.86 (1H, s), 10.95 (1H, br s), 10.98 (1H, s).
A stirred solution of 4-fluoro-5-methyl-N-{1-[cis-4-(propyloxy)cyclohexyl]-4-piperidinyl}-1,2-benzenediamine (D34, 290 mg, 0.80 mmole) and diisopropylethylamine (0.21 ml, 1.20 mmole) in dichloromethane (20 ml) at 0° C. under argon was treated with solid triphosgene (95 mg, 0.32 mmole) and maintained at 0° C. for 1 h. The mixture was treated with water (10 ml) followed by dil. NaHCO3 solution (15 ml) and extracted with dichloromethane (2×20 ml). The combined extract was dried (Na2SO4) and concentrated under vacuum. The residue was triturated with diethyl ether to afford the title compound as a white solid (157 mg, 51%). A portion of this material (117 mg) was dissolved in dichloromethane (2 ml) and methanol (0.2 ml), treated with 1M HCl/diethyl ether (0.45 ml) and concentrated under vacuum to give the hydrochloride salt as a white solid.
1H NMR (HCl salt) (d6DMSO, 400 MHz): 0.90 (3H, t), 1.38-1.58 (4H, m), 1.62-1.77 (2H, m), 1.80-2.05 (5H, m), 2.23 (3H, s), 2.82-3.00 (2H, m), 3.18-3.40 (6H, m), 3.44-3.55 (3H, m), 4.50-4.65 (1H, m), 6.69 (1H, d), 7.71 (1H, d), 10.78 (1H, br s), 10.95 (1H, s).
A stirred solution of 4-fluoro-5-methyl-N-{1-[trans-4-(propyloxy)cyclohexyl]-4-piperidinyl}-1,2-benzenediamine (D36, 158 mg, 0.44 mmole) and diisopropylethylamine (0.12 ml, 0.66 mmole) in dichloromethane (15 ml) at 0° C. under argon was treated with solid triphosgene (52 mg, 0.18 mmole) and maintained at 0° C. for 40 minutes. The mixture was treated with water (10 ml) followed by dil. NaHCO3 solution (15 ml) and extracted with dichloromethane (2×15 ml). The combined extract was dried (Na2SO4) and concentrated under vacuum. Trituration of the residue with 1:1 ethyl acetate/diethyl ether (8 ml) produced a white solid which was filtered off, washed with cold 1:1 ethyl acetate/diethyl ether and dried at 50° C. under vacuum to afford the title compound as a white solid (89 mg, 53%). This material was dissolved in dichloromethane (1 ml) and methanol (0.3 ml), treated with 1M HCl/diethyl ether (0.34 ml) and the solvent evaporated off under a stream of air to leave the hydrochloride salt as a white solid.
1H NMR (HCl salt) (d6DMSO, 400 MHz): 0.86 (3H, t), 1.14-1.30 (2H, m), 1.43-1.63 (4H, m), 1.80-1.90 (2H, m), 2.05-2.22 (4H, m), 2.24 (3H, s), 2.82-2.98 (2H, m), 3.14-3.30 (4H, m), 3.30-3.40 (2H, m), 3.44-3.54 (2H, m), 4.5-4.62 (1H, m), 6.79 (1H, d), 7.71 (1H, d), 10.86 (1H, br s), 10.95 (1H, s).
A stirred solution of 5-bromo-N-{1-[cis-4-(propyloxy)cyclohexyl]-4-piperidinyl}-4-(trifluoromethyl)-1,2-benzenediamine (D38, 190 mg, 0.40 mmole) and diisopropylethylamine (0.107 ml, 0.60 mmole) in dichloromethane (15 ml) at 0° C. under argon was treated with solid triphosgene (47 mg, 0.16 mmole) and maintained at 0° C. for 1.5 h. The mixture was treated with water (10 ml) followed by dil. NaHCO3 solution and extracted with dichloromethane (2×15 ml). The combined extract was dried (Na2SO4) and concentrated under vacuum. The residual solid was treated with ethyl acetate (15 ml), stirred for 10 minutes and the remaining solid filtered off, washed with ethyl acetate and dried to afford the title compound as a white solid (124 mg, 62%). This material was dissolved in dichloromethane (2 ml) and methanol (0.5 ml), treated with 1M HCl/diethyl ether (0.37 ml) and then concentrated under vacuum to leave the hydrochloride salt as a white solid.
1H NMR (HCl salt) 5 (d6DMSO, 400 MHz): 0.90 (3H, t), 1.40-1.58 (4H, m), 1.62-1.78 (2H, m), 1.85-2.05 (6H, m), 2.70-2.88 (2H, m), 3.16-3.40 (5H, m), 3.46-3.58 (3H, m), 4.56-4.68 (1H, m), 7.34 (1H, s), 8.08 (1H, s), 10.38 (1H, br s), 11.50 (1H, s).
To a solution of 5-bromo-N-{1-[trans-4-(propyloxy)cyclohexyl]-4-piperidinyl}-4-(trifluoromethyl)-1,2-benzenediamine (D40, 170 mg, 0.4 mmole) in dichloromethane (10 ml), diisopropylethylamine (0.09 ml, 1.5 eq., 0.5 mmole) was added at room temperature. The mixture was cooled to 0° C. and bis(trichloromethyl)carbonate (40 mg, 0.4 eq., 0.14 mmole) was added. After 30 minutes the mixture was poured onto water/brine; the aqueous solution was extracted with dichloromethane (2×) and the organics were alternatively washed with brine and water (2×). The organics were combined, dried over Na2SO4, filtered and the solvent was evaporated. The product was treated with HCl (3 ml of a 1M solution in diethyl ether) to yield the title product (40 mgs, 22%). M+−H=504.
1H NMR (free base) δ (d6DMSO, 400 MHz) 0.85 (3H, t), 1.13 (2H, q), 1.28 (2H, q), 1.46 (2H, m), 1.66 (2H, d), 1.78 (2H, d), 2.00 (2H, d), 2.29 (4H, m), 2.90 (2H, s, br), 3.12 1H, m), 3.33 (m), 4.12 (1H, m), 7.29 (1H, s), 7.69 (1H, s), 10.35 (1H, s).
A stirred solution of containing a mixture of 5,6-dimethyl-1-(4-piperidinyl)-1,3-dihydro-2H-benzimidazol-2-one and 5,6-dimethyl-1-(1,2,3,6-tetrahydro-4-pyridinyl)-1,3-dihydro-2H-benzimidazol-2-one (D78, 220 mg, 0.90 mmole) in DCM (8 ml) at room temperature under argon was treated with 4-ethoxycyclohexanone (D18, 156 mg, 1.10 mmole) followed by sodium triacetoxyborohydride (317 mg, 1.50 mmole) and maintained for 18 hrs. Further 4-ethoxycyclohexanone (100 mg) and sodium triacetoxyborohydride (150 mg) was added and stirring maintained for 4 days. The reaction mixture was concentrated under vacuum and the residue treated with 10% Na2CO3 solution and extracted with EtOAc. The extract was dried and concentrated under vacuum. The residue was chromatographed on silica gel (20 g) eluting with 0-10% MeOH/dichloromethane to give a yellow oil, which was dissolved in a mixture of EtOH (15 ml) and acetic acid (1 ml), treated with 10% Pd/C (20 mg) and shaken under 50 psi hydrogen pressure for 20 hrs. The catalyst was removed by filtration through Kieselguhr and the filtrate concentrated under vacuum. The residue was treated with 10% Na2CO3 solution (10 ml) and extracted with EtOAc (2×10 ml). The combined extract was dried (Na2SO4) and concentrated under vacuum to leave a beige solid containing a mixture of cis and trans isomers. This was chromatographed on silica gel (40 g) eluting with 10-13% MeOH/dichloromethane to afford partial separation. Fractions containing the higher rf material were combined, concentrated under vacuum and the residue crystallised from EtOAc to afford the title compound trans isomer (E15) as a white solid (7.7 mg). MH+ 372.
1H NMR δ (CDCl3, 400 MHz): 1.20-1.40 (4H, m), 1.21 (3H, t), 1.80-1.90 (2H, m), 1.90-2.00 (2H, m), 2.10-2.20 (2H, m), 2.25 (3H, s), 2.27 (3H, s), 2.35-2.50 (5H, m), 3.00-3.13 (2H, m), 3.15-3.25 (1H, m), 3.53 (2H, q), 4.27-4.40 (1H, m), 6.90 (1H, s), 7.09 (1H, s), 9.53 (1H, s).
Fractions containing the lower rf material were combined and concentrated under vacuum to afford the title compound cis isomer (E14) as a white solid (27 mg). MH+ 372.
1H NMR δ (CDCl3, 400 MHz): 1.20 (3H, t), 1.36-1.50 (2H, m), 1.55-2.05 (8H, m), 2.25 (3H, s), 2.28 (3H, s), 2.30-2.50 (5H, m), 3.10 (2H, br s), 3.46 (2H, q), 3.48-3.55 (1H, m), 4.35 (1H, br s), 6.90 (1H, s), 7.11 (1H, br s), 9.52 (1H, s).
A solution of trans-4-bromo-5-methyl-N-[1-(4-ethoxycyclohexyl)-4-piperidinyl]-1,2-benzenediamine (D81, 130 mg) in dichloromethane (6 ml) at 0° C. was treated with triphosgene (40 mg) then diisopropylethylamine (0.08 ml), and then maintained at 0° C. for 1 h. The mixture was partitioned between dichloromethane and aqueous sodium bicarbonate. Drying, evaporation and chromatography (10 g silica, 0-10% methanol in dichloromethane) gave the title compound isolated as the hydrochloride salt from diethyl ether, 70 mg.
1HNMR (HCl salt) (d6DMSO): 1.1 (3H, t), 1.2 (2H, m), 1.55 (2H, m), 1.9 (2H, m), 2.15 (4H, m), 2.35 (3H, s), 2.8 (2H, m), 3.1-3.5 (11H, m), 4.6 (1H, m), 7.1 (1H, s), 7.7 (1H, s), 10.5 (1H, br s), 11.0 (1H, s), MH+436 and 438.
A stirred solution of 4-chloro-N-{1-[trans-4-(ethyloxy)cyclohexyl]-4-piperidinyl}-5-methyl-1,2-benzenediamine (D83, 195 mg, 0.81 mmole) in dichloromethane (25 ml) at 0° C. under argon was treated with diisopropylethylamine (0.21 ml, 1.20 mmole) followed by the addition of solid triphosgene (95 mg, 0.32 mmole) and maintained at 0° C. for 45 mins. The mixture was treated with water (10 ml) followed by dil. NaHCO3 solution (15 ml), stirred well for 15 mins, then extracted with dichloromethane (2×25 ml). The combined extract was dried (Na2SO4) and concentrated under vacuum to leave a beige solid, which was recrystallised from a mixture of EtOAc (20 ml) and MeOH (3 ml) to afford the free base of the title compound as a white solid (220 mg, 70%). This was dissolved in dichloromethane (4 ml) and MeOH (12 ml), treated with 1M HCl/Et2O (0.8 ml) and concentrated under vacuum. The residue was triturated with Et2O (15 ml) to give a white solid which was filtered off, washed with Et2O and dried to afford the title compound as a white solid. M++H=392.
1H NMR δ (d6DMSO, 400 MHz): 1.09 (3H, t), 1.13-1.30 (2H, m), 1.48-1.62 (2H, m), 1.80-1.90 (2H, m), 2.06-2.22 (4H, m), 2.34 (3H, s), 2.83-2.96 (2H, m), 3.14-3.30 (4H, m), 3.42-3.55 (4H, m), 4.52-4.65 (1H, m), 7.00 (1H, s), 7.85 (1H, s), 10.90 (1H, br s), 10.98 (1H, s).
A solution of trans-5-chloro-4-methyl-N-[1-(4-ethoxycyclohexyl)-4-piperidinyl]-1,2-benzenediamine (D86, 95 mg) in dichloromethane (3 ml) at 0° C. was treated with triphosgene (30 mg) then diisopropylethylamine (0.1 ml), and then maintained at 0° C. for 30 min. The mixture was partitioned between dichloromethane and aqueous sodium bicarbonate. Drying, evaporation and crystallisation from diethyl ether gave the title compound which was isolated as the hydrochloride salt from diethyl ether, 75 mg.
1HNMR (HCl salt) (d6DMSO): 1.1 (3H, t), 1.2 (2H, m), 1.55 (2H, m), 1.9 (2H, m), 2.15 (4H, m), 2.35 (3H, s), 2.8 (2H, m), 3.1-3.5 (13H, m), 4.6 (1H, m), 6.9 (1H, s), 7.6 (1H, d, J=5 Hz), 10.2 (1H, br s), 11.0 (1H, s), MH+392 and 394.
To a solution of [2-chloro-4-(trifluoromethyl)phenyl]{1-[trans-4-(ethyloxy)cyclohexyl]-4-piperidinyl}amine (D88, 0.30 mmol, 128 mgs) in dichloromethane (10 ml), diisopropylethylamine (1.5 eq., 0.45 mmol, 0.08 ml) was added at room temperature. The mixture was cooled to 0° C. and bis(trichloromethyl)carbonate (0.4 eq., 0.10 mmol, 43 mgs) was added. After 60 minutes, water was added and the mixture passed through a hydrophobic filter and then purified by chromatography (MeOH—NH3-dichloromethane) on silica column. The solvent was evaporated to yield the free base of the title compound, 48 mgs, 36%, M++H=446. This was subsequently converted into the title compound using 2 ml HCl solution (1M in Et2O) to afford 65 mg, M++H=446.
1H NMR δ (CD3OD, 400 MHz, monohydrochloride salt) 1.179 (3H, t), 1.392 (2H, m), 1.655 (2H, q), 2.187 (6H, q), 2.87 (2H, q), 3.290 (5H, obs), 3.563 (2H, q), 3.67 (2H, d), 4.583 (1H, m), 7.405 (1H, s), 7.614 (1H, s).
A solution of trans-4-bromo-5-methyl-N-[1-(4-propoxycyclohexyl)-4-piperidinyl]-1,2-benzenediamine (D90, 140 mg) in dichloromethane (6 ml) at 0° C. was treated with triphosgene (35 mg) then diisopropylethylamine (0.07 ml), and then maintained at 0° C. for 1 h. The mixture was partitioned between dichloromethane and aqueous sodium bicarbonate. Drying, evaporation and chromatography (10 g silica, 0-10% methanol in dichloromethane) gave the title compound isolated as the hydrochloride salt from diethyl ether, 55 mg.
1HNMR (HCl salt) (d6DMSO): 0.85 (3H, t), 1.2 (2H, m), 1.5 (4H, m), 1.85 (2H, m), 2.15 (4H, m), 2.35 (3H, s), 2.8 (2H, m), 3.1-3.5 (13H, m), 4.6 (1H, m), 7.1 (1H, s), 7.7 (1H, s), 10.5 (1H, br s), 10.95 (1H, s), MH+ 450 and 452.
To a solution of 2-amino-5-chloro-4-(trifluoromethyl)phenyl]{1-[trans-4-(propyloxy)cyclohexyl]-4-piperidinyl}amine (D92, 0.40 mmol, 158 mgs) in dichloromethane (10 ml), diisopropylethylamine (1.5 eq., 0.50 mmol, 0.09 ml) was added at room temperature. The mixture was cooled to 0° C. and bis(trichloromethyl)carbonate (0.4 eq., 0.10 mmol, 43 mgs) was added. After 30 minutes, the mixture was poured onto water/brine; the aqueous solution was extracted with dichloromethane. The solvent was evaporated to yield the free base of the title compound, 60 mgs, 36%, M++H=460. This was subsequently converted into the title compound using 2 ml HCl solution (1M in Et2O) to afford 48 mg. M++H=460.
1H NMR δ (CD3OD, 400 MHz, monohydrochloride salt): 0.937 (3H, q), 1.176 (2H, t), 1.339 (4H, q), 1.595 (4H, m) 2.186 (6H, m), 2.819 (2H, q), 3.48 (3H, m), 3.665 (2H, d), 4.580 (1H, t), 7.405 (1H, s), 7.61 (1H, s)
A stirred solution of 4-fluoro-5-methyl-N-(1-{trans-4-[(1-methylethyl)oxy]cyclohexyl}-4-piperidinyl)-1,2-benzenediamine (D94, 205 mg, 0.56 mmole) in dichloromethane (15 ml) at 0° C. under argon was treated with diisopropylethylamine (0.15 ml, 0.84 mmole) followed by the addition of solid triphosgene (65 mg, 0.22 mmole) and maintained for 1 hr. The mixture was treated with dil. NaHCO3 solution (20 ml), stirred well for 5 mins, then extracted with dichloromethane. The extract was dried (Na2SO4) and concentrated under vacuum to leave a beige solid, which was recrystallised from a mixture of EtOAc (15 ml) and dichloromethane (5 ml) to afford the free base of the title compound as a white solid (150 mg, 68%). This was dissolved in dichloromethane (4 ml) and MeOH (12 ml), treated with 1M HCl/Et2O (0.55 ml) and concentrated under vacuum. The residue was triturated with Et2O (10 ml) to give a white solid which was filtered off, washed with Et2O and dried to afford the title compound as a white solid. MH+=390.
1H NMR δ (d6DMSO, 400 MHz): 1.07 (6H, d), 1.13-1.30 (2H, m), 1.50-1.65 (2H, m), 1.83 (2H, br d), 2.00 (2H, br d), 2.17 (2H, br d), 2.23 (3H, s), 2.85-3.00 (2H, m), 3.15-3.40 (4H, m), 3.49 (2H, br d), 3.63-3.77 (1H, m), 4.52-4.66 (1H, m), 6.79 (1H, d), 7.78 (1H, d), 10.95 (1H, s), 11.00 (1H, br m).
To a solution of (2-amino-4-fluoro-5-methylphenyl){1-[trans-1-methyl-4-(methyloxy)cyclohexyl]-4-piperidinyl}amine (D96, 0.189 mmol, 66 mgs) in dichloromethane (5 ml), diisopropylethylamine (1.5 eq., 0.284 mmol, 0.05 ml) was added at room temperature. The mixture was cooled to 0° C. and bis(trichloromethyl)carbonate (0.4 eq., 0.08 mmol, 22 mgs) was added. After 60 minutes, the mixture was quenched with brine and basified with 2M NaOH to Ph 10. The aqueous solution was extracted with EtOAc (2×); The organics were combined dried over Na2SO4, filtered and the solvent was evaporated to afford the crude product. The crude product was purified by chromatography (MeOH—NH3-dichloromethane) on silica column to afford the free base of the title compound, 31 mgs, 40%, M++H=376. This was subsequently converted into the title compound using 1 ml of HCl solution (1M in Et2O) to afford 16 mg.
1H NMR δ (d6DMSO, 400 MHz) 1.283 (5H, m), 1.939 (8H, m), 2.242 (3H, d), 2.886 (2H, q), 3.097 (1H, m), 3.163 (3H, m) 3.259 (3H, s), 3.645 (2H, d), 4.078 (1H, m), 4.585 (1H, m), 6.795 (1H, d), 7.682 (1H, d), 10.2 (1H, s br), 10.9 (1H, s).
A stirred solution of N-{1-[trans-4-(ethyloxy)-1-methylcyclohexyl]-4-piperidinyl}-4-fluoro-5-methyl-1,2-benzenediamine (D98, 90 mg, 0.248 mmole) in dichloromethane (10 ml) at 0° C. under argon was treated with diisopropylethylamine (0.066 ml, 0.372 mmole) followed by the addition of solid triphosgene (29 mg, 0.099 mmole) and maintained for 2 hr. The mixture was treated with dil. NaHCO3 solution (10 ml) and extracted with dichloromethane (2×10 ml). The extract was dried (Na2SO4), concentrated under vacuum and the residue crystallised from 1:1 Et2O/EtOAc to afford the free base of the title compound as a white solid (77 mg, 80%). This was dissolved in DCM (3 ml) and MeOH (4 ml), treated with 1M HCl/Et2O (0.30 ml) and concentrated under vacuum. The residue was triturated with Et2O to give a solid which was filtered off, washed with Et2O and dried to afford the title compound as a white solid (59 mg). MH+=390.
1H NMR δ (d6DMSO, 400 MHz): 1.10 (3H, t), 1.24-1.40 (2H, m), 1.33 (3H, s), 1.85 (2H, br d), 1.90-2.05 (assume 5H, m), 2.40 (3H, s), 2.88-3.02 (2H, m), 3.10-3.26 (4H, m), 3.47 (2H, q), 3.64 (2H, br d), 4.54-4.67 (1H, m), 6.79 (1H, d), 7.77 (1H, d), 10.45 (1H, m), 10.94 (1H, s).
A stirred solution of 4-chloro-N-{1-[trans-4-(ethyloxy)-1-methylcyclohexyl]-4-piperidinyl}-5-methyl-1,2-benzenediamine (D100, 195 mg, 0.51 mmole) in dichloromethane (12 ml) at 0° C. under argon was treated with diisopropylethylamine (0.136 ml, 0.76 mmole) followed by the addition of solid triphosgene (60 mg, 0.20 mmole) and maintained for 40 mins. The mixture was treated with dil. NaHCO3 solution (10 ml) and extracted with dichloromethane (2×15 ml). The combined extract was dried (Na2SO4) and concentrated under vacuum to leave a solid which was recrystallised from EtOAc/dichloromethane to afford the free base of the title compound as a white solid (60 mg, 29%). This was dissolved in dichloromethane (2 ml) and MeOH (2 ml), treated with 1M HCl/Et2O (0.25 ml) and concentrated under vacuum. The residue was triturated with Et2O to give a solid which was filtered off, washed with Et2O and dried to afford the title compound as a white solid (65 mg). MH+=406.
1H NMR δ (d6DMSO, 400 MHz): 1.10 (3H, t), 1.22-1.40 (5H, m), 1.82-2.05 (assume 7H, m), 2.34 (3H, s), 2.80-2.97 (2H, m), 3.12-3.25 (3H, m), 3.30-3.42 (assume 1H, m), 3.47 (2H, q), 3.65 (2H, br d), 4.52-4.65 (1H, m), 6.70 (1H, s), 7.79 (1H, s), 10.20 (1H, br m), 10.96 (1H, s).
Triphoshene (0.047 g) was added to a solution of 4-fluoro-5-methyl-N-{1-[cis-1-methyl-4-(propyloxy)cyclohexyl]-4-piperidinyl}-1,2-benzenediamine (D102, 0.15 g), dichloromethane (10 ml) and diisopropylethylamine (0.2 ml) stirred at ice bath temperature. The solution was stirred to room temperature overnight then washed with saturated sodium bicarbonate solution, brine and the solvent was removed. The residue was chromatographed on silica gel eluted with dichloromethane-methanolic ammonia 0-5%, to give the free base of the title as a white solid. This was dissolved in dichloromethane, treated with hydrogen chloride in ether and the solvent was removed to give the title compound as a white solid (0.12 g). MH+=404.
1H NMR (d6DMSO, 400 MHz): 0.90 (3H, t), 1.35 (3H, s), 1.55 (4H, m), 1.73 (2H, m), 1.85-2.0 (7H, m), 2.25 (3H, s), 2.8 (2H, m), 3.25 (obs, m), 3.46 (2H, m), 4.56 (1H, m), 6.81 (1H, d), 7.50 (1H, m) 9.63 (1H, m), 10.92 (1H, s).
19F NMR (d6DMSO)-125.67 ppm.
A stirred mixture of 4-fluoro-5-methyl-N-{1-[trans-1-methyl-4-(propyloxy)cyclohexyl]-4-piperidinyl}-1,2-benzenediamine (D104, 280 mg, 0.74 mmole) in dichloromethane (20 ml) was treated with diisopropylethylamine (0.4 ml, 2.2 mmole) and portionwise addition of triphosgene (88 mg, 0.30 mmole) at 0° C. under argon for 15 minutes. The mixture was allowed to warm to room temperature, then washed with sat. NaHCO3 solution and extracted with dichloromethane. The extract was dried (Na2SO4) and concentrated under vacuum, then crystallised from pentane and collected by filtration to afford the free base of the title compound (120 mg, 40%). This was dissolved in dichloromethane (10 ml), treated with 1M HCl/Et2O (5 ml) and concentrated under vacuum to afford the title compound as a white solid (123 mg). MH+=404
1H NMR δ (d6DMSO, 400 MHz): 0.87 (3H, t), 1.20-1.40 (2H, m), 1.33 (3H, s), 1.40-1.57 (2H, m), 1.86 (2H, br d), 1.90-2.07 (5H, m), 2.24 (3H, s), 2.82-3.00 (2H, m), 3.10-3.37 (3H, m), 3.30-3.45 (assume 3H, m), 3.62 (2H, br d), 4.53-4.65 (1H, m), 6.79 (1H, d), 7.75 (1H, d), 10.4 (1H, br m), 10.92 (1H, s).
Triphoshene (0.05 g) was added to a solution of 4-fluoro-5-methyl-N-{1-[cis-1-methyl-4-(D106, (propyloxy)cyclohexyl]-4-piperidinyl}-1,2-benzenediamine 0.167 g), dichloromethane (10 ml) and diisopropylethylamine (0.2 ml) stirred at ice bath temperature. The solution was stirred to room temperature overnight then washed with saturated sodium bicarbonate solution, brine and the solvent was removed. The residue was chromatographed on silica gel eluted with dichloromethane-methanolic ammonia 0-5%. The product was dissolved in dichloromethane, treated with hydrogen chloride in ether and the solvent was removed to give the title compound as a white solid (0.102 g). MH+=420.
1H NMR (d6DMSO, 400 MHz): 0.90 (3H, t), 1.36 (3H, s), 1.55 (4H, m), 1.70 (2H, m), 1.85-2.2 (7H, m), 2.34 (3H, s), 2.9 (2H, m), 3.2 (2H, m), 3.35 (obs, m), 3.49 (1H, m), 3.67 (2H, m), 4.59 (1H, m), 7.0 (1H, s), 7.76 (1H, s) 10.0 (1H, m), 11.0 (1H, s).
A stirred mixture of 4-chloro-5-methyl-N-{1-[trans-1-methyl-4-(propyloxy)cyclohexyl]-4-piperidinyl}-1,2-benzenediamine (D108, 300 mg, 0.76 mmole) in dichloromethane (25 ml) was treated with diisopropylethylamine (0.4 ml, 2.2 mmole) and portionwise addition of triphosgene (90 mg, 0.30 mmole) at 0° C. under argon for 15 minutes. The mixture was allowed to warm to room temperature, then washed with sat. NaHCO3 solution and extracted with dichloromethane. The extract was dried (Na2SO4) and concentrated under vacuum, then crystallised from pentane and collected by filtration to afford the free base of the title compound (175 mg, 55%). This was dissolved in dichloromethane (10 ml), treated with 1M HCl/Et2O (5 ml) and concentrated under vacuum to afford the title compound as a white solid (181 mg). MH+=420.
1H NMR δ (d6DMSO, 400 MHz): 0.87 (3H, t), 1.22-1.40 (5H, m), 1.42-1.55 (2H, m), 1.85 (2H, br d), 1.85-2.06 (5H, m), 2.34 (3H, s), 2.85-3.00 (2H, m), 3.10-3.25 (3H, m), 3.30-3.45 (assume 3H, m), 3.65 (2H, br d), 4.55-4.70 (1H, m), 6.99 (1H, s), 7.88 (1H, s), 10.45 (1H, br m), 10.96 (1H, s).
A stirred mixture of 5-bromo-N-{1-[trans-1-methyl-4-(propyloxy)cyclohexyl]-4-piperidinyl}-4-(trifluoromethyl)-1,2-benzenediamine (D110, 420 mg, 0.85 mmole) in dichloromethane (40 ml) was treated with diisopropylethylamine (0.45 ml, 2.55 mmole) and portionwise addition of triphosgene (101 mg, 0.34 mmole) at 0° C. under argon for 10 minutes. The mixture was allowed to warm to room temperature, then washed with NaHCO3 solution and extracted with dichloromethane. The extract was dried (Na2SO4) and concentrated under vacuum, then crystallised from pentane and collected by filtration to afford the free base of the title compound (290 mg, 66%). This was dissolved in dichloromethane (10 ml), treated with 1M HCl/Et2O (5 ml) and concentrated under vacuum to afford the title compound as a white solid (180 mg). MH+=520.
1H NMR δ (d6DMSO, 400 MHz): 0.86 (3H, t), 1.20-1.40 (5H, s+m), 1.42-1.54 (2H, m), 1.85-2.07 (8H, m), 2.83-3.00 (2H, m), 3.10-3.28 (3H, m), 3.30-3.43 (assume 2H), 3.67 (2H, br d), 4.61-4.74 (1H, m), 7.34 (1H, s), 8.27 (1H, s), 10.6 (1H, br m), 11.54 (1H, s).
(2-Amino-4,5-dimethylphenyl){1-[trans-4-(ethyloxy)-1-methylcyclohexyl]-4-piperidinyl}amine (D120, 30 mg, 0.084 mmol) stirred under argon in tetrahydrofuran (5 ml) at ice bath temperature was treated with diisopropylethylamine (89 μl, 0.42 mmol), followed by addition of triphosgene (12.5 mg, 0.042 mmol). The mixture was allowed to warm to room temperature, and then stirred under argon at this temperature over the weekend. A solid formed in the solution. Minimal methanol was added to dissolve the solid, and the solution was loaded onto a 2 g SCX cartridge. The product was eluted with NH3 in methanol (2M) and the solvent was then removed. The resulting solid was dissolved in a small amount of ethanol, and then concentrated under vacuum to give orange crystals (25 mg). The crystals were dissolved in dichloromethane (≈2 ml) and 1M hydrogen chloride in diethyl ether (0.5 ml) was added. The solvent was then removed, and the resulting solid dried in a vacuum oven giving the title compound as a brown solid (20 mg). MH+=386.
1HNMR δ DMSO, 400 MHz): 1.1 (3H, t), 1.2-1.4 (obs), 1.827 (2H, d), 1.91-2.05 (obs), 2.19 (3H, s), 2.23 (3h, s), 2.92 (2H, q), 3.15-3.3 (3H, m), 3.47 (2H, q), 3.63 (2H, d), 4.54-4.6 (1H, m), 6.76 (1H, s), 7.612 (1H, s), 10.4 (1H, m), 10.7 (1H, s).
N-{1-[trans-4-(Ethyloxy)-1-methylcyclohexyl]-4-piperidinyl}-4,5-difluoro-1,2-benzenediamine (D121, 650 mg, 1.7 mmol) stirred under argon in dichloromethane at ice bath temperature was treated with diisopropylethylamine (1 ml, 4.7 mmol), followed by addition of triphosgene (155 mg, 0.52 mmol). The mixture was allowed to warm to room temperature, and then stirred under argon at this temperature overnight. Solvent removed to give dark brown crystals (600 mg). These crystals were purified using a Waters Xbridge chromatography column eluting with a gradient using aqueous ammonium bicarbonate (10 mmolar) adjusted to pH10 with ammonia and acetonitrile as the mobile phase to give the pure product. Once obtained, this was dissolved in dichloromethane and 1M hydrogen chloride in diethyl ether was added. The solvent was then blown off and the product was triturated in diethyl ether. The solvent was removed and the resulting solid was dried to give the title compound as a fawn coloured solid (48 mg). MH+=394.
1HNMR δ DMSO, 400 MHz): 1.09 (assume 3H, m), 1.23-1.36 (obs), 1.86-2.0 (obs), 2.86 (2H, q), 3.17 (3H, m), 3.47 (2H, q), 3.65 (2H, d), 4.62 (1H, m), 7.1 (1H, m), 7.96 (1H, m), 10.35 (1H, m), 11.15 (1H, s).
Diisopropylethylamine (120 μL, 0.71 mmole) was added to a solution of (2-amino-4-chlorophenyl){1-[trans-1-methyl-4-(methyloxy)cyclohexyl]-4-piperidinyl}amine (D123, 84 mg, 0.24 mmole) in CH2Cl2 (10 mL) at room temperature under argon. The reaction was cooled to 0° C. and triphosgene (28 mg, 0.09 mmole) was added portion-wise. The reaction was stirred overnight before the addition of 2M NaOH (10 mL). The mixture was partitioned and the aqueous layer extracted with CH2Cl2 (2×). The combined organics were dried (Na2SO4) and reduced in volume by rotary evaporation before being chromatographed (silica, CH2Cl2-0.5% NH3/9.5% MeOH/90% CH2Cl2) to give the free base of the title compound as a yellow solid. The free base was suspended in MeOH (2 mL) and then 1M HCl in Et2O (0.3 mL) was added. The mixture was stirred for 30 min and then filtered, with the precipitate being washed with Et2O (2×) to give the title compound (51 mg, 52%) as a beige solid. M(Cl-35)+ 378, M(Cl-37)H+ 380.
1H NMR δ (DMSO-d6, 400 MHz): 1.24-1.39 (5H, m), 1.83-2.08 (8H, m), 2.86 (2H, m), 3.05-3.21 (3H, m), 3.21 (3H, s), 3.64 (2H, m), 4.62 (1H, m), 7.04 (2H, m), 7.73 (1H, d, J 9), 10.24 (1H, m), 11.12 (1H, s).
(2-Amino-4-chlorophenyl){1-[trans-4-(ethyloxy)-1-methylcyclohexyl]-4-piperidinyl}amine (D125, 102 mg, 0.28 mmole) in CH2Cl2 (10 mL) at room temperature under argon. The reaction was cooled to 0° C. and triphosgene (33 mg, 0.11 mmole) was added portion-wise. The reaction was stirred overnight before the addition of 2M NaOH (10 mL). The mixture was partitioned and the aqueous layer extracted with CH2Cl2 (2×). The combined organics were dried (Na2SO4) and reduced in volume by rotary evaporation before being chromatographed (silica, CH2Cl2-0.5% NH3/9.5% MeOH/90% CH2Cl2) to give the free base of the title compound as a yellow solid. The free base was suspended in MeOH (2 mL) and then 1M HCl in Et2O (0.5 mL) was added. The mixture was stirred for 2 h and then filtered, with the precipitate being washed with Et2O (2×) to give the title compound (77 mg, 64%) as a cream solid. M(Cl-35)+ 392, M(Cl-37)H+ 394.
1H NMR δ (DMSO-d6, 400 MHz): 1.10 (3H, t, J 7), 1.26-1.39 (5H, m), 1.79 (2H, m), 1.89-2.05 (6H, m), 2.75 (2H, m), 3.14-3.25 (3H, m), 3.47 (2H, q, J 7), 3.65 (2H, m), 4.60 (1H, m), 7.03 (1H, d, J 2), 7.08 (1H, m), 7.52 (1H, d, J 8), 9.54 (1H, m), 11.12 (1H, s).
A solution of 1,1′-bis(diphenylphosphino)ferrocene (6.4 mg, 0.0116 mmole) in dioxane (5 ml) at room temperature under argon was treated with N-(5-chloro-4-cyano-2-iodophenyl)-N′-{1-[trans-4-(ethyloxy)cyclohexyl]-4-piperidinyl}urea (D126, 103 mg, 0.194 mmole) and stirred for 10 minutes, then sodium t-butoxide (56 mg, 0.582 mmole) was added and the mixture heated at 95° C. for total of 20 hours. The mixture was cooled, concentrated under vacuum and the residue treated with 10% Na2CO3 solution and extracted with dichloromethane. The extract was dried (Na2SO4) and concentrated under vacuum. The residue was initially purified by passage through an SCX cartridge, then further purified by MDAP to afford the title compound as a white solid (5 mg). MH+ 403.
1H NMR δ (CDCl3, 400 MHz): 1.21 (3H, t), 1.20-1.42 (4H, m), 1.84 (2H, br d), 1.95 (2H, br d), 2.14 (2H, br d), 2.26-2.50 (5H, m), 3.10 (2H, br d), 3.15-3.26 (1H, m), 3.52 (2H, q), 4.22-4.37 (1H, m), 7.23 (1H, s), 7.56 (1H, s), 10.30 (1H, br s).
The title compound can be prepared from 4,5-dimethyl-1,2-benzenediamine and 1-[trans-1-methyl-4-(methyloxy)cyclohexyl]-4-piperidinone (D58) using a similar procedure to that described in Description 120 and Example 31.
The title compound can be prepared from 4,5-difluoro-1,2-benzenediamine and 1-[trans-1-methyl-4-(methyloxy)cyclohexyl]-4-piperidinone (D58) using a similar procedure to that described in Description 121 and Example 32.
The title compound can be prepared from 4-amino-2-chloro-5-iodobenzonitrile (J. Med. Chem. 2001, 44 (23), 3866) and 1-[trans-1-methyl-4-(methyloxy)cyclohexyl]-4-piperidinamine (D59) using a similar procedure to that described in Description 126 and Example 35.
The title compound can be prepared from 4-amino-2-chloro-5-iodobenzonitrile (J. Med. Chem. 2001, 44 (23), 3866) and 1-[trans-4-(ethyloxy)-1-methylcyclohexyl]-4-piperidinamine (D68) using a similar procedure to that described in Description 126 and Example 35.
| Number | Date | Country | Kind |
|---|---|---|---|
| 0605784.8 | Mar 2006 | GB | national |
This application is a Continuation of application Ser. No. 13/282,604 filed Oct. 27, 2011 which is a continuation of Ser. No. 12/293,572 filed Apr. 8, 2010 which is a 371 National Phase Entry of Application No. PCT/EP2007/052639 filed 20 Mar. 2007 which claims the priority of GB Application No. GB0605784.8 filed Mar. 22, 2006.
| Number | Date | Country | |
|---|---|---|---|
| Parent | 13282604 | Oct 2011 | US |
| Child | 13585020 | US | |
| Parent | 12293572 | Apr 2010 | US |
| Child | 13282604 | US |
